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Rapid restoration of blood flow to ischemic myocardium is essential, however it causes 
further injury called reperfusion injury. Apoptosis contributes significantly to 
cardiomyocyte cell death during ischemia reperfusion injury, in which caspase family 
proteases play an essential role as they are the executioners of apoptosis. Caspase inhibitors 
showed promising cardioprotective results when administered before ischemia or at the 
start of reperfusion. However, before applying them in pre clinical studies of myocardial 
ischemia, several investigations needed to be taken to determine their therapeutic window 
post reperfusion, their effect on functional recovery of myocardium post ischemia, their 
mechanism of action. 
 
Methods 
Isolated perfused rat hearts were subjected to 35 min ischemia followed by 2 hr reperfusion 
where caspase inhibitors [broad spectrum caspase inhibitor (ZVAD, 0.1µM), specific 
caspase 3 inhibitor (DEVD, 0.07µM)] were added at the start of reperfusion, 15, 30 and 60 
min after starting reperfusion at the presence or absence of Wortmannin (WORT, 100nM, 
PI3-kinase inhibitor). Hearts underwent triphenyl tetrazolium staining for infarct size 
assessment, or were frozen for Western blot analysis. Freshly isolated adult rat ventricular 
myocytes were subjected to 6 hr hypoxia followed by either 18 hr, where caspase inhibitors 
(ZVAD, 25µM and DEVD, 25µM)] were added at the start of reoxygenation, 15, 30 and 60 
min after starting reoxygenation at the presence or absence of Wortmannin (WORT, 
100nM). Cardiomyocytes were analysed for viability, apoptosis, necrosis and intracellular 
caspase-3 activity using flow cytometry analysis. Isolated adult rat ventricular papillary 
muscles were subjected to 35 min hypoxia followed by 100 min reperfusion where caspase 
inhibitors [ZVAD (0.1 µM, 2.5µM) and DEVD (2.5µM)] were added at the start of 






Both caspase inhibitors significantly reduced infarcted tissue within the risk zone, 
apoptotic, necrotic cellular death and intracellular caspase 3 activity level when 
administered at the start of reperfusion, 15, 30 and 60 min after initiation of reperfusion. 
Work loop studies showed that the broad spectrum caspase inhibitors at high dose of 2.5µM 
significantly improved post ischemic power out put recovery, however the specific caspase 
3 inhibitor has no significant effect on power output recovery post ischemia. Inhibition of 
PI3-Akt by WORT at the start of reperfusion abrogated the cardioprotective effect of both 
caspase inhibitors. However, WORT did not block the cardiprotection of both caspase 
inhibitors when administered at 15 min and 30 min after starting reperfusion. Western blot 
analysis showed that cytochrome c is released to cytosol during ischemia/reperfusion 
injury; however both caspase inhibitors failed to inhibit cytochrome c release during 
reperfusion injury at all time points during reperfusion. Western blot showed a significant 
increase in phospho-Akt at 5 min and 10 min reperfusion in both caspase inhibitors treated 
groups compared to ischemic control group. However there was no significant increase at 
20 min and 120 min reperfusion when compared to ischemic control. WORT blocked the 
increase in phospho-Akt at 10 min reperfusion. 
 
Conclusion 
This study is the first to show that administration of caspase inhibitors at various time 
points post reperfusion can still reduce myocardial injury, which implies that the 
therapeutic window of caspase inhibitors in myocardial infarction treatment can be 
extended for an hour after starting reperfusion. It also showed that broad inhibition of 
caspase resulted in a significant functional recovery post ischemia using for the first time 
work loop technique to measure the power output. This study is also the first to show that 
cardioprotection by caspase inhibitors at early reperfusion phase is mediated via PI3-Akt 
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 Acute myocardial infarction or commonly known as “Heart attack” is the leading cause of 
death in developed countries such as UK and USA, but third to AIDS and lower respiratory 
infections in developing countries (Okrainec et al., 2004). The estimated incidence rate of 
myocardial infarction in UK is about 55,000 heart attacks per year in men aged under 75 
and 20,000 in women giving a total of 75,000 (Allender et al., 2007).  
Coronary arteries are the blood vessels that supply the heart muscle with blood and oxygen. 
Blockage of a coronary artery deprives the heart muscle of blood and oxygen, causing 
injury and subsequently death to the heart muscle (Myocardial infarction). Atherosclerosis 
is the common cause of myocardial infarction (Ross, 1999). It involves the formation of 
fatty deposits (plaques) on the walls of the coronary arteries. Rupture of the atherosclerotic 
plaques causing a blood clot to be formed on the surface of the plaque, which can cause a 
complete block of the coronary artery causing a heart attack (Ross, 1999). The cause of 
rupture that leads to the formation of a clot is largely unknown, but contributing risk factors 
may include cigarette smoking or other nicotine exposure, elevated blood cholesterol, 
elevated levels of blood catecholamines (i.e adrenaline), high blood pressure, and other 
mechanical and biochemical forces (Altman, 2003). 
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Acute myocardial infarction treatment is considered a challenge for clinicians and 
researchers because of its associated high rate of mortality and morbidity. In UK, around 
one in five men and one in six women die from the disease. Coronary heart disease caused 
just under 114,000 deaths in the UK in 2003 (Allender et al., 2007). Recent statistics 
published by the American Heart Association (AHA) indicate that approximately 25% of 
men and 38% of women will die within 1 year of having an initial recognized myocardial 
infarction, and people who survive the acute stage have an increased risk of illness and 
death that is up to 15 times higher than that of the general population (Thom et al., 2006).  
 
A lot of interventional programs attacking the primary risk factors have been developed, 
however their impact is still limited (Yellon & Baxter, 2000). Therefore, there is a need for 
effective forms of secondary prevention and treatments that will be able to preserve 
myocardial viability during acute myocardial ischemia insult. To date the only proven way 
of salvaging ischemic heart tissue is urgent revascularisation and restoration of blood flow 
(de Boer et al., 1994). Currently, the most effective methods used in standard clinical 
reperfusion treatment are thrombolysis, percutaneous coronary angioplasty (primary 
PCTA), or bypass surgery (de Boer et al., 1994, Wong & White, 2003.). Although early 
reperfusion halts the ongoing process of ischemic injury, paradoxically the process of 
reperfusion can itself causes myocyte cell death, a phenomenon called reperfusion injury 
(Hearse & Bolli, 1992, Yellon & Baxter, 2000). This phenomenon may have major clinical 
implications because reperfusion after a period of ischemia occurs not only during 
myocardial infarction but also in other frequent and important clinical conditions such as 
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angina and cardioplegic arrest during cardiac surgery. Therefore pharmacological therapy 
administered during reperfusion is needed to limit ischemia/reperfusion injury. 
1.1 Pathogenesis of ischemia/reperfusion injury 
 
The inability of the myocardium to meet oxygen and nutrient supply with respect to 
demand is referred to as myocardial ischemia (Asano et al., 2003).  Numerous conditions 
may elicit an ischemic myocardium, the most important and frequent cause is 
atherosclerosis of coronary arteries. Atherosclerosis occurs as a result of the development 
of atherosclerotic plaques that protrude into the lumen of the coronary arteries resulting in 
obstruction of blood flow (Ross, 1999). A 50 % reduction in the coronary artery diameter 
can lead to a significant reduction in the blood flow and ischemia can occur (Hoffman et 
al., 2004). 
 
Reduced blood flow during ischemia indicates that there is a reduced flow of oxygen to the 
ischemic tissues. While there is reduced oxygen, there is a reduction in oxidative 
phosphorylation, which leads to a reduction in the rate of formation of ATP, which is the 
primary source of energy substrates for myocytes (Guyton, 1991). ATP levels decrease by 
65% after 15 minutes of ischemia and by 90% after 40 minutes of ischemia (Reimer & 
Jennings, 1986). As a result, the muscle has less ability to generate active force, and ion 
homeostasis is lost. The ATP dependent ion exchangers and transporters can no longer 
function, with the result that potassium ions start to leak into the extracellular space, and 
calcium ions leak into the cell. This leads to electrical instability and failure of the cells to 
relax. This process of ischemia proceeds until the myocytes are swollen, acidotic, and show 
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signs of structural disorganization (Maxwell & Lip, 1997). In addition, during ischemia, 
glutathione (GSH) is also depleted. GSH is a sulphydryl that acts to protect the cellular 
proteins and lipids from oxidative damage. Therfore, reduced glutathione results in 
exacerbation of oxidative stress (Patterson & Rhoedes, 1988). 
 
Cell death following myocardial ischemia is dependent on both the duration and the 
severity of myocardial ischemia (DeBoer et al., 1983). Therefore, reperfusion of ischemic 
myocardium carried out at the earliest possible time following coronary occlusion is 
considered as an important goal. Although reperfusion is essential and an absolute 
prerequisite for survival of the ischemic myocardium, the process itself can lead to 
additional myocardial injury and other associated pathologies which are referred to as 
“reperfusion injury” (Hearse & Bolli 1992, Yellon & Baxter, 2000). 
 
Reperfusion injury was described in the literature as early as 1960 by Jennings et al. They 
reported both structural and electrophysiological changes associated with coronary 
reperfusion and they were the first to suggest that reperfusion accelerated the necrotic 
process of irreversibly injured myocytes. Since then, numerous studies described the same 
phenomenon and its underlining mechanisms and therapeutic approaches which have been 
reviewed by different papers (Cohen 1989, Forman et al. 1990, Hearse, 1990, Jennings et 
al., 1995, Lucchesi, 1997, Frangogiannis et al. 1998, Jordan et al. 1999, Park & Lucchesi 
1999). The major controversy about the nature of reperfusion injury is whether reperfusion 
merely exacerbates tissue damage that would in any case have occurred during ischemia as 
suggested by Jennings and his group (1960) or whether there is an additional injury caused 
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merely by reperfusion itself. Therefore, defining reperfusion injury is not straightforward, 
but it can be defined as "those metabolic, functional, and structural consequences of 
restoring coronary arterial flow that can be avoided or reversed by modification of the 
conditions of reperfusion" (Park & Lucchesi, 1999). 
 
Reperfusion injury can be considered as a syndrome consisting of different clinical and 
pathological events including: reperfusion arrhythmias, vascular damage and no-reflow, 
myocardial functional stunning, and extension of the mass of tissue injury (Maxwell & Lip, 
1997). Several mechanisms and mediators of reperfusion injury have been described. The 
most frequently cited mechanisms are oxygen free radicals, polymorphonuclear leucocytes, 
alteration in calcium handling and altered myocardial metabolism (Maxwell & Lip, 1997). 
1.1.1 Oxygen free radicals  
 
Oxygen free radicals or reactive oxygen species (ROS) play an important role in the 
pathophysiology of ischemia reperfusion injury. Oxygen free radicals have unpaired 
electron, which makes them extremely reactive and capable of inducing oxidative 
modification of other molecules. According to existing evidence, molecular oxygen, when 
reintroduced into a previously ischemic myocardium, undergoes a sequential reduction 
leading to the formation of oxygen free radicals within a few minutes of reperfusion 
(Zewier 1988, Bolli et al., 1989). ROS can also be generated from sources other than 
reduction of molecular oxygen. These sources include enzymes, such as xanthine oxidase, 
cytochrome oxidase, and cyclooxygenase, and the oxidation of catecholamines (Singal et 
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al., 1983). In addition, reperfusion stimulates neutrophil activation and accumulation, 
which in turn are considered as potent stimuli for ROS accumulation (Jordan et al., 1999). 
 
The damage produced by ROS is through reaction with polyunsaturated fatty acids, 
resulting in the formation of lipid peroxides and hydroperoxides that damage the 
sarcolemma and impair the function of membrane-bound enzyme systems (Verma et al., 
2002). In addition, free radicals stimulate the endothelial release of platelet activating 
factor, which attracts more neutrophils and amplifies the production of oxidant radicals and 
the degree of reperfusion injury (Forde & Fitzgerald, 1997). Reactive oxygen species also 
reduce nitric oxide, thus exaggerating endothelial injury and microvascular dysfunction 
(Verma et al., 2002). In addition, endogenous oxidant scavengers reduced during ischemia, 
which exacerbates the oxidative stress (Park & Lucchesi, 1999). 
 
ROS are strongly implicated in the pathogenesis of postischemic myocardial stunning 
(Bolli et al., 1988), necrosis (Tavazzi et al., 1998) and programmed cell death (apoptosis) 
(Maulik et al., 1998). The effects of antioxidants and free radical scavengers have been 
investigated in numerous experimental and clinical models with varying success 
(Przyklenk, 2001). This variability in outcomes can be attributed to species differences in 
collateral blood flow and the different durations of ischemic insults used in these 
experiments. Even though positive results were shown in classical animal models of 
experimental ischemia and reperfusion, human clinical studies with antioxidants have been 
disappointing as they have failed to show any beneficial effects after using human 
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recombinant superoxide dismutase (anti-oxidant) (Flaherty et al., 1994). Conflicting results 
between animal studies and human trials may be the result of species differences.  
 
Recently Kevin et al., (2005) showed that ROS involved in the signalling cascade for 
cardiopotection induced by brief exposure to a volatile anaesthetic agents. ROS, therefore, 
although injurious in large quantities, can have a paradoxical protective effect within the 
heart in smaller quantities.  
1.1.2 The polymorphonuclear leucocytes (PMNs) 
 
Accumulating evidence has indicated that myocardial ischemia elicits an acute 
inflammatory response that is greatly augmented by reperfusion and that a significant part 
of total myocardial injury after ischemia and reperfusion is attributable to the inflammatory 
response (Park & Lucchesi, 1999). The polymorphonuclear leucocytes (PMNs) represent a 
major cellular component of that inflammatory response. The role of the PMNs in 
myocardial ischemia and reperfusion injury was first demonstrated by histological studies 
showing a direct correlation between both the duration of ischemia and infarct size and the 
extent of PMNs accumulation within the myocardial tissue (Romson et al., 1983). In 
addition, induction of neutropenia (lack of PMNs), as well as the inhibition of PMNs 
adhesion (Simpson et al., 1990), results in a cardioprotective effect, further implicating the 
importance of PMNs in contributing to the development of myocardial reperfusion injury. 
 
PMNs have the capacity to produce oxygen-derived free radicals (Metha et al., 1988) when 
activated by appropriate stimuli as mentioned earlier.  In addition to the damage caused by 
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free radicals production, PMNs degranulate to release proteases, collagenases, 
lipoxygenases, phospholipases, elastases and myeloperoxidase. Elastase is a major 
contributor to PMNs mediated damage, due party to the effect of its highly cationic nature 
on membrane charge distribution. Elastase also hydrolyzes the extracellular matrix 
components elastin, fibronectin, and collagen types III and IV (Jordan et al., 1999).  In 
addition, PMNs activation stimulates phospholipase A2 and generates leukotriene B4 and 
platelet activating factor. The latter two are potent stimulants of PMNs chemotaxis, 
degranulation, and adhesion to endothelial cells, which might then amplify neutrophil 
recruitment and injury (Jordan et al., 1999). Cytokine-induced PMNs activation increases 
not only adherence properties but also cytoskeletal rigidity, so the PMNs are no longer 
flexible, and so they then embolize (Jordan et al., 1999). 
 
However, the exact role of PMNs in the pathogenesis of reperfusion injury is still a point of 
controversy. Some studies completely discredit the role of PMNs in reperfusion injury. 
Briaud and his group (2001) used mice with a deficiency (via gene deletions) of P-selectin 
and intercellular adhesion molecule-1 (ICAM-1), which mediate early interaction and 
adhesion of neutrophils to coronary endothelial cells and myocytes after myocardial 
ischemia and reperfusion. They found that the infarct size assessed 24 hours after 
reperfusion was not different between wild-type and deficient mice after 30 minutes and 1 
hour of ischemia. In addition in-vitro models of ischemia/reperfusion which doesn’t involve 
blood or any PMNs interactions in their setting (e.g. Langendorff model and isolated cell 




1.1.3 Alteration in calcium homeostasis 
 
Changes in intracellular calcium homeostasis play an important role in the development of 
reperfusion injury. Cytosolic calcium concentration is increased during prolonged ischemia 
(Marban et al., 1990) and this is often exacerbated following reperfusion (Nayler et al., 
1980). This reperfusion induced calcium overload has been explained by Grinwald (1982) 
as follows: during ischemia, intracellular sodium accumulates due to energy depletion, but 
Na+–H+ exchange is inhibited by the concomitant acidosis. Upon reperfusion, the rapid 
reversal of acidosis reactivates Na+-Ca2+ exchange at a time when sodium overload has not 
yet been resolved, driving calcium into the cells. Mitochondrial matrix calcium overload 
considered one of the key factors responsible for mitochondrial permeability transition pore 
(MPTP) opening during reperfusion injury (Halestrap et al., 2004). MPTP opening results 
in release of pro-apoptotic proteins like cytochrome c and AIF (Halestrap et al., 2004) thus, 
initiating apoptosis, which will be discussed later. In addition to intracellular calcium 
overload, alterations in myofilament sensitivity to calcium have been implicated in 
reperfusion injury (Verma et al., 2002). Activation of calcium-dependent proteases 
(calpains) with resultant myofibril proteolysis has been implicated too. These “calpains” are 
enzymes that cleave other proteins when cell calcium concentration is elevated (Gao et al., 
1996, 1997). 
1.1.4 Altered myocardial metabolism 
 
Reperfusion of an ischemic myocardium results in altered metabolism, which may 
contribute to delayed functional recovery (Verma et al., 2002). Lack of oxygen during 
ischemia induces anaerobic metabolism, with a net production of lactate, which persists 
 
 10 
during reperfusion (Rao et al., 2001). In addition, the activity of mitochondrial pyruvate 
dehydrogenase (PDH) is inhibited by 40% after ischemia and remains depressed up to 30 
minutes after reperfusion (Merante et al., 1988). Therefore, the persistent anaerobic lactate 
production during reperfusion contributes significantly to impaired ventricular function 
recovery (Rao et al., 2001). These findings suggest that the persistent anaerobic metabolism 
may be an important contributor to reperfusion injury, therefore improving the recovery of 
aerobic myocardial metabolism may serve as an important target to attenuate reperfusion 
injury. Different studies that used interventions to improve aerobic metabolism using 
insulin or adenosine showed rapid recovery of aerobic metabolism and left ventricular 
function after post-cardiac surgery reperfusion (Rao et al., 2000). 
1.2 Cell death during Ischemia/Reperfusion injury  
 
Necrosis is believed to be the major form of pathological cell death after 
ischemia/reperfusion injury. However, recent evidence suggests that apoptosis 
(programmed cell death) is a significant contributor to cell death during 
ischemia/reperfusion injury (Saraste et al., 1997, Zhao et al., 2000, Gottlieb et al., 1994).  
 
Necrosis and apoptosis differ in several morphological and cellular regulatory features 
(Kerr et al., 1972). Necrosis is a destructive irreversible death process (Searle et al., 1982). 
It involves swelling of the cell and its organelles, disruption of mitochondria, membrane 
rupture and cell lyses and significant inflammatory response (Searle et al., 1982). In 
contrast apoptosis is energy dependent and a genetically controlled programmed cell death 
(Kerr et al., 1972). It is originally defined by its morphological characteristics, which 
 
 11 
include cell shrinkage, chromatin condensation, DNA fragmentation, formation of 
cytoplasmic blebs and apoptotic bodies, no loss of cell integrity and no inflammatory 
response (Kerr et al., 1972). This form of cell death requires caspase activation, as these 
enzymes can activate the endonucleases responsible for DNA degradation (Smulson et al., 
2000). 
 
A large body of publications have shown that apoptosis is induced during 
ischemia/reperfusion injury (Gottleib et al., 1994, Fliss et al., 1996, Kajstura et al., 1996, 
Freud et al., 2000, Zhao et al., 2000, Borutaite et al., 2003); however whether apoptosis is 
induced during the ischemia period or after starting reperfusion is still controversial. One of 
the earliest studies in apoptosis showed that apoptosis was detected in ischemic 
myocardium after 30 min of ischemia and 4 hour of reperfusion in the rabbit myocardium, 
but not in ischemic only myocardium (Gottleib et al., 1994). The same observation was 
confirmed by Zhao et al., (2000), where they showed that apoptosis only appeared in dog 
myocardium subjected to a brief period of ischemia followed by reperfusion (60 min 
ischemia and 6 hrs reperfusion), and not  in ischemic tissue (7 hrs ischemia) without 
reperfusion. Freud et al., (2000) also showed that in the experiments with 90 min ischemia 
in isolated canine hearts, apoptotic cell death was only observed after initiation of 
reperfusion. In addition Dumont et al., (2000) showed that the level of apoptosis is 
dependent on reperfusion duration. Studies on isolated myocardial rat cells have again 
shown that apoptosis is the predominant mode of cell death during reoxygenation, but that 
non-apoptotic cell death predominates during prolonged hypoxia alone (Kang et al., 2000). 
In contrast, Fliss et al., (1996) showed that either continuous ischemia or ischemia followed 
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by reperfusion can cause apoptosis in the rat model of coronary artery occlusion. Anvesa et 
al., (1998) quantified the level of apoptosis and reported that, the level is 30 times higher 
after 2 hours of ongoing ischemia when compared with the start of ischemia. In addition 
Borutaite et al., (2003) showed that activation of caspase, which are the hallmark of 
apoptosis, was dependent on the time of ischemia. The reasons for these contradictory 
results are unclear, but may be related to species differences, degree of anoxia used and 
different apoptosis assays used.  
 
In general, the above studies may suggest that apoptosis is either triggered or accelerated 
during reperfusion. The fact that apoptosis is an energy dependent process and ATP levels 
are depleted during ischemia and replenished on reperfusion may explain why apoptosis 
might be triggered and accelerated with reperfusion (Leist et al., 1997, Freud et al., 2000). 
This raises the importance of adjunctive therapy introduced during reperfusion to limit 
apoptosis and consequently protect myocardium from further injury. 
 
Even though human studies are limited, several reports have documented the occurrence of 
apoptosis in human heart specimens obtained from patients who died following myocardial 
infarction (Olivetti et al., 1996, Saraste et al., 1997). In addition autopsies from patients 
with acute myocardial infarction suggest that apoptosis is the early and predominant form 
of cell death in infarcted human myocardium, and its appearance is accelerated in 
reperfused myocardium (Veinot et al., 1997). The apoptotic cells were significantly more 
numerous in the border zone of the infarcted tissue (Olivetti et al., 1996, Saraste et al., 
1997). This distribution suggests that apoptosis may be in part responsible for extending 
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infarction over time after the onset of reperfusion (Olivetti et al., 1996). Zhao et al., (2001) 
found that myocardial apoptosis in the peri-necrotic myocardium progressively developed 
during the reperfusion period and was consistent with extension of infarction size and 
attenuation of contractile function. Later Zhao et al., (2003) found that inhibition of 
apoptosis during reperfusion was associated with a reduction in infarction size and 
improvement in contractile function. These two studies suggested that apoptosis may 
exacerbate myocardial injury. Therefore, these studies highlighted the importance of 
reducing apoptosis which will limit infarction extension and preserve myocardial function. 
 
Even though the above studies showed the significance of apoptosis, the relationship 
between apoptotic and necrotic cell death during ischemia reperfusion injury is another 
unresolved problem in the literature. It has been shown that these two forms of cell death 
occur simultaneously during the reperfusion phase (Zhao et al., 2001). The anti-apoptotic 
proteins Bcl-2 and Bcl-xL effectively retarded the chemical hypoxia-induced necrotic cell 
death (Shimizu et al., 1996). The necrotic cell death is also retarded by inhibitors of ICE (-
like) proteases, including interleukin-1beta converting enzyme (ICE), which are common 
mediators of apoptosis (Shimizu et al., 1996). In addition pharmacological inhibition of 
apoptosis using caspase inhibitors (apoptosis excutioners) resulted in attenuation of both 
apoptotic and necrotic cells (Yoita et al., 1998, Mocanu et al., 2000, Zhao et al., 2003). 
These results suggest the possibility of cross-talk between the two forms of cell death and 
they may share common molecular pathways (Shimizu et al., 1996). Therefore Gottlieb & 
Engler (1999) reported that the the distinction between apoptosis and necrosis is blurred in 
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the case of a pathologic insult such as ischemia-reperfusion injury and suggested that it is 
more useful to view cell death in the context of whether or not it can be prevented. 
1.3 Caspase (the executioners of apoptosis) 
 
Caspase (Cystine aspartate specific Proteinase) represent the downstream effectors and the 
executionary machine of apoptosis (Cryns & Yaun, 1998). The idea that caspase activation 
is necessary and sufficient for apoptotic cell death is based on the observation that the 
caspase product of the CED-3 gene is essential for all the developmental programmed cell 
deaths in the nematode worm Caenorhabditis elegans (Thomberry et al., 1992). Yaun et 
al., (1993) showed a homology between CED-3 product and interleukin-1β-converting 
enzymes (ICE, Caspase-1). More recently researchers have identified other caspase of the 
large family of mammalian CED-3/ICE-like proteases (Thornberry & Lazebnik, 1998). 
Currently there are about 14 known caspase (Nicholson, 1999). They exist within the cell as 
inactive pro-forms or zymogens. These zymogens can be cleaved to form active enzymes 
following the induction of apoptosis (Cryns & Yaun, 1998).  
 
Caspase constitute a family of cysteine proteases that cleave their substrates after aspartic 
acid residue (Nicholson, 1999). The inactive caspase (zymogenes) composed of a large and 
a small subunit preceded by a variable length N-terminal prodomain (Nicholson, 1999). 
Both the large and the small subunits, which together make up the active form of the 
enzyme, are liberated from the zymogen through proteolysis at specific Asp residues 
residing between the prodomain, long and short subunits. This proteolysis results in 
activation of caspase via exposure of the active sites. Crystallographic studies showed that 
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the active caspase is a tetramer of two heterodimers, thus containing two active sites 
(Nicholson, 1999). Active caspase recognize a very short tetrapeptide (P1,P2,P3,P4) 
sequence within targeted substrate polypeptides and these motifs have formed the basis for 
substrate specificity as well as specific peptide inhibitors for caspase (Nicholson, 1999). 
 
The caspase implicated in apoptosis can be divided into two functional subgroups based on 
their known or hypothetical roles in the apoptotic process: initiator caspase (caspase-2, -8, -
9, and -10) and effector caspase (caspase-3, -6, and -7) (Enari et al., 1996). Usually, 
initiator caspase, once activated, will activate the downstream effector caspase in a cascade-
like pattern (Slee et al., 1999). The effector caspase are responsible for the cleavage of the 
key cellular proteins that leads to the typical morphological changes observed in cells 
undergoing apoptosis (Fan et al., 1999). 
1.4 Caspase activation pathways 
 
There are a number of pathways through which caspase can be activated in cells and 
eventually commit cells to apoptosis. The well studied pathways in cardiomyocytes involve 
death receptor pathway (extrinsic pathway) and the mitochondrial pathway (intrinsic 
pathway) (Gill et al., 2002). 
1.4.1 Death receptor pathway (extrinsic pathway) 
 
Death receptors are cell surface receptors that transmit apoptosis signals initiated by 
specific ligands (Ashkenazi & Dixit, 1998). These receptors include tumour necrosis factor 
receptor 1 (TNFR1, also called p55 or CD120a), Fas (CD95 or Apo1), death receptor 3 
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(DR3), death receptor 4 (DR4) and death receptor 5 (DR5). The binding of TNFα, FasL 
(FAS-Ligand) and TRAIL (TNF-related apoptosis-inducing ligand) to their receptive 
receptors initiates signal transduction pathways that result in the induction of apoptosis 
(Muzio et al., 1996). These death receptors contain death domain (DD) in their cytoplasmic 
portion (Chinnaiyan et al., 1995). The death receptors interact via their DD with 
intracellular DD- containing adapters, such as FADD (Fas-associating protein with DD) 
and TRADD (TNF receptor associated DD) and recruit these adapters to the cell membrane 
(Chinnaiyan et al., 1995, Hsu et al., 1999), Figure 1.1. Thus, binding of Fas ligand to the 
Fas receptor leads to clustering of the Fas receptor’s DD. The adapter, FADD, binds 
through its own DD to the clustered receptor DD. FADD also contains a ‘death effector 
domain’ (DED) that binds to an analogous domain within procaspase-8 protein. Upon 
recruitment by FADD, procaspase-8 oligmerisation drives its own activation to caspase 8 
through self cleavage (Yue et al., 1999), Figure 1.1. Caspase 8 can activate other effector 
caspase either directly or through activating the mitochondrion-mediated pathway by 
truncating Bid (a pro-apoptotic Bcl-2 family member), a kind of proapoptotic protein in the 
cytosol, into its active form, tBid. tBid will trigger the activation of the mitochondrion 
pathway and apoptosis is induced (Li et al., 1998), Figure 1.1. The activation pathway 
mediated by procaspase-10, with a DED-containing prodomain, is similar to that mediated 
by procaspase-8. Caspase-10 functions mainly in the apoptosis of lymphoid cells (Wang et 
al., 2001). 
 
The involvement of the receptor death pathway in cardiomyocyte death during ischemia 
reperfusion injury is supported by studies that report expression of Fas and Fas ligand in the 
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heart (Tanaka et al., 1994, Yamaguchi et al., 1999). Furthermore, enhanced expression of 
Fas found in association with increased apoptosis in experimental models of myocardial 
infarction (Kajstura et al., 1996) and hypoxia (Tanaka et al., 1994). Similarly, TNF was 
found to be elevated in serum of humans with heart failure (Levine et al., 1990), where 
apoptosis played a significant role (Gill et al., 2002). TNF receptors were also shown to be 
expressed by cardiomyocytes (Krown et al., 1995). However, the role of the death receptor 
pathway in cardiac myocyte apoptosis during ischemia reperfusion injury has been 
controversial. There were some studies demonstrated data suggesting that the CD95/Fas is 
directly involved in cell death after myocardial ischemia using isolated rat heart model and 
primary adult rat cardiomyocytes culture model (Jeremias et al., 2000) and in vivo model 
(Lee et al., 2003). However, Comiz et al., (2005) reported that mitochondrial permeability 
transition rather than activation of Fas plays a pivotal role in cardiomyocyte death after a 
prolonged ischemia-reperfusion insult in mice model. Moreover, mice treated systemically 
with an activating Fas antibody die from massive hepatocyte apoptosis but exhibit no 
cardiac pathology (Ogasawara et al., 1993). These studies raise the possibility that Fas 
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Figure 1.4: Apoptotic death receptor pathways (Fan et al., 2005). 
 
1.4.2 Mitochondrial pathway (intrinsic pathway) 
 
 The intrinsic death pathway is regulated by mitochondrial activity. Mitochondria play an 
important role in the regulation of apoptosis. Not only do they provide the energy essential 
for completion of apoptosis, but they also release important proapoptotic factors into the 
cytosol (Liu et al., 1996, Zamzami et al., 1997). Cytochrome c and AIF (apoptosis-
inducing factor) are released from the mitochondrial intermembrane space in response to 
cell stimulation (Figure 1.2) (Liu et al., 1996). Then cytochrome c directly forms a trimetric 
complex with Apaf-1 in an ATP dependent manner. This complex activates procaspase-9 
resulting in cleavage into caspase 9, which then processes and activates other caspase to 
orchestrate the biochemical execution of cells (Li et al., 1997). The activated caspase-3 will 
then activate pro-caspase-9 and form a positive feedback activation pathway (Fan et al., 
2005) (Figure 1.2). AIF exerts its action directly by stimulating caspase (Zhao et al., 2002). 
Recently a new mitochondrial factor was found to induce apoptosis called second 
mitochondria-derived activator of caspase (SMAC; Due et al., 2000) also known as 
DIABLO (direct IAP-binding protein with low pI) (Verhagn et al., 2000). Upon receiving 
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pro-apoptotic signals, SMAC/DIABLO is released from mitochondria into the cytosol 
where it interacts with IAPs (Inhibitory protein of apoptosis) and abrogates their caspase 
inhibitory activity, thereby potentiating apoptosis. 
 
The involvement of the mitochondrial-cytochrome c mediated pathway in cardiomyocytes 
death during ischemia reperfusion injury is addressed by Bialik et al., (1999). They showed 
that deprivation of serum and glucose, components of ischemia in vivo, resulted in myocyte 
apoptosis (as determined by nuclear fragmentation), internucleosomal cleavage of DNA, 
and processing of caspase substrates. Furthermore, it has been reported that mitochondrial 
cytochrome c release, activation of caspase-3, and PARP cleavage are involved in reactive 
oxygen species-induced cardiomyocyte apoptosis, a situation occurring during ischemia 
reperfusion injury (Von Harsdorf et al., 1999). Kang et al., (2000) showed that during 
reoxygenation of adult rat ventricular myocytes, cell death occurred predominantly via 
apoptosis associated with appearance of cytosolic cytochrome c and activation of caspase-3 
and -9. These results suggest that apoptosis predominates in cardiomyocytes after 




Figure 1.2 Apoptotic mitochondrial pathway (adapted from Fan et al., 2005) 
The mitochondrial proapoptotic factors reside in mitochondrial intermembrane space 
(Kluck et al., 1997), therefore a releasing mechanism is required. Two mechanisms have 
been suggested; the first one involves formation of a large channel in the outer 
mitochondrial membrane, due to oligemirisation of certain Bc1-2 homologous proteins 
(Gross et al., 1998). Opening of the mitochondrial permeability transition pore (mPTP) is 
the second mechanism (Hunter & Haworth, 1979, Kromeor et al., 1998). The mPTP refers 
to the massive swelling and depolarization of mitochondria due to opening of a non-
specific pore in the inner mitochondrial membrane, known as mitochondrial permeability 
transition pore (mPTP) (Halestrap et al, 2002). The exact molecular composition of mPTP 
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is still under debate (Halestrap et al., 2002). However, several studies describe it as a non-
selective pore formed at the site of contact between the mitochondrial inner and outer 
membrane, and that the pore consists of a complex of the adenine nucleotide translocator 
(ANT), the mitochondrial voltage-dependent anion channel (VDAC), cyclophidine D, 
creatine kinase and possibly other proteins (Crompton 1999, Halestrap et al., 2002, 2004). 
Several studies have shown that mPTP opens during reperfusion and not during ischemia 
(Crompton et al., 1987, Griffith & Halestrap, 1995, Halestrap et al., 2004). The probability 
of inducing the mPTP opening increased by the same factors that prevail in the setting of 
reperfusion injury. Pharmacological inhibition of mPTP is shown to be cardioprotective 
(Nazareth et al., 1991, Griffiths & Halestrap 1993, Kroemer et al., 1998). There is 
increasing evidence that almost any procedure that reduces reperfusion injury is associated 
with either a decrease in mPTP opening, or an increase in subsequent pore closure 
(Hausenloy et al., 2002, Halestrap et al., 2004). 
Recently, a new pathway has been involved in apoptosis induction which is the 
endoplasmic reticulum (ER) stress-induced apoptotic pathway (Fan et al., 2005). Following 
ER stress, leakage of Ca2+ from ER stores into the cytosol may have serious deleterious 
consequences. Irregular Ca2+ concentrations activate the Ca2+ dependent protease, calpain 
which is thought to process caspase-12 which then processes and activates other caspase to 
induce apoptosis. In addition, Ca2+ is the principle trigger of Mitochondrial Permeability 
Transition Pore (MPTP) opening (Duchen, 2000), which then initiates mitochondrial 




Figure 1.3 Endoplasmic reticulum (ER) stress-induced apoptotic pathway (adapted 
from Fan et al., 2005) 
 
From the above discussion, we can see a cross talk between the three pathways through 
their convergence at caspase 3 activation and through Bid as shown in Figure 1.3. 
1.5 Caspase substrates during apoptosis 
The enzyme poly (ADP-ribose) polymerase, or PARP, is an abundant nuclear protein. 
PARP is involved in repair of DNA damage and functions by catalyzing the synthesis of 
poly (ADP-ribose) and by binding to DNA strand breaks and modifying nuclear proteins. It 
was the first protein identified as a substrate for the executioner caspase 3 and 7 (Smulson 
et al., 2000). The ability of PARP to repair DNA damage is prevented following cleavage 
by caspase and eventually DNA degradation will ensue (Smulson et al., 2000). DNA 
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topoisomerase II is a nuclear enzyme essential for DNA replication and repair. Caspase can 
also inactivate this enzyme leading to DNA damage (Haung et al., 2003).  
The fragmentation of DNA into nucleosomal units - as seen in DNA laddering assays of 
apoptosis is caused by an enzyme known as CAD (caspase activated Deoxyribonuclease) 
(Enari et al., 1998, Mukae et al., 1998). Normally CAD exists as an inactive complex with 
ICAD (inhibitor of CAD, also known as DNA fragmentation factor45). During apoptosis, 
caspase-9 damages the nuclear pores in an unknown fashion, so that caspase-3 can enter the 
nucleus to cleave ICAD (Fan et al., 2005). This will result in CAD release and rapid 
fragmentation of the nuclear DNA follows (Sakahira et al., 1998). 
Lamins are intra-nuclear proteins that maintain the shape of the nucleus and mediate 
interactions between chromatin and the nuclear membrane. Degradation of lamins by 
caspase 6 results in the chromatin condensation and nuclear fragmentation commonly 
observed in apoptotic cells (Ruchaud et al., 2002). Fodrin is an essential nuclear and 
cytosolic skeleton and its cleavage by caspase-3 results in apoptotic body formation during 
apoptosis (Fan et al., 2005). Communal et al., (2002) also showed that caspase-3 cleaved 
myofibrillar proteins such as troponin T and actin, resulting in impaired force production 
and myofibrillar ATPase activity and eventually impaired myocardial contractile function.  
Activation of caspase during apoptosis collectively results in a series of changes including 
further positive feedback activation of more caspase, DNA damage, decrease in DNA 
repair ability, cytoskeleton disassembly and chromatin condensation. The cell inevitably 
undergoes apoptosis. Therefore, caspase activation has been viewed as the “point of no 
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return” (Golstein, 1997) and inhibition of caspase could provide a valuable therapeutic 
approach in diseases where apoptosis play a significant role such as myocardial ischemia 
reperfusion injury. 
1.6 Endogenous Caspase regulators and inhibitors 
Endogenous caspase inhibitors have been identified that regulate caspase activity such as 
cFLIP (cellular FLICE-inhibitory protein), IAP (inhibitory apoptosis protein) and ARC 
(apoptosis repressor with caspase recruitment domain) (Gill et al., 2002, Fan et al., 2005).  
As mentioned earlier Bc1-2 family proteins also played an important role in regulating the 
mitochondrial pathway of activating caspase. According to functional and structural 
criteria, the Bc1-2 members can be divided into two groups (Fan et al., 2005). Group I 
proteins are all anti-apoptotic proteins such as Bcl-2 and Bcl-xL. The mechanism of their 
anti-apoptotic functions is via inhibition of proapoptotic proteins of the Bcl-2. Group II 
proteins are all proapoptotic proteins such as Bad, Bak Bax, Bcl-xS, Bid, Bik, and Bim. 
After apoptosis induction, Bax and Bak can translocate to the mitochondrial outer 
membrane where they undergo conformational changes, oligomerization and insertion into 
the mitochondrial outer membrane and eventually initiate the mitochondrial pathway as 
mentioned earlier. These proteins are involved in the setting of ischemia reperfusion injury 
where reactive oxygen species increase the expression of proapoptotic Bad and elicit 
translocation of Bax and Bad to the mitochondria, resulting in cytochrome c release, 
activation of caspase-3, and cleavage of PARP (von Harsdorf et al., 1999). In addition 
overexpression of Bcl-2 in ventricular myocytes prevents apoptosis (Kirshenbaum et al., 
1997). Furthermore, cardioprotection by preconditioning (Transient non-lethal episodes of 
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myocardial ischemia and reperfusion confer protection against a subsequent lethal episode 
of prolonged myocardial ischemia) was found to be mediated through up-regulation of the 
antiapoptotic Bcl-2 pathway (Maulik et al., 1999). 
Calcium (Ca2+) plays an important signaling role during apoptosis. It is well established that 
changes in intracellular Ca2+ are associated with reperfusion injury and apoptosis as 
discussed earlier. Numerous Ca2+-regulated effectors have been identified such as 
Ca2+/calmodulin-regulated phosphatase calcineurin, which promotes apoptosis through 
dephosphorylation of Bad, which then translocates to the mitochondria and effect 
cytochrome c release (Wang et al., 1999). Ca2+-dependent cysteine protease calpain is 
another regulatory protein. It is generally believed that calpain is activated in both necrosis 
and apoptosis (McGinnis et al., 1999). Procaspase-12 activation is thought to be dependent 
on Ca2+ and calpains (Mandic et al., 2003). Calpains also reported to cleave Bax, promoting 
its proapoptotic activity (Wood &Newcomb, 2000). In addition, calpains can also cleave 
Bid to an active fragment capable of mediating cytochrome c release and promoting 
apoptosis (Chen et al., 2001). Calpain was found to first cleave procaspase-3 into 29 kDa 
fragments to facilitate its further cleavage and activation in the brain cells of rats suffering 
from unilateral hypoxia-ischemia (Blomgren et al., 2001). Furthermore caspase-3 shares 
many common substrates with calpains including fodrin and PARP (Wang, 2000). 
Pharmacological inhibition of calpains has been found to reduce myocardial infarction size, 
apoptosis and improve function during ischemia repefusion injury (Yoshida et al., 1995, 
Khalil et al., 2005,). 
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1.7 Synthetic caspase inhibitors and myocardial ischemia reperfusion injury 
Several caspase have been shown to be activated in the heart in response to ischemia 
reperfusion stimuli (Holly et al., 1999) and their activation has been accelerated with 
reperfusion (Black et al., 1998, Vanden Hoek et al., 2002). The use of synthetic caspase 
inhibitors showed promising results in different studies of myocardial ischemia reperfusion. 
Broad spectrum caspase inhibitors significantly reduced myocardial infarct size (Yaoita et 
al., 1998, Holly et al., 1999, Mocanu et al., 2000), which has been attributed to reduced 
apoptotic cell death. Specific caspase inhibitors also showed significant reduction in 
apoptotic cell death, however, their effect on reducing infarct size was different between 
studies. Okamura et al., (2000) found that administration of caspase-1 and caspase-3 
inhibitors 5 minutes before ischemia resulted in significant reduction in apoptotic cell death 
without significant change in infarct size. In contrast Mocanu et al., (2000) found a 
significant reduction in infarct size after using broad spectrum caspase inhibitor (ZVAD) 
and caspase 8, 9 and 3 inhibitors, which were added at the time of reperfusion. This 
discrepancy in results could be attributed to differences in timing of administration of the 
caspase inhibitors.  
The effect of delayed administration of caspase inhibitors after starting reperfusion on 
myocardial damage is still not known. This delayed administration is clinically more 
feasible as patients are usually presented to hospital after the onset of ischemic attack. 
Furthermore spontaneous reperfusion may occur in some patients before any hospital 
intervention due to dislodgment of the thrombus or relieved coronary spasm (Christian et 
al., 1998). Therefore investigating the potential therapeutic window of caspase inhibitors 
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after the onset of reperfusion is considered to be important. Caspase inhibitors were found 
to be neuroprotective even when administered 9 hours after reperfusion using a brain 
ischemia/reperfusion model (Fink et al., 1998), while others found that they were 
neuroprotective only when given only at the time of reperfusion (Hara et al., 1997). 
Armstrong et al., (2001) presented an abstract at the American Heart Association showing 
that a caspase inhibitor currently under investigation by scientists at Idun Pharmaceutical, 
Inc. (San Diego, CA), reduced infarct size up to 55% even when administered one hour 
after the heart attack using in vivo rat model. However Li et al., (2001) using isolated adult 
rabbit cardiomyocytes showed that caspase inhibitors (unspecified, labeled with numbers) 
were partially protective if added 15 min after reperfusion and the effect was completely 
lost with a delay of 30 or 60 minutes. This discrepancy could be attributed to the different 
inhibitors used (both used unknown inhibitors identified by numbers) and different models 
used. Therefore further research is needed before applying caspase inhibitors in the clinical 
field. 
The effect of caspase inhibitors on post ischemic functional recovery showed mixed results. 
Some studies showed functional recovery improvement after treatment with caspase 
inhibitors (Kovac et al., 2001, Balsam et al., 2005), where others showed non significant 
change in functional parameters (Perrin et al., 2003, Holly et al., 1999, Mocanu et al., 
2000). This controversy between studies could be attributed to the use of different 
inhibitors, different functional parameters, different ischemia reperfusion models and 
different timing of caspase inhibitors administration.  
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Specificity of synthetic caspase inhibitors should be taken with extreme care even though 
they have been reported to be specific by manufacturing companies. Sufficiency of a P4-P1 
tetrapeptide for caspase recognition and high-affinity binding has been the platform for 
most of the currently available caspase inhibitors (Nicholson, 1999). Virtually, all of the 
current commercially available caspase inhibitors and probes have been designed based on 
the reported optimal substrate specificity profiles for the caspase (Thornberry et al., 1997). 
However, these primary peptide sequences may provide only limited selectivity when used 
in the context of a small molecule inhibitor. Berger et al., (2006) showed that none of the 
inhibitors compounds they tested are highly selective and all exhibit broad inhibition when 
used at high concentrations. Furthermore, they showed that it is possible that other 
“selective” caspase inhibitors designed to target other caspase may demonstrate similar 
cross-reactivity when used at concentrations required for cell-based studies. The similar 
significant cardioprotection offered by the broad spectrum and selective caspase inhibitors 
found by Mocanu et al., (2000) raises the possibility that these compounds might have non-
specific actions. The caspase inhibitors might have an inhibitory effect on other proteases 
implicated in myocardial ischemia reperfusion injury such as calpains. Calpains, which are 
also cysteine proteases and share many common substrates with caspase 3 (Wang, 2000), 
are involved in both necrotic and apoptotic cell death during myocardial ischemia 
reperfusion injury (McGinnis et al., 1999). Calpain inhibitors have also been shown to 
reduce myocardial ischemia reperfusion injury (Perrin et al., 2003, Khalil et al., 2005). In 
addition caspase inhibitors have also been found to efficiently inhibit cathepsin B activity 
in vitro and in tissue culture cells (Schotte et al., 1998, Gray et al., 2001), which is another 
cystein protease enzyme that has already been implicated in some apoptotic models 
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(Guicciardi et al., 2000, Stoka et al., 2001) and myocardial ischemia reperfusion injury 
(Tsuchida et al., 1986). Therefore non-caspase related mechanisms should be considered 
when interpreting the effect of caspase inhibitors.  
In conclusion synthetic caspase inhibitors provide a promising route for development of 
therapies to attenuate reperfusion-induced injury in the heart. However, additional research 
is needed to further investigate the role of caspase inhibitors in reducing myocardial 
damage during reperfusion post ischemic injury before applying them in the clinical field. 
The optimum timing of treatment with caspase inhibitors and whether delayed 
administration of caspase inhibitors will be cardioprotective, is still not known. The long 
term effect of caspase inhibitors is not known yet. Whether caspase inhibition will result in 
long term tissue salvage or only short lived cardioprotection. Their effect on functional 
recovery of the myocardium following ischemia reperfusion is still controversial. The 
underlying mechanism of their action and their specificity is still not cleared by pervious 
investigations. 
1.8 Ischemic preconditioning and postconditioning 
 
Ischemic preconditioning firstly described by Murry et al., (1986), whereby episodes of 
intermittent sublethal ischemia (conditioning ischemia) and reperfusion confer resistance 
against a subsequent lethal episode of myocardial ischemia using dog model. The same 
phenomenon has been described using different animal models (Schott et al., 1990, Liu et 
al., 1991) and also using human models (Walker et al., 1995, Kloner et al., 2002). The 
preconditioning phenomenon reported to have different cardioprotective effects including: 
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reduction in infarct size (Murry et al., 1986), preservation of vascular endothelial function 
(Thourani et al., 1999), decrease in polymorphonuclear neutrophils (PMNs) accumulation 
(Nakamura et al, 2000), and reduction in the appearance of apoptosis (Gottlieb et al., 1996, 
Nakamura et al., 2000). 
 
An overwhelming number of studies have investigated the underlying mechanisms and the 
signalling cascades involved. Knowledge of these signalling cascades is essential to 
understand how various drugs could mimic ischemic preconditioning or interfere with it. 
During the pre-conditioning ischaemia, the heart releases several trigger substances 
including adenosine (Liu et al., 1991), bradykinin (Goto et al., 1992) and opioids (Schultz 
et al 1998). These three ligands occupy their respective receptors (GPCRs) which 
ultimately work in parallel to activate PKC. PKC has long been known to play a central 
role in preconditioning (Ytrehus et al., 1994).The pathway by which each of these ligands 
activates PKC is quite different, as shown in Figure 1.4. Bradykinin and opioid both 
activate osphatidylinositol 3-kinase (PI3K), which causes phosphorylation and activation of 
Akt. Akt phosphorylates endothelial NO synthase (eNOS), causing it to generate NO. NO 
activates soluble guanylyl cyclase (GC) causing it to make cGMP which then activates 
protein kinase G (PKG). PKG acts on mitochondria, causing opening of ATP-
mitochondrial sensitive potassium channel on the inner membrane. Opening of 
mitochondrial ATP-sensitive potassium channel has two known actions: swelling of the 
matrix and generation of reactive oxygen species (ROS). ROS can directly activate PKC. 
Protection from a pulse of bradykinin or opioid can be blocked by co-administration of a 
PI3K inhibitor, eNOS inhibitor, GC inhibitor, mitochondrial ATP-sensitive potassium 
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channel blocker, or a ROS scavenger (Costa et al., 2008). Adenosine mediated 
cardioprotection found also to be mediated through activation of PI3K pathway where it 
appears to have a second coupling to PKC (Costa et al., 2005) as shown in figure 1.4. After 
this triggering phase, an intracellular signalling cascade through activation of PI3K, 
MEK1/2 – erk1/2 and PKC (Hausenloy et al., 2005) finally brings the cell into its protected 
phenotype through convergence on mitochondrial end effectors including ATP-sensitive 
potassium channel (Gross et al., 1992) and the mitochondrial permeability transition pore 
(Hausenloy et al., 2004) which protects the cardiomyocytes against both necrotic and 




Figure 1.4 Simplified siganling pathways of myocardial preconditioning. MMP; 
matrix metalloproteinases; HB-EGF, heparin-binding epidermal growth factor-like 
growth factor; Pro, pro-HB-EGF; PDK, phospholipid-dependent kinase; PI3K, 
phosphatidylinositol 3-kinase; PI4,5P2, phosphatidylinositol bisphosphate; PI3,4,5P3, 
phosphatidylinositol trisphosphate; MEK, mitogen activated protein kinase; ERK, 
extracellular-signal regulated kinase; NO, nitric oxide; NOS, NOS synthase; eNOS, 
endothelial NOS; GC, guanylyl cyclase; PKG, protein kinase G; PKC, protein kinase 
C; KATP, mitochondrial ATP-dependent potassium channel; p70S6K, p70S6 kinase; 
GSK-3b, glycogen synthase kinase-3b; MPT, mitochondrial permeability transition 
(adapted from Costa et al., 2008). 
 
Although, preconditioning has been clinically successful in attenuating the ischemia 
reperfusion injury in setting of percutaneous transluminal coronary angioplasty (Deutsch et 
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al., 1990, Tomai et al., 2001), its practical use in clinical arena is limited by the inability to 
predict the onset of ischemia, which is the case in patients presented with myocardial 
infarction. However, the implementation of cardioprotective therapy at the time of 
reperfusion is clinically more feasible because the onset of reperfusion is more predictable 
and is under the clinician's control. In this respect, the newly described phenomenon of 
ischemic postconditioning, in which the application of intermittent episodes of myocardial 
ischemia and reperfusion at end of the index ischemic period confer a cardioprotective 
effect similar to ischemic preconditioning (Zhao et al., 2003), provides one such 
intervention. 
 
Postconditioning has been shown to reduce infarct size (Zhao et al., 2003), reduce 
endothelial activation, dysfunction and neutrophil adherence (Zhao et al., 2003) and 
significantly reduce apoptotic cell death (Zhao et al., 2005). These cardioprotective effects 
found to be mediated through recruitment of signal transduction pathways as is the case in 
ischemic preconditioning. Recent studies suggest that ischemic postconditioning protects 
the myocardium by activating the PI3K–Akt pathway (Tsang et al., 2004, Bopassa et al., 
2005, Yang et al., 2005) and MEK1/2-erk1/2 pathway (Darling et al., 2005, Yang et al., 
2004) at the time of myocardial reperfusion. Adenosine has been found to be one of the 
triggering mediators for activation of these signalling cascades (Kin et al., 2004). 
Mitochondrial permeability transition pore believed to be the potential end effector 




Figure 1.5. Schematic representation of the key mediators involved in ischaemic 
postconditioning mediated cardioprotection. (Adapted from Tsang et al., 2004). 
 
Although, two clinical studies demonstrated that ischemic postconditioning is an efficient 
cardioprotective intervention for treatment of reperfusion injury in patients with ischemic 
heart disease (Laskey, 2005, Staat et al., 2005), reintroduction of ischemia at the time of 
reperfusion may lead to potential complications (coronary plaque rupture and resultant 
restenosis and emboli) and also it is not clinically feasible during thrombolytic drug 
therapy. However, the concept of "pharmacological postconditioning", where 
pharmacological agents that mimic the effect of ischemic postconditioing by upregulation 
of survival signaling pathways is a more feasible way. Insulin (Jonassen et al., 2001), 
Insulin like growth factor (Parrizas et al., 1997), Urocortin (Brar et al 2000, Schulman et al 
2002), Fibroblast growth factor (Cuevas et al., 1997), Braykinin (Li & Sato, 2001) and 
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adenosine agonists (Schulte & Fredholm, 2000) has been used adjunctively to reperfusion 
therapy. Their cardioprotective effects found to be mediated through upregulation of 
survival signalling pathways, which mimics postconditioning cardioprotective mechanism. 
Therefore it is interesting to investigate whether cardioprotective agents introduced at the 
time of reperfusion exerts their effects through upregulation of the survival signalling 
pathways in a similar mechanism as ischemic postconditioning. 
1.9 Pro-survival Kinase cascades 
 
Several protein kinases have been implicated in the setting of ischemia reperfusion injury, 
which have been involved in both, the upstream induction phase of apoptosis and 
downstream execution phase of apoptosis (Cross et al., 2000). Some kinase pathways play 
a pro-apoptotic role like c-Jun NH2-terminal protein kinase (JNK), while others play a pro-
survival role such as phosphatidylinositol-3-OH kinase (PI3K)–Akt and p42/p44 extra-
cellular signal-regulated kinases (Erk 1/2) (Hausenloy & Yellon, 2004). However the role 
of p38 mitogen-activated protein kinase (MAPK) in apoptosis is a matter of debate. In 
endothelial cells, some researchers have shown that induction of apoptosis by treatment 
with thrombospondin-1 (Jimenez et al., 2000) or high levels of D-glucose (Nakagami et al., 
2001) requires p38 MAPK activity, whereas others have reported that inhibition of 
apoptosis by estradiol is mediated via activation of p38 MAPK (Razandi et al., 2000). 
Therefore there is accumulating evidence that the involvement of p38 MAPK in apoptosis 




The PI3K–Akt signalling cascade is activated in response to the activation of a wide range 
of receptors, including those for growth factors and G-protein-coupled receptors (Cross et 
al., 2000). Signalling through PI3 kinase has been demonstrated to confer protection 
against ischemia–reperfusion injury (Matsui et al., 1999), through its activation of the 
serine–threonine kinase, Akt (Datta et al., 1996). The Erk 1/2 or p42/p44 signalling cascade 
is a member of the mitogen-activated protein kinases (MAPKs), which have been shown to 
be activated in the setting of ischemia–reperfusion, and also can mediate cellular protection 
(Shimizu et al., 1998, Yue et al., 2000). These two pathways have been shown to mediate 
cardioprotection induced by different growth factors and pharmacological agents 
introduced at the time of reperfusion such as Insulin (Jonassen et al., 2001), Insulin like 
growth factor (Parrizas et al., 1997), Urocortin (Brar et al., 2000, Schulman et al., 2002), 
Fibroblast growth factor (Cuevas et al., 1997), Bradykinin (Li & Sato, 2001) and adenosine 
agonists (Schulte & Fredholm, 2000). In addition, the cardioprotection offered by ischemic 
preconditioning is mediated by up-regulation of PI3-Akt and Erk1/2 signalling cascades at 
the time of reperfusion (Hausenloy et al., 2003). Furthermore, the cardioprotection induced 
by post conditioning also found to be mediated by upregulation of these two pathways 
(Hausenloy & Yellon, 2006). Recently, Hausenloy et al., (2004) have proposed a cross talk 
between the PI3K and the Erk1/2 during early reperfusion. They showed that blockade of 
the PI3K activity upregulated ERK1/2 phosphorylation and blockade of ERK1/2 
upregulated Akt phosphorylation. 
 
Most studies suggested that the cardioprotection provided by PI3-Akt and Erk1/2 signalling 
pathways could be attributed to their ability to phosphorylate and inactivate the pro-
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apoptotic proteins. Phosphorylation of BAD (pro-apoptotic protein) by activated PI3-Akt or 
the MEK1/2-Erk1/2 results in its binding to 14-3-3 proteins, which prevent it from binding 
to its mitochondrial target, therefore preventing apoptosis (Zha et al., 1997). In addition 
activation of these pro-survival pathways inhibits the conformational change of Bax (pro-
apoptotic protein) required for its translocation to mitochondria, thereby preventing 
apoptosis (Yamaguchi & Wang, 2001). Another study also showed that inhibition of either 
PI3-Akt or Erk1/2 resulted in an increase in BIM (pro-apoptotic protein) expression 
(Weston et al., 2003). Furthermore activation of the PI3-Akt pathway was found to target 
other proapototic proteins like P53 through phosphorylation of Mdm2 (Mayo & Donner, 
2001). 
 
At the mitochondrial level of apoptosis, PI3-Akt activation was able to inhibit 
mitochondrial cytochrome c release and maintain mitochondrial membrane potential, 
independent of BAD phosphorylation (Kennedy et al., 1999). This could be through 
phosphorylation of eNOS (Balakirev et al., 1997). AKT has been shown to phosphorylate 
eNOS, which will produce nitric oxide, which has been shown to inhibit opening of the 
mPTP (Balakirev et al., 1997). However, recently Davidson et al., (2006) showed that 
activation of the PI3K-Akt pro-survival kinase pathway inhibits opening of the mPTP, and 
demonstrated an important link between the survival kinases and the mPTP. In addition, 
signalling through PI3-Akt pathway has been shown to activate protein kinase C, which 




Downstream at the caspase level of apoptosis, Akt activation has been found to 
phosphorylate and inactivate pro-caspase 9, and thereby inhibiting apoptosis (Cardone et 
al., 1998). Ehardt et al., (1999) found that addition of cytochrome c to cytosol of cells over-
expressing B-Raf (which results in activation of Erk1/2) failed to induce caspase activation, 
which suggest that the B-Raf-MEK/Erk pathway confers protection against apoptosis at the 
level of cytosolic caspase activation, downstream of release of cytochrome c from 
mitochondria. Furthermore Erk1/2 kinase activation in haematopoietic cells was found to 
inhibit apoptosis through inhibition of caspase-3 activation (Terada et al., 2000). 
 
Akt and Erk pathways cardioprotective effects have been shown to be mediated through 
gene expression regulation. Akt phosphorylates and activates IKK-α, which leads to 
activation and translocation of NF-κB, where it acts as a transcription factor for a variety of 
survival pathways (Romashkova &. Makarov, 1999) Akt activation was also found to 
phosphorylate Forkhead transcription factor FKHRL1 by sequestering it in the cytosol and 
preventing FKHRL1-mediated transcription of death inducing genes such as Fas ligands 
(Brunet et al., 1999). Erk activation has been found to phosphorylate p90RSK, which is 
linked to regulation of proteins concerned with genes concerned with cellular survival 
(Bonni et al., 1999). 
 
Therefore, it is apparent that therapeutic interventions which target and activate the PI3-Akt 
and Erk1/2 cell signalling pathways during the early reperfusion phase can be used as an 
adjunct to current reperfusion therapy, and may provide a new therapeutic approach to limit 
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infarction size and maintain myocardial viability in patients presenting with an acute 
myocardial infarction.  
 
Synthetic caspase inhibitors have been shown to be cardioprotective when administered 
during early phase of reperfusion (Haung et al., 2000, Mocanu et al., 2000); however the 
precise mechanism behind their cardioprotection is not yet clear. Caspase can be activated 
by two main pathways, the cell surface death receptors and mitochondrial pathway (for 
details check section 1.4). The caspase inhibitors failed to inhibit cytochrome c release 
from mitochondria as showed by previous studies, which suggests that cytochrome c 
release is upstream and independent of caspase activation (Bialik et al., 1999, de Moissac 
at al., 1999, Suzuki et al., 2001). Therefore, caspase inhibitors mediated cardioprotection is 
not dependent on mitochondrial cytochrome c pathway and an alternative mechanism 
operating at the level of cytosolic caspase activation can be suggested. This theory can be 
supported by the fact that both the broad and the specific caspase inhibitors were effective 
to approximately the same degree (Mocanu et al., 2000), which raised the possibility that 
they might share simillar pathway. As mentioned above cadioprotection by 
pharmacological agents that mimic preconditioning effect and drugs applied during the 
early phase of reperfusion were mediated through activation of PI3-Akt and Erk 1/2 cell 
signalling pathways. Therefore, it appeared that activation of these survival kinase 
pathways may constitute a common survival pathway sufficient to induce a cardio-
protective response during early reperfusion phase (Hausenloy & Yellon, 2004). Caspase 
inhibitors showed a promising cardioprotection when applied during early phase of 
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reperfusion, which could also be hypothesized to be mediated by activation of these cell 
survival pathways. 
 
Wu et al., (2000) showed a novel link between PI3-kinase pathway and suppression of 
caspase 3 activation independent of Bad phosphorylation using cardiac muscle cells. Akt 
pathway also has been found to inhibit caspase mediated apoptosis through direct 
phosphorylation of caspase 9 (Cardone et al., 1998). Furthermore Widmann et al (1998) 
demonstrated that active caspase turn off survival signals by degredation of Akt and other 
signalling proteins using Jurkat and U937 cell model. Therfore caspase inhibitors 
cardioprotection during reperfusion could be hypothesised to be mediated through PI3-Akt 
pathway 
1.10 Experimental models for the study of myocardial ischemia reperfusion injury 
 
In the arena of cardiovascular research, the ultimate aim of the researchers is to improve the 
understanding of the mechanisms underlying normal cardiovascular function and enhancing 
the ability to understand and ameliorate cardiovascular disease. Ischemic heart diseases is 
an increasing worldwide health problem, therefore developing an experimental models to 
study the underlying pathophysiology of ischemia and reperfusion injury, important 
pathways involved in mediating cell death and the efficacy of pharmacological 




In assessing the utility of an investigative model, it is useful to identify the endpoints which 
can be used either as a measure of the normal function of the organ under study or of the 
disease which is afflicting it. In the case of the heart research, the main endpoints are: 1) 
cardiac size, shape and growth, 2) its pump function via a host of hemodynamic, contractile 
or work indices, 3) heart rate, rhythm and electrical activity, 4) biochemistry via substrate 
uptake or the many aspects of cellular metabolism and its regulation, 5) pharmacological 
responsiveness, particularly to drugs influencing contractile, vascular or electrical activity 
and cellular death, 6) ultrastructure, 7) excitation-contraction coupling and ion regulation, 
and 8) the regulation and expression of the genetic machinery of the cell (Hearse & 
Sutherland, 2000). Therefore, the choice of a good experimental model depends on the 
ability to balance between the quality of measured endpoints and their clinical relevance. In 
addition, the choice of the model depends heavily on the problem under examination, and 
the hypothesis that is to be tested. 
 
In general human tissue models are the more clinically relevant, however they are not 
easily available and costly. Results obtained from animal experimental models of the 
ischemic heart have been of tremendous importance in understanding ischemia reperfusion 
injury and contributes significantly to future development of therapeutic interventions. 
Experimental animal models in use for the study of the ischemic heart involve studies on 
the integrated organism, experiments with isolated hearts or multicellular preparation, and 
also studies of cells isolated from the heart. This review will focus on the different animal 
experimental models used in this study and their advantages and disadvantages. 
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1.10.1 Isolated perfused heart-Langendorff perfusion system 
 
Langendorff (1895) was the first one to describe the isolated perfused heart preparation. It 
probably represents the optimal compromise in the conflict between the quantity and 
quality of data that can be acquired from an experimental model and its clinical relevance, 
especially in relation to the modelling of ischemia (Sutherland & Hearse, 2000). The basic 
principle of this model is rapid removal of the heart from the animal and thereafter 
mounting in a langendorff perfusion system with a perfusion solution (i.e. Krebs–
Henseleits bicarbonate buffer gassed with 5% CO2 and 95% O2) that secures a supply of 
energy substrate. It involves the cannulation of the aorta to the langendorff perfusion 
system containing oxygenated perfusion fluid. This fluid is then delivered in a retrograde 
direction down the aorta either at a constant flow rate (delivered by an infusion or roller 
pump) or a constant hydrostatic pressure (usually in the range of 60-100 mmHg). In both 
instances, the aortic valves are forced shut and the perfusion fluid is directed into the 
coronary ostia thereby perfusing the entire ventricular mass of the heart, draining into the 
right atrium via the coronary sinus (Sutherland & Hearse, 2000).The left ventricular heart 
chamber is empty or sparsely filled with fluid, therefore the preparation performs minimal 
external work. Different modes of ischemic conditions can be induced, global ischemia is 
caused by clamping the aortic inflow, hypoxia by reducing oxygen supply to the perfusion 
solution and regional ischemia by a ligature around a coronary artery (Ytreuhs, 2000). 
 
At a practical level, the isolated heart, especially from small mammals, provides a highly 
reproducible preparation which can be studied quickly and in large numbers at relatively 
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low cost. Furthermore, the isolated heart preparation allows experiments to be continued in 
the face of events such as infarction-induced loss of pump function, cardiac arrest or 
arrhythmias, which would normally jeopardise the survival of an in vivo experiment 
(Sutherland & Hearse, 2000). It has been a first-choice model for studies of the metabolic, 
biochemical and cellular consequences of myocardial ischemia through venous effluent and 
myocardial tissue samples (conserved by freeze-clamping in liquid nitrogen) which can 
easily be obtained (Ytreuhs, 2000). These studies can be made in the absence of the 
confounding effects of other organs, the systemic circulation and a host of peripheral 
complications such as circulating neurohormonal factors. This model with the aid of 
conventional histochemistry techniques provides a valuable method to study the ischemic 
effect on infarct size, which represents the ultimate endpoint of the ischemic process 
(Ytreuhs, 2000). 
 
An intraventricular balloon connected to a pressure transducer is used for measurements of 
contractile function. Left ventricular systolic, diastolic, developed pressure and heart rate 
can be recorded. This provides provision of baseline data and helps to monitor the stability 
of the heart and the extent of any disturbances of cardiac rhythm. However the isolated 
heart working langendorff model allows measurement of cardiac output with different 
filling pressures and afterloads which provides more sensitive parameters of contractile 
function (Ytreuhs, 2000). 
 
One of the main disadvantages of isolated heart-langendorff model is that it is a constantly 
deteriorating preparation and able to maintain cellular haemostasis only for limited time. 
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The use of intraventricular balloon might cause ischemia induced necrosis to papillary 
muscle as it is not always well perfused. The perfusion solution is lacking blood cells, 
plasma proteins, growth factors and hormones which lead to changes in vascular function 
independent of the ischemia-induced changes in vascular function. Conventional histology 
for ischemia-induced necrosis is not possible with this model (Ytreuhs, 2000). 
1.10.2 Multicellular tissue model 
 
Multi-cellular preparations are mostly papillary muscle or atria trabecula muscle harvested 
from different species and superfused with buffer. The main endpoints that can be 
measured using this model are contractile force, electrical conduction and enzyme release 
(Ytreuhs, 2000). 
 
The main advantages of this model is when the supply of heart tissue is very limited (an 
important example is the use of human atria trabecula) and also allows expensive molecular 
probes to be used since both tissue size and volume of superfusate are limited (Ytreuhs, 
2000). The disadvantage of this model is spontaneous deterioration of the tissue due to 
inappropriate oxygenation. In some experimental conditions there is a need to use 
temperatures below 37 oC and electrical stimulation rates below the heart rate of the actual 







1.10.3 Cardiomyocyte Model 
 
Cardiomyocytes have been successfully isolated from hearts of all species and maintained 
in suspension for hours. Both suspensions and cultures of cardiomyocytes have been used 
in ischemia reperfusion studies. With cellular model it is almost impossible to create 
conditions similar to ischemia, however ischemia can be simulated by manipulation of the 
incubation buffer, hypoxia, or pelleting and sealing under paraffin. The time course of 
ischemic injury in cell models is usually substantially extended compared to intact tissue 
(Ytreuhs, 2000).  
 
In this model there is a lack of attachment conditions and communication between isolated 
cardiomyocytes and other types of cells and compounds in the interstitium. This creates 
immense difference in living conditions between an isolated myocyte and the same cell as a 
part of an organism. Another disadvantage of this model is that spontaneous deterioration 
of myocytes will always be superimposed on the deterioration caused by simulated 
ischemia (Ytreuhs, 2000). 
 
Using this cellular model, several possible endpoints for quantification of hypoxic cell 
injury and death exists. This model also allows clarifying whether a response to ischemia 
can be pinpointed to a single cell type. In this study, this model used to quantify the 
differential contribution of different types of cell death (apoptosis and necrosis) in response 
to ischemia reperfusion injury. Also this model allowed us to measure the intracellular 
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caspase-3 activity level which further expands our results about cardiomyocytes response to 
ischemia reperfusion injury and pharmacological treatment. 
1.11 Methods to detect apoptosis 
 
In order to evaluate the importance and contribution of apoptosis in different pathological 
diseases, it is critical to be able to quantitatively and qualitatively measure apoptosis. There 
are various approaches currently being used to measure apoptotic cell death based on 
cellular and biochemical changes during apoptosis (Loo & Rillema, 1998). 
1.11.1 Cell morphology 
 
The standard morphological features of apoptosis are best seen by electron microscopy, but 
can be also observed at the light microscopic level using nucleic acid-binding dyes, such as 
haematoxylin, acridine orange, or propidium iodide (Coles et al., 1993, Hall et al., 1994). A 
cell undergoing apoptosis proceeds through various stages of morphological changes. 
These are shrinkage of the cell away from its neighbors, plasma membrane blebbing, 
cytoplasmic and nuclear condensation, non-random cleavage of chromatin, margination of 
chromatin in the nucleus, nuclear fragmentation, and cellular fragmentation into smaller 
apoptotic bodies (Kerr et al., 1972).  Apoptotic bodies are generally phagocytosed by 
surrounding cells. Therefore, the most common sign of apoptosis in a tissue section is the 
presence of apoptotic bodies, which may be seen as extracellular bodies, or, after 
phagocytosis, inside other cells (Wyllie et al., 1984). Apoptotic bodies have a diverse 
appearance, particularly in regard to their size. They are generally oval or round in shape, 
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and are most easily recognised when they contain large amounts of homogeneous, 
condensed chromatin (Kerr et al., 1972). 
 
This method provides the most definitive morphological evidence of apoptosis; however, it 
does not provide quantitative data, and thus is not an appropriate method to quantify 
apoptosis between experimental conditions or over the time course of an experimental 
treatment (Loo & Rillema, 1998). 
1.11.2 DNA fragmentation  
 
During apoptosis the genomic DNA is cleaved into internucleosomal DNA segments by an 
endonuclease selectively activated during apoptosis (Wyllie, 1980). Internucleosomal DNA 
fragmentation appears to be preceded by the formation of larger DNA fragments with 
lengths of 50 and 300 kb (Wyllie, 1980).  Separation of cellular DNA on agarose gels 
shows a characteristic ladderlike pattern of fragments with multiples of 200 bp in length 
(DNA laddering) (Loo & Rillema, 1998). However, this technique is not specific, since 
such analysis requires the extraction of DNA from a large numbers of cells which can be 
contaminated with other non-cardiomyocytes, whose number exceeds cardiomyocyte in 
myocardial tissue (Loo & Rillema, 1998). Therefore, other techniques have been developed 
based on detection of DNA strand breaks (‘3-OH ends). This is done through addition of 
certain enzymes that can add labeled nucleotides to the DNA ends. The labeled nucleotides 
can then be identified by immunological methods akin to immunohistochemistry. One of 
these methods termed TUNEL (terminal deoxynucleotidyl transferase mediated UTP nick 
end labeling). This method utilizes the activity of terminal deoxynucleotidyl transferase 
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(TdT) enzyme to incorporate biotinylated dUTP onto 3’ ends of fragmented DNA (Gavrieli 
et al., 1992). The other method called in situ end labeling (ISEL), which relies on the 
activity of DNA polymerase I to fill in recessed 3’ ends of DNA fragments with 
biotinylated-dUTP (Ansari et al., 1993). These methods are highly sensitive for apoptosis 
detection, however they are not specific. This because ‘3-OH DNA ends is not a unique 
feature of apoptosis and may occur during DNA repair and non-specific DNA damage 
(Eastman & Barry, 1992). Other disadvantage of these methods is that, not all cells 
undergoing apoptosis exhibit measurable internucleosomal DNA fragmentation (Loo & 
Rillema, 1998).  
1.11.3 Cell membrane alterations 
 
In normal cells the distribution of phospholipids is asymmetric with the inner membrane 
containing anionic phospholipids, such as phosphotidyl serine (PS) and the outer membrane 
having mostly neutral phospholipids. In apoptotic cells, the amount of PS on the outer 
surface of the membrane increases exposing PS to the surrounding liquid (Martin et al., 
1995). Annexin V, a calcium dependent phospholipids binding protein, has a high affinity 
for PS. Annexin V binds to PS in the outer membrane of apoptotic cells, thus providing a 
suitable way of detecting apoptosis (Martin et al., 1995). Translocation of PS to the 
external cell surface is not unique to apoptosis, but occurs also during cell necrosis. The 
difference between these two forms of cell death is that during the initial stages of 
apoptosis the cell membrane remains intact, while at the very moment that necrosis occurs 
the cell membrane looses its integrity and becomes leaky. Therefore the measurement of 
Annexin V binding to the cell surface as indicative for apoptosis has to be performed in 
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conjunction with a dye exclusion test to establish integrity of the cell membrane (Vermes et 
al., 1995).  
 
Flow cytometry can be utilized for quantitative analysis of the number of viable, apoptotic 
and necrotic cells by the rate of uptake and retention of certain dyes. Vermes et al., (1995) 
developed a novel assay for apoptosis flow cytometric detection of PS expression on early 
apoptotic cells using fluorescein labelled Annexin V. Simultaneously with dye exclusion 
technique (e.g propidium iodide, PI) and a dye to stain viable cells, this test will enable 
quantitative discriminative measurement of cellular apoptosis, necrosis and viable cells. 
This assay is rapid, however its sensitivity is time dependent and don’t detect early 
apoptotic cells (Vermes et al., 2000). 
1.11.4 Apoptosis induced caspase 
 
Caspase activation is a cellular event associated with the onset of apoptotic death. Detection 
of caspase activity provides a useful assay for analyzing one of the earliest known 
biochemical events associated with apoptosis. Determination of caspase activation can be 
performed in different ways. This includes the analysis of pro-caspase processing using the 
immunoblot technique, analysis of enzyme activity by the cleavage of synthetic substrates, 
affinity labeling of activated caspase and immunoblot analysis of the cleavage of caspase 
substrates (Kohler et al., 2002). Recently a flow cytometry asssays has been developed to 
measure intracellular caspase activity (Komoriya et al, 2000). Caspase-3 is a key effector 
caspase in the apoptosis process. The active caspase-3 proteolytically cleaves and activates 
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other caspase as well as relevant targets in the cell like poly (ADP-ribose) polymerase 
(PARP) in the nucleus as mentioned earlier. Nicholson et al., (1995) have identified the 
tetrapeptide Asp–Glu–Val–Asp (DEVD) as a consensus cleavage site for caspase-3 through 
mapping of the cleavage site of PARP. Based on this information Polyclonal antibodies 
recognizing only the active form of caspase-3 has been developed and formed the basis of 
flow cytometry techniques to demonstrate intracellular caspase-3 activity. These antibodies 
were made against an active human caspase-3 fragment and bind to a conformational 
epitope which is exposed by activation-induced cleavage of pro-caspase-3. By using 
specific caspase-3 fluorogenic substrate, one can demonstrate intracellular caspase-3 by 
flowcytometry (Vermes et al., 2000). 
 
The estimation of activated caspase in whole cells by flow cytometry has the advantage that 
it is possible to identify, and even separate, the quantity of the cells in a population, which 
contain activated caspase. This cannot be achieved by analysis of cell lysates used to 
calculate the total amount of activated caspase in a cell population. Furthermore, it is a 
quantitative method having the advantage of speed and sensitivity with small samples. The 
availability of a reliable antibody is the main limiting factor in this method (Kohler et al., 
2002). 
 
As seen above, there are a lot of methods that can be used to detect apoptosis; however, 
none of them can be considered as highly specific and sensitive. Therefore combination of 
more than one method is advised to achieve high accuracy in measuring apoptosis. The 
choice will depend on the experimental model, on cell type and researcher experience. In 
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addition it is important to apply a rigorous quantitation process through out the intended 








1. To determine whether the broad spectrum caspase inhibitor (ZVAD) and specific 
caspase 3 inhibitor (DEVD) when administered at different time points during 
reperfusion (at the start of reperfusion, 15 minutes, 30 minutes and 60 minutes after 
starting reperfusion) protects the myocardium from ischemia reperfusion injury 
using the Langendorff ischemic-reperfused heart model.  
 
2. To determine whether the broad spectrum caspase inhibitor (ZVAD) and specific 
caspase 3 inhibitor (DEVD) can attenuate apoptosis, necrosis and caspase-3 activity 
when administered at different time points during reoxygenation (at the start of 
reoxygenation, 15 minutes, 30 minutes and 60 minutes after starting reoxygenation) 
using the Isolated adult rat ventricular myocytes model of ischemia and reperfusion.  
 
3. To determine whether PI3-Akt cell survival pathway is involved in the 
aforementioned caspase inhibitors mediated cardioprotection using a specific Akt 
inhibitor (Wortmanin).  
 
4. To determine whether the broad spectrum caspase inhibitor (ZVAD) and specific 
caspase 3 inhibitor (DEVD) can still attenuate apoptosis, necrosis and caspase-3 
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activity after an extended period of  reoxygenation (36 hrs) using the isolated adult 
rat ventricular myocytes model of ischemia and reperfusion.  
 
5. To determine whether the administration of broad spectrum caspase inhibitor 
(ZVAD) and specific caspase 3 inhibitor (DEVD) at reperfusion can improve post 
ischemic functional recovery of isolated adult rat papillary muscles when using the 
work-loop technique to measure power output. 
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CHAPTER 3  
 




Adult male Sprague-Dawley rats (350 ± 100 g body mass; mean ± SD) were used in these 
experiments. All animals were originally purchased from Charles River Laboratories 
(Wilmington, UK) then were kept and received human care at Coventry University Animal 
House (Coventry, UK). They were handled in compliance with the home office Guidance 
on the Operation of Animals (Scientific Procedures) Act 1986. 
3.2 Chemicals and drugs 
Chemicals used to prepare Krebs Henseleit buffer and triphenyltetrazolium chloride (TTC) 
used to stain the infarction were purchased from Sigma-Aldrich chemicals (Poole, UK). 
Cell permeable Caspase inhibitors were purchased from Calbiochem (Nottingham, UK). 
ZVAD-fmk (ZVAD) is a broad spectrum, non-selective and irreversible caspase inhibitor. 
Ac-DEVD-CMK (DEVD) is an irreversible inhibitor of caspase-3. Wortmannin (WORT) 
(Tocris, Bristol, UK) is a potent, selective, cell-permeable and irreversible inhibitor of 
phosphatidylinositol 3-Akt (PI3-Akt). Each inhibitor was dissolved in dimethylsulphoxide 
(DMSO) and aliquots were frozen at -20 oC. Aliquots were then diluted in Krebs Henseleit 
buffer immediately before use to a final concentration of 0.1-25μm for ZVAD, 0.07-25μm 
for DEVD (Mocanu et al., 2000, Kang et al., 2000) and 100nM for Wortmannin. The final 
concentrations of the DMSO in the final buffer solution did not exceed 0.02%, a 
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concentration which has previously been shown to have no effect on cardiac function or 
infarct size (Mocanu et al., 2000). 
3.3 Krebs Henseleit Buffer (KHB) 
 
Hearts were perfused with KHB, which mimics the ionic content of blood or plasma (Krebs 
& Henseleit, 1932). The KHB was composed of (in mM):  NaCl 118.5, NaHCO3 25.0, KCL 
4.8, MgSO4 1.2, KH2PO4, 1.2, CaCl2 1.7, and glucose 12. The buffer was prepared freshly 
each day and was continuously bubbled with 95% oxygen and 5% carbon dioxide. The 
temperature maintained at 37 oC and pH at 7.4-7.5. 
3.4 Langendorff heart reperfusion studies 
 
In the Langendorff perfusion studies, the heart aorta is cannulated and perfused in a 
retrograde fashion (Langendorff, 1895). In this mode the aortic valves are forced shut 
because of the weight of the perfusate column, and the perfusion fluid is then directed into 
the coronary arteries, thereby perfusing the entire ventricular mass of the heart. 
3.4.1 Heart Isolation 
 
Rats were killed by cervical dislocation, and then transferred to the dissecting table. The 
neck was immediately cut to relieve pressure on the heart via blood drainage from carotid 
arteries. The thoracic diaphragm was accessed through a trans-abdominal incision and was 
then dissected to expose the thoracic cavity. The anterior chest wall was then reflected and 
removed to expose the heart. The heart was then isolated by cutting the aorta, vena cava 
and pulmonary vessels. The heart was then immediately immersed into a dish containing 
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ice-cold KHB. Thereafter, the heart was quickly cannulated via an aortic cannula attached 
to the Langendorff perfusion system. 
3.4.2 Langendorff perfusion system 
 
In this perfusion system, the heart aorta was cannulated via an aortic cannula which was 
then attached to a reservoir containing oxygenated KHB (Figure 3.1) at a height of 0.8 m. 
The Langendorff perfusion system and the heart chamber are jacketed by warm water to 
maintain the temperature at 37 oC. 
 
Figure 3.1: Langendorff perfusion system (adapted from Sutherland & hearse, 2000) 
 
The heart was perfused retrogradely through the aorta using oxygenated KHB. The KHB 




forced closed and the perfusion fluid was directed into the coronary arteries and thereby 
infusing the entire ventricular mass and then drained into the right atrium via the coronary 
sinus.  
Once the cannulation was completed, the left atrium was cut away and a latex balloon was 
inserted into the left ventricle. The balloon was inflated with water to give a preload of 4-8 
mm Hg. The balloon was then attached to a physiological pressure transducer and a bridge 
Amp connected to a power lab (ADI Instruments, UK). Once the balloon was in position, 
left ventricular systolic developed pressure and heart rate were measured. 
3.4.3 Measured haemodynamic parameters 
 
Once the procedure of heart cannulation was completed, the coronary perfusion was started 
and contractile function of the heart was started within a few seconds. Heart rate (HR) and 
left ventricular developed pressure (LVDP) were measured using the latex balloon inserted 
into the left ventricle. Coronary flow (CF) was measured by collecting the perfusate at a 
regular time interval into a graduated cylinder. Temperature of the heart was continuously 
measured and maintained at 37 oC. 
3.4.4 Inclusion/exclusion criteria 
 
A set of exclusion criteria were used to ensure experimental reproducibility: 
• LVDP at the end of stabilisation priod < 90 mmHg 
• CF at the end of stabilisation period < 5 ml/minute or > 25 ml/minute 
• HR at the end of stabilisation period < 290 beats /minute 
• Failure to revert arrhythmia within 5 minutes. 
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3.4.5 Experimental protocol 
 
Hearts were allowed to stabilize for 20 minutes before exposure to regional ischemia for 35 
minutes. Regional ischemia was induced by occluding the left main coronary artery. This 
was done using a threaded surgical needle passed under the artery, with the ends of the 
thread passed through small plastic tubes to form a snare (Figure 3.2). Ischemia was 
induced by tightening the snare and was confirmed by a decrease in LVDP and coronary 










Figure 3.2: Photograph showing surgical thread passed under the left main coronary 
artery, with the ends of the thread passed through small plastic tubes to form a snare. 
Ischemia was induced by tightening the snare 
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The hearts were allocated to one of the experimental groups as shown in Figure 3.3 (n=5 



























Figure 3.3: Illustrative diagram showing the experimental protocol. Control ischemic 
hearts were stabilised for 20 minutes before being exposed to 35 minutes regional 
ischemia, followed by 120 minutes perfusion with normal KHB. Treatment groups, 
hearts were treated with either broad spectrum caspase inhibitor (ZVAD, 0.1µM) or 
specific caspase-3 inhibitor (DEVD, 0.07µM) in the presence and absence of PI3-Akt 
specific inhibitor (WORT, 100nM). Treatments were introduced at different time 
points during reperfusion, at the start of reperfusion, 15 minutes, 30 minutes and 60 


























































3.4.6 Infarct size measurement 
 
At the end of the 120 minutes reperfusion period, the snare was tightened to re-occlude the 
coronary artery. Evans blue solution (0.25%) was infused slowly into the aorta to delineate 
the non-ischemic zone of the myocardium as a dark blue area (Figure 3.4). After freezing at 
-20 0C, hearts were sliced into 1 mm-thick transverse sections and incubated in 
triphenyltetrazolium chloride solution (1% phosphate buffer, pH 7.4) at 37 0C for 15 
minutes. The sections were then fixed overnight in 10% formalin. At the end of this 
procedure, the risk area stained red or pink and the infarcted tissue appeared pale (Figure 
3.5). The slices were then drawn onto acetate sheets. Computerized planimetry (ImageTool 
version 3.1, Rockford, USA) was used to measure the areas of infarcted tissues and risk 
area. The Infarction/Risk ratio (I/R %) was calculated as total infarcted tissue/total risk area 
x 100 for each heart. 
 
Figure 3.4: Photograph showing infused Evans blue solution into the aorta to 
delineate the non-ischemic zone of the myocardium as a dark blue area and risk zone 





Fig 3.5: Heart slice showing the infarcted pale area and pinkish risk area after 
staining with triphenyltetrazolium chloride (TTC). 
3.5 Western blot studies 
3.5.1 Tissue Isolation 
 
Adult male Sprague-Dawley rats (350 ± 100 g body mass; mean ± SD) hearts were isolated 
as described earlier (section 3.4.1), then quickly cannulated and perfused retrogradely with 
KHB using Langendorff perfusion system (section 3.4.2). At the end of reperfusion period, 
the snare was tightened to re-occlude the coronary artery. The hearts were then perfused 
with 0.25% Evans Blue via the aorta to delineate the non-ischemic zone of the myocardium 
which stained blue, and the risk zone, stained pink (Figure 3.4). Risk areas were separated 








3.5.2.1 Cytochrome-c analysis 












Figure 3.6: Illustrative diagram showing the experimental protocol for cytochrome-c 
analysis using western blot. Basal control hearts were perfused with normal KHB for 
120 minutes. Control ischemic hearts were stabilised for 20 minutes before being 
exposed to 35 minutes regional ischemia, followed by 120 minutes perfusion with 
normal KHB. Treatment groups, hearts were treated with either broad spectrum 
caspase inhibitor (ZVAD, 0.1µM) or specific caspase-3 inhibitor (DEVD, 0.07µM). 
Treatments were introduced at different time points during reperfusion, at the start of 
reperfusion, 15 minutes, 30 minutes and 60 minutes after starting reperfusion. At the 
end of the experimental protocol, risk areas were separated from the heart using a 
sharp sterile scalpel, then frozen in liquid nitrogen and stored at -80°C for later 
western blot analysis. (n=5 each group).           Drug treatment 
Control 
Basal 


































































3.5.2.2 Phospho-Akt analysis 
Figure 3.7: Illustrative diagram showing the experimental protocol for phosphor PI3-
Akt analysis using western blot. Basal control hearts were perfused with normal KHB 
for 120 minutes before tissue isolation. Control ischemic hearts were stabilised for 20 
minutes before being exposed to 35 minutes regional ischemia, followed by 5, 10, 20 or 
120 minutes reperfusion with normal KHB before tissue isolation. Treatment groups, 
hearts were treated with either broad spectrum caspase inhibitor (ZVAD, 0.1µM) or 
specific caspase-3 inhibitor (DEVD, 0.07µM) for 5, 10, 20 or 120 minutes reperfusion 
before tissue isolation. PI3-Akt inhibitor (Wortmannin, WORT, 100nM) treated 
groups in the presence or absence of caspase inhibitors (ZVAD/0.1 µM, 
DEVD/0.07µM) perfused for 10 minutes before tissue isolation.   Indicates time of 
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3.5.3 Mitochondrial and Cytosolic Protein Isolation  
 
Mitochondrial and cytosolic proteins were isolated using a method previously described by 
Iwai et al (2002). Frozen tissue from the risk area was homogenized (Ultra-Turrax–T25 
Basic ,IKA - WERKE) in ice cold isolation buffer (in mM: Mannitol 210, Sucrose 70, 
EDTA 1, DTT 10, PMSF 0.5, Protease inhibitor cocktail 1.5 tab and Cyclosporine 0.1 µM, 
pH 7.4). Cyclosporine (Tocris, Bristol, UK) was included in the isolation buffer to reduce 
the permeability transition pore opening during protein isolation (Bouutaite et al., 2002). 
 
The homogenized tissue was then centrifuged (Jouan HS centrifuge, UK) at 900 x g for 10 
min at 2 0C. The supernatant was then decanted into fresh pre-chilled tubes and then 
centrifuged at 8000 x g for 30 min at 2oC.  
 
The resulting supernatant was the cytosolic fraction, which was then decanted off and 
centrifuged at 100,000 x g (Sorvall ultra centrifuge, UK) for 30 min at 2oC to pellet any 
mitochondrial proteins. 2 x 5 µl aliquots were taken for an assay of protein concentration 
(section 3.5.5). The cytosolic fraction was assayed for citrate syntahse (section 3.5.6). The 
remaining supernatant was then further diluted 2x in sample buffer (Tris-HCL 250 mM, 
SDS 4%, Glycerol 10%, Bromophenol blue 0.006%, ß-mercaptoethanol 2%, pH 6.8) and 





The mitochondrial pellet was resusupended with ice cold isolation buffer (in Mm, Mannitol 
210, Sucrose 70, TRIS 10, pH 7.4). The mitochondrial pellet was broken down by multiple 
freeze thaw cycles using liquid nitrogen. 2 x 5 µl aliquots were taken for protein 
concentration assay (section 3.5.5). The remaining solution was diluted with 2 x volume 
sample buffer and stored at -20oC for later electrophoresis (section 3.5.7). 
3.5.4 Protein isolation for phospho Akt analysis 
 
The frozen risk area tissue was homogenized (Ultra-Turrax–T25 Basic ,IKA-WERKE) in 
ice-cold lysis buffer (in mM NACL 100, TRIS 10, EDTA 1, (pH 8.0), Sodium 
Pyrophosphate 2, Sodium Floride 2, ß-Glycerophosphate 2, PMSF 0.1 mg/ml and protease 
inhibitor cocktail tablets). The homogenised sample was then centrifuged (Jouan HS 
centrifuge, UK) at 11,000 rpm, and 4°C for 10 minutes. 2 x 5 µl aliquots were taken for 
protein concentration assay (section 3.5.5). The remaining supernatant was then further 
diluted in 2x volume sample buffer and subsequently boiled for 10 min at 100oC before 
storage at -20oC for later electrophoresis (section 3.5.7). 
3.5.5 Sample protein concentration determination 
 
The bicinchoninic acid (BCA TM) protein assay kit (Perbio Science, Cramlington, UK) was 
used to determine sample protein concentration. The principle of the assay relies on the 
formation of a Cu2+-protein complex under alkaline conditions, followed by reduction of 
the Cu2+ to Cu1+ as shown below: 
Protein (peptide bonds) + Cu 2+  tetradentate-Cu1+ complex 
Cu1+ + 2 bicinchoninic acid (BCA)  BCA-Cu1+ complex 
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The amount of reduction is proportional to the protein present.  BCA forms a purple-blue 
complex with Cu1+ in alkaline environments, which can be measured by optical 
densitometry at 562 nm (Smith et al., 1985). The relationship between the absorbance at 
562 nm and protein content is linear over a wide concentration range (20-2000µg/ml); 
therefore the protein content of the samples can be estimated through comparison with a 
standard curve. 
 
A standard curve was generated using bovine serum albumin (BSA) as a standard protein. 
BSA at incremental concentration was mixed with suspension buffer, BCA buffer and 
water as shown in table 3.1. 
 
Sample Final protein 
concentration (µg) 






A 0 0 5 45 
B 20 10 5 35 
C 40 20 5 25 
D 60 30 5 15 
E 80 40 5 5 
 





Then BSA standards samples were incubated at 37oC for 30 minutes. The absorbance at 
562 nm was then measured using spectrophotometer (Shimadzu UV 2100, UK). A standard 
curve was produced (Figure 3.8). 
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Figure 3.8: Calibration curve produced with BSA as standard protein. 
The protein concentrations of cytosolic and mitochondrial samples were then quantified 
using the same method, and the sample absorbance value compared against the standard 
curve to provide an estimate of the protein concentration. This protein estimation method 
enabled equal loading of protein into polyacrylamide gel (section 3.5.7). 
3.5.6 Citrate synthase assay  
 
Citrate synthase is a mitochondrial matrix enzyme, which can be considered as a 
mitochondrial marker. This assay was done to assess any damage to mitochondria during 
protein isolation. Citrate synthase is the initial enzyme of the tricarboxylic acid (TCA) 
cycle) (Srere, 1969). This enzyme catalyzes the reaction between acetyl coenzyme A 
(acetyl-CoA) and oxaloacetic acid (OAA) from citric acid. The acetyl-CoA contributes 2 
carbons to the 4 carbons of oxaloacetate resulting in citrate with 6 carbons. The hydrolysis 
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of the thioester of acetyl-CoA results in the formation of CoA with a thiol group (CoA-SH) 
(equation 1).  
Equation 1: Reaction catalyzed by citrate synthase 
Acetyl CoA + Oxaloacetate → Citrate + CoA-SH + H+ + H2O 
The thiol reacts with the 5,5’-dithiobis-(2-nitrobenzoic acid; DTNB) in the reaction mixture 
to form 5-thio-2-nitrobenzoic acid (TNB). This yellow product (TNB) is observed 
spectrophotometrically by measuring absorbance at 412 nm (equation 2). 
Equation 2: Colorimetric reaction in assay: 
CoA-SH + DTNB → TNB + CoA-S-S-TNB. 
 
The assay solutions contained in mM (Tris 100 (pH 8.1), OAA 10, Acetyl CoA 30, DTNB 
10; Sigma-Aldrich, Poole, UK) and was warmed to 25 oC. Cytosolic samples reactions 
were prepared in duplicate 1 ml cuvettes (Table 3.2).  
Sample 100 mM Tris 
buffer 





solution (To be 
added last) 
50 µl 880 µl 10 µl 10 µl 50 µl 
 
Table 3.2: Table showing the volumes used to prepare the citrate synthase assay. 
 
The absorbance of the reaction was followed using a spectrophotometer (412nm) at kinetic 
mode (Perkin Elmer, Bucks, UK) for 1.5 minute to measure the baseline reaction (the 
endogenous levels of thiol or deacetylase activity). Then 50 µl of OAA was added to 
initiate the reaction and the absorbance was again followed for 1.5 min to measure the total 
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activity. The absorbance values (A 412) were plotted against time for each reaction. The 
change in absorbance was measured (ΔA412)/minute, in the linear range of the plot, for the 
endogenous activity and for the total activity after addition of OAA. The net citrate 
synthase activity was then calculated by subtracting the (ΔA412)/minute of the endogenous 
activity from the (ΔA412)/minute of the total activity of the sample. Finally this value used 
for calculating the citrate synthase activity (equation 3)using the following equation:  
Equation 3: Citrate Synthase Activity (μmole/ml/min) = (ΔA412)/min x V(ml) x dil 
 
Where dil= the dilution factor of the original sample; V(ml)=the reaction volume=1ml; 
Venz (ml)= the volume of the enzyme sample in ml; εmM (mM-1 cm-1)= the extinction 
coefficient of TNB at 412 nm which is 13.6; and L (cm)= pathlength for absorbance 
measurement, for 1 ml cuvette, pathlength = 1 cm. 
3.5.7 Polyacrylamide Gel Electrophoresis (PAGE) 
 
3.5.7.1 Gel preparation 
 
Each 12.5 % acrylamide gels was prepared by adding 12ml distilled water, 15ml 30 % 
acrylamide (Bio-Rad, Hemel Hempstead, UK), 15 ml running gel base, 40µl TEMED (Bio-
Rad, Hemel Hempstead, UK) and 200µl ammonium persulphate (APS, Fisher Scientific, 
Loughborough, UK). The gel was made between two glass plates separated by spacers of 
1.5 mm thickness and then secured in a casting frame. Once the gel was set, a 5% stacking 
gel (7 ml distilled water, 3 ml stacking gel base, 2 ml 30% acrylamide, 24µl TEMED and 
εmM x L (cm) x Venz (ml) 
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120 µl 10% ammonium persulfate) was added at the top. Protein loading wells were made 
in the stacking gel by inserting a multi well comb. 
3.5.7.2 Electrophoresis 
 
The gel was then placed into a tank filled with a 1X running buffer. A total of 50-60 µg of 
protein for each sample was loaded into the gel. Precision plus molecular marker (New 
England Biolabs, Hitchin, UK) and biotinylated ladder (New England Biolabs, Hitchin, 
UK) (10 µl each) were also loaded. The gel was then allowed to run for 55 min at 120 V 
using the powerpac HC TM (Biorad, Hemel Hempstead, UK). 
3.5.7.3 Electrotransfer 
 
Following electrophoresis, the gel was removed and immersed in 1X transfer buffer and 
allowed to equilibrate for 15 minutes under gentle agitation. The Hybond-P Polyvinyl 
Difluoride membrane (PVDF) (Amersham, Buckinghamshire, UK) was cut to the size of 
the gel and pre-wetted with 100% methanol for 10 seconds and then washed out with 
distilled water and then immersed in 1X transfer buffer for 15 minutes. Sponges and the 
Whatman filter papers were also wetted with transfer buffer. 
The gel was carefully opposed to the PVDF membrane, and then sandwiched between 
sponges and Whatman filter papers, with care taken to avoid air bubbles. The transfer 
cassette was then placed in a transfer tank and immersed with transfer buffer and allowed to 




After transfer, the membrane was removed and stained with ponceau stain (Sigma-Aldrich, 
Poole, UK) to assess efficient transfer. Then the stain was washed out with TBS-Tween 
buffer. 
3.5.7.4 Membrane Blocking 
 
The membrane was blocked with 5% milk  (Marvel) buffer (25 ml TBS-Tween and 1.25g 




After blocking, the membrane was washed 3 times with TBS-Tween for 5 minutes each. 
The membrane was then incubated with the primary antibody diluted in antibody dilution 
buffer (0.1 % milk in TBS-T for cytochrome c and VDAC; 5% BSA in TBS-T for 
phospho-Akt) overnight with gentle agitation in an orbital shaker at 4oC. Cytochrome c 
primary antibody (New England Biolabs, Hitchin UK), VDAC (abcam, Cambridge, UK) 
and phospho-Akt (Ser473) (New England Biolabs, Hitchin, UK) were used in 1:1000 
dilutions. 
 
The membrane was then washed with TBS-Tween buffer for 3 x 5 min. The membrane was 
then incubated with HRP conjugated secondary antibody buffer (anti-rabbit IgG antibody, 
New England Biolabs, Hitchin, UK) at a dilution of 1:2000 for 1 hour with gentle agitation 
at room temperature. The membrane was then washed again with TBS-Tween buffer for 3 
x 5 minutes. 
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3.5.7.6 Protein detection 
 
Proteins were detected using enhanced chemiluminescence (ECL PLUS, Amersham, 
Buckinghamshire, UK). Its principle relies on the enzymatic conversion of a luminol-like 
molecule to a reactive molecule by horseradish peroxidase (HRP). This molecule generates 
light in the presence of hydrogen peroxide (Thorpe et al., 1986).  
 
The membrane was incubated with ECL PLUS reagents for 5 minutes, then wrapped in a 
piece of Clingfilm and then exposed to radiography for one minute. The radiography film 
(Amersham, Buckinghamshire, UK) was then placed in a developer and then fixer solutions 
(Kodack, UK), then washed with distilled water and allowed to dry. 
3.5.7.7 Detection of loading control (α-tubulin) 
 
The PVDF membranes were reprobed with the loading control α-tubulin as described by 
Liao et al. (2000). After incubation with the ECL Plus Western Blotting detection kit, the 
PVDF membranes were kept in fresh TBS-T at 4 oC for a day. The PVDF membranes were 
washed 3 times for 5 minutes with TBS-T. These membranes were reprobed with α-tubulin 
(Abcam, Cambridge, UK) (dilution 1:2000) in 5% milk overnight at 4oC.  
 
Membranes were then incubated with the secondary antibody at 1:5000 dilutions (Goat 
polyclonal to Rabbit IgG HRP, abcam, Cambridge, UK). After washing, protein was 






Autoradiography films were scanned on a scanner and the digital image was then imported 
to Quantity One Analysis Software (BioRad, Hemel Hempstead, UK). The relative 
densitometry of each band was determined after subtracting the background noise. 
 
 
3.6 Adult rat ventricular myocytes isolation 
3.6.1 Cardiomyocytes Isolation 
 
Adult rat ventricular myocytes were isolated from Sprague Dawley male rats (300 ± 100g 
body mass) by enzymatic dissociation method. The rats were killed by cervical dislocation, 
then the hearts were quickly excised and mounted on a modified Langendorff apparatus and 
perfused for 5 minutes with perfusion buffer (PB) containing (in mM); NaCl 116, KCl 5.4, 
MgSO4.7.H20 0.4, Glucose 10, Taurine 20, Pyruvate 5, Na2HPO4.12H20 0.9, CaCl2 1.7 and 
25 NaHCO3. The PB was bubbled with 95% O2 and 5% CO2, pH maintained at 7.4 and 
temperature at 37oC. Then the hearts were switched to calcium free PB for another 5 
minutes. Finally hearts were perfused with PB containing 0.75mg/ml Collagenase 
(Worthington type II) and 44µM calcium for 5-10 min at a rate of 10ml/min. The hearts 
were then removed from the perfusion apparatus and the atria trimmed away. The ventricles 
were minced and incubated in a shaking bath for 10-20 min in collagenase-containing PB 
and bubbled with 95% O2 and 5% CO2. Cells were then filtered through nylon mesh and 
washed with restoration buffer (in mM); 116 NaCL, 5.4 KCl, 0.4 MgSO4, 10 Glucose, 20 
Taurine, 5 Pyruvate, 0.9 NaHPO4, 25 NaHCO3, 2 Carnitine, 5 Creatine, 50µM CaCl2 2g 
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BSA and 1% pen-strep (pH 7.4, 37oC). The calcium concentration of the cell suspension 
was gradually increased to a final concentration of 1.25 mM. The cells were kept in 
incubator at 37oC and an atmosphere of 21% O2 and 5% CO2. For each experiment, a 




3.6.2 Experimental protocol 
 
The hypoxic condition was created by replacing the normal restoration buffer with  
ischemic buffer (containing in mM; 137 NaCl, 12 KCl, 0.49 MgCl2, 0.9 CaCl2, 4 HEPES, 
20 Na lactate, 10 deoxyglucose) and then the cells were incubated in an air-tight hypoxic 
chamber with an atmosphere of 5% CO2 and 95% N2 at 37oC. For reoxygenation, cells 
were removed from the hypoxic chamber and the hypoxic medium was replaced with the 
normal restoration buffer. The cells were then placed in an incubator at 37oC and 
atmosphere of 21% O2 and 5% CO2. Experimental groups were divided into control groups, 
cells were exposed to 6 hrs of hypoxic condition and 18 hours of reoxygenation condition. 
Treated groups, cells were exposed to 6 hrs of ischemic conditions and 18 hrs of 
reoxygenation condition where caspase inhibitors (ZVAD-fmk, 25µM and Ac-DEVD-
CMK, 25µM) were added at the start of roxygenation, 15 min, 30 min and 60 min after 
starting reoxygenation  in the presence or absence of PI3-Akt inhibitor; wortmannin 
(WORT, 100 nM) Figure 3.9. The same control hypox/reox group was used in all 



















Figure 3.9: Illustrative diagram showing the experimental protocol for isolated adult rat 
ventricular myocytes. Normoxia contol group, cells were exposed to normal oxygenated 
conditions for 24 hours. Hypox/Reox control group cells were exposed to 6 hrs of hypoxic 
conditions and 18 hours of reoxygenation condition. Treated groups, cells were exposed to 
6 hrs of ischemic conditions and 18 hrs of reoxygenation condition where caspase 
inhibitors (ZVAD, 25µM and DEVD, 25µM) were added at the start of roxygenation, 15 
min, 30 min and 60 min after starting reoxygenation  in the presence or absence of PI3-
Akt inhibitor; wortmannin (WORT, 100 nM). (n=8). 
Hypoxia                Oxygenation                   Drug treatment 
6 hours Hypoxia 18 hours Reoxygenation 
Normoxia 
Control 








at 15 min Reox 
ZVAD±WORT 
DEVD±WORT 
at 60 min Reox 
ZVAD±WORT
DEVD±WORT 






For prolonged reperfusion studies, the same experimental protocol (figure 3.9) was 
followed, however at the end of the first 18 hours reperfusion, cells were collected and then 
resuspended in a fresh reperfusion buffer and caspase inhibitors added freshly. Then they 
were incubated for another 18 hours in the same reoxygenation conditions to make 36 hours 
total reoxygenation time. 
3.6.3 Quantitative Analysis of Cellular Viability, Apoptosis and Necrosis 
 
The Vybrant ® Apoptosis Assay Kit #10 (Invitrogen, Paisley, UK) was used for 
quantitative analysis of cellular viability, apoptosis and necrosis. This kit provides a rapid 
and convenient assay for apoptosis. In normal cells the distribution of phospholipids is 
asymmetric with the inner membrane containing anionic phospholipids, such as 
phosphotidyl serine (PS) and the outer membrane having mostly neutral phospholipids. In 
apoptotic cells, the amount of PS on the outer surface of the membrane increases exposing 
PS to the surrounding liquid (Martin et al., 1995). Annexin V, a calcium dependent 
phospholipids binding protein, has a high affinity for PS. Annexin V binds to PS in the 
outer membrane of apoptotic cells, thus providing a suitable way of detecting apoptosis 
(Martin et al., 1995). This kit contains, recombinant annexin V conjugated to 
allophycocyanin (APC) to stain apoptotoic cells. APC is an extremely fluorescent 
phycobiliprotein, which can be easily excited with a helium-neon (HeNe) laser at 633 nm. 
This kit also contains C12-resazurin which is reduced by viable cells to orange-fluorescent 
C12-resorufin Resazurin has been used extensively to detect the metabolic activity of many 
different cell types. Necrotic cells detected with the SYTOX ® Green dye which is 
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impermeant to live and early apoptotic cells, but stains dead cells with intense green 
fluorescence by binding to cellular nucleic acids. 
At the end of the experimental protocol, the cells were harvested and transferred to a 
labelled ependorff tubes and centrifuged at 500 rpm for 5 mins.  The supernatant was 
removed and the cell pellet washed with Annexin V buffer. Then the tubes were 
centrifuged again at 500rpm for 5 min. The supernatant was decanted off and the cells were 
suspended in Annexin V buffer. The cells were then stained with Annexin V conjugated 
APC, C12 resazurin and SYTOX Green dyes according to the kit instruction sheet. The 
ependorff tubes were then covered in foil to protect from light and incubated at 37oC, 5% 
CO2 for 15 min. The samples were then diluted with more Annexin V binding buffer and 
analysed immediately by flow cytometery (FACS, Becton Dickinson, Oxford, UK). The 
samples were analysed on the FL-2 and FL-4 channels and setup to count 10,000 events. 
The cells population should separate into three groups: live cells with only a low level of 
green and far-red fluorescence and a high level of orange fluorescence; apoptotic cells with 
a high level of far-red fluorescence, intermediate orange fluorescence, and no green 
fluorescence; and dead cells with a high level of green and far-red fluorescence and a low 
level of orange fluorescence. The most commonly used analysis plot consists of a square 
divided into four quadrants. The position of a dot on the plot depends upon whether the cell 
is positive for one flourchrome, both, or neither (Figure 4.6). The percentage of events that 
fall into each quadrant is reported by the computer, and this report correlates with the 
density of the dots in the respective quadrant. Numerous studies have shown the use of 
flow cytometry quadrant based analysis as a reliable method for the assessment of apoptotic 




Figure 3.10: Representative diagram showing flow cytometry analysis of adult rat 
ventricular myocytes using the Vybrant® Apoptosis Assay Kit #10. Myocytes were 
incubated with the reagents in the Vybrant® Apoptosis Assay Kit #10, and then 
analyzed by FACS flow cytometry. The SYTOX® Green fluorescence versus APC 
(allophycocyanin) fluorescence dot plot shows resolution of live, apoptotic, and 
necrotic cell populations. a. Normoxia, b. 6 hours of hypoxia followed by 18 hours of 
reoxygenation, c. anti-apoptotic drugs (caspase inhibitors). 
 
3.6.4 Measurement of Caspase-3 activity 
 
At the end of the experimental protocol, cells were harvested into labelled ependorff tubes, 
and then were centrifuged at 1200 rpm for 2min. Cells were then resuspended in Phosphate 
Buffer Saline (PBS). Cells were then fixed with 3% formaldehyde for 10 min at 37oC. Cells 
were then permeabilized by adding ice cold 90% methanol for 30 min at 4oC. Cells were 
then washed with incubation buffer (0.5% BSA in PBS) and then blocked with the 
incubation buffer for 10 min, and then blocked with the primary antibody (cleaved caspase-
3 (Asp 175) (5A1) rabbit mAb; New England Biolabs, Hitchin, UK) at 1:100 dilution for 1 
hour at room temperature. Cells were then washed using incubation buffer and then 
resuspended in alexa flour@ conjugated secondary antibody (Alexa flour@488 F (ab’) 2 











room temperature. Finally cells were washed with incubation buffer and resuspended in 
PBS and immediately analysed using flow cytometry on the FL1 channel (Vermes et al., 
2000). Histograms were plotted for each of the groups showing the Mean fluorescence for 
10,000 counts (Figure 4.7). 
 
Figure 3.11: Representative flow cytometric histograms of intracellular Caspase-3 
activity in myocytes subjected to normoxia conditions (blue), hypoxia/reoxygenation 
conditions (green) and hypoxia/reoxygenations conditions with caspase inhibitors 
treatment (red). 
3.7 Work loop studies 
3.7.1 Muscle preparation 
 
Adult male Sprague-Dawley rats (250 g + 100 g body mass) were used. 24 rats were 
obtained from Coventry University Animal House (Coventry, UK). All rats were killed by 
cervical dislocation in accordance with the home office Guidance on the Operation of 
Animals (Scientific Procedures) Act 1986. The heart was rapidly excised and pinned out on 
Petri dish on a Sylgard 184 base (Dow Corning) and immersed in fresh oxygenated Krebs 
Henseleit  (KHB) buffer (in mM: NaCl 118.5, NaHCO3 25.0, KCl 4.8, MgSO4 1.2, KH2PO4 




An incision was made through the right ventricle to expose the papillary muscles. A 
suitable papillary muscle was then dissected by cutting through the valvular chordae 
tendeneae at one end and the ventricular muscle wall at the other end. Aluminium foil clips 
were wrapped as close as possible to the ends of the papillary muscle preparation around 
the tendon at one end and the ventricular wall at the other end. The dissection was 
performed rapidly at room temperature and KH buffer was continuously replaced with fresh 
oxygenated KHB. 
 
The muscle was then attached horizontally via the foil clips to a force transducer (UFI, 
Pioden Controls Ltd, UK) at one end and a displacement transducer (V201, Ling Dynamic 
Systems, UK) at the other end in a flow through chamber containing circulating oxygenated  
(95% O2; 5% CO2) KHB maintained at 37oC. A linear variable-displacement transducer 
(model DFG5.0, Solarton Metrology, UK) was used for position detection. Two platinum 
wire electrodes positioned parallel to the muscle within the chamber were used to stimulate 
the muscle preparation. The muscle was allowed 20 minutes before starting the experiment 
to allow both recovery from the dissection and adjustment to higher temperature of 37 oC. 
3.7.2 Isometric studies 
 
The muscle preparation was stimulated via the platinum electrodes while held at constant 
length to yield an isometric twitch, which was displayed and measured on a digital 
oscilloscope. Stimulation amplitude and muscle length were optimised via several isometric 
twitches to maximise force output. The muscle length was increased gradually in 0.2mm 
increments using a micromanipulator, and then active force was elicited and measured at 
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each length. This procedure was repeated until active force was seen to decline. The muscle 
length that generated the maximum active force was then measured using a graticule eye 
piece. The muscle length that generated the maximum active force under isometric 
conditions was defined as Lmax.  
3.7.3 Work loop studies 
 
The work loop technique was used to measure the power output of the muscle during 
cyclical length changes (Josephson, 1985). The muscle was subjected to a sinusoidal length 
change wave form and phasically stimulated to simulate in-vivo function (Semafuko & 
Bowie, 1975). 
 
Preliminary experiments were done to determine the optimal muscle length (Lopt, the length 
for maximum work production), cycle frequency (frequency of the sinusoidal length 
changes), strain (extent of length change expressed as a proportion of Lopt) and phase shift 
(start of stimulation expressed relative to the maximum length achieved during the 
sinusoidal length change) that produce maximal power output. These optimal parameters 
were then used in all subsequent experiments. 
 
In subsequent experiments , each muscle at Lmax was subjected every five minutes to a set 
of four sinusoidal length change cycles at 6 Hz cycle frequency, -20 ms phase shift and 
strain of 0.12 for the whole experimental protocol. Muscle length and stimulation were 
controlled using custom written software (Testpoint, CEC, MA, USA). A plot of force 
against length produced a ‘work loop’ that represents the net work done by the muscle 
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during the length change cycle. The first work loop of each set of cycles was found to 
produce the maximum power output and was used to indicate power output of the muscle. 
3.7.4 Experimental protocol 
 
Ischemia was simulated by perfusion with hypoxic buffer (composition in mM: 118.5 
NaCl, 25 NaHCO3, 4.8 KCl, 1.2 MgSO4, 1.2 KH2PO4, 1.7 CaCl2, and 7.0 choline chloride) 
bubbled with a gas mixture of 95% N2: 5% CO2.  For reoxygenation, the hypoxic buffer was 
replaced with normal oxygenated (95% O2:5% CO2) KHB. 
 
The experimental groups were baseline non-ischemic, ischemic control and treatment 
groups (Figure 3.12). In the baseline group, muscles were bathed continuously with 
circulating oxygenated normal KHB for 155 minutes.  In the ischemic control group (n=6), 
muscles were bathed with circulating oxygenated normal KHB for 20 minutes, then bathed 
with circulating hypoxic buffer for 35 minutes, then reoxygenated with circulating normal 
oxygenated KHB for 100 minutes. Treatment groups (n=6 each), caspase inhibitors 
(ZVAD, 0.01µM or 2.5µM and DEVD, 2.5µM) were added at the start of reoxygenation 
(Figure 3.12). In each experimental group, four work loops were delivered every 5 minutes 















Figure 3.12: Illustrative diagram showing the experimental protocol used for work 
loop studies. Baseline group, muscles were bathed continuously oxygenated KHB for 
155 minutes. Ischemic control group, muscles were bathed with oxygenated KHB for 
20 minutes, then bathed with hypoxic buffer for 35 minutes, then reoxygenated with 
oxygenated KHB for 100 minutes. Treatment groups, caspase inhibitors (ZVAD, 
0.01µM or 2.5µM and DEVD 2.5µM) were added at the start of reoxygenation (n=6 
each). Normal oxygenated KHB            
 Hypoxic buffer                    Drug treatment 
 
3.7.5 Muscle mass measurement and dimension calculations 
 
At the end of the experimental protocol, the papillary muscle was removed and dissected 
away from the tendon and the ventricular wall. Excess KH buffer was removed from the 
muscle before measurement of muscle mass. Muscle power output was then normalised to 
muscle mass (W Kg-1). Mean muscle cross sectional area was calculated from muscle mass, 
muscle length and an assumed muscle density of 1060 kg m-3. Isometric stress was then 
calculated as force divided by cross sectional area (KN m-2). 
 
 
155 min oxygenated KHB 
20 min 35 min 
ischemia 
100 min reoxygenation 
20 min 35 min 
ischemia 










3. 8 Statistical analysis 
 
Results are presented as group means ± standard error of the mean (SEM). All data were 
analysed using SPSS statistical software (SPSS, version 14).  
 
All values for I/R % are expressed as mean I/R % + Standard Error of the Mean (SEM). 
Data were analysed using SPSS one-way ANOVA. Tukey’s post hoc test was performed to 
test for significant differences between groups when a significant main effect (ANOVA) 
had been found. A p value of <0.05 was considered to be statistically significant. 
 
All values for measured haemodynamic parameters (LVDP, HR, and CF) are expressed as 
mean stabilisation percentage ± Standard Error of the Mean (SEM). Data were analysed 
using two way ANOVA (time and experimental group) with Tukey’s post hoc test to test 
statistical difference. One way ANOVA with Tukey’s post hoc test was then used to test for 
statistical difference at specific time points (start of ischemia, end of ischemia, start of 
reperfusion and end of reperfusion period). A p value of <0.05 was considered to be 
statistically significant. 
 
All values for densitometry values of western blot are expressed as mean density + 
Standard Error of the Mean (SEM). Data were analysed using SPSS one-way ANOVA. 
LSD test was performed to test for significant differences between groups when a 





All values of adult rat venricular myocytes studies were presented as mean % cell 
populations ± Standard Error of the Mean (SEM). Data was analysed using SPSS one-way 
ANOVA followed by Tukey’s post hoc test to test for statistical difference. A p value of 
<0.05 considered to be statistically significant. 
 
All data of maximum power output were expressed as a percentage of the mean of the first 
20 minutes stabilisation values. All the percentage data were then transformed to arcsine 
values to meet the requirements of parametric statistical analysis. Using SPSS statistical 
software, two way ANOVA (time and experimental groups) with Tukey’s post hoc test was 
used to test for statistical difference. One way ANOVA with Tukey’s post hoc test was then 
used to test for statistical difference at specific time points. One way ANOVA with Tukey’s 
post hoc test was used to test for significant differences in isometric stress and mean 






Myocardial Ischemia Reperfusion Injury Is Reduced By Administration 
Of Caspase Inhibitors At Various Time Points During Reperfusion.  
 
4.1 Introduction and Objectives 
 
Coronary heart diseases and subsequent myocardial infarction is the leading cause of high 
mortality and morbidity worldwide (Okrainec et al., 2004). The prerequisite for rescuing 
viable myocardium after acute myocardial ischemia is the early restoration of coronary 
blood flow (reperfusion) (de Boer et al., 1994) However, reperfusion itself has the potential 
to introduce additional lethal injury that is not evident at the end of ischemia termed lethal 
reperfusion injury (Hearse & Bolli 1992, Yellon & Baxter 2000). There has been 
significant research over the last two decades focused on either pharmacological or 
mechanical ways to attenuate reperfusion injury and limit infarct size. Ischemic 
preconditioning phenomenon (whereby episodes of intermittent sublethal ischemia and 
reperfusion confer protection against a subsequent lethal episode of myocardial ischemia) 
which protects the myocardial tissue through adaptive mechanisms exerted primarily during 
ischemia (Murray et al., 1986) has been described twenty years ago. Although, 
preconditioning has been considered as a gold standard cardioprotective mechanism, its 
practical use in the clinical arena is limited by the inability to predict the onset of ischemia, 
which is the case in patients presented with myocardial infarction. However, the 
implementation of cardioprotective therapy at the time of reperfusion is clinically more 
feasible because the onset of reperfusion by either thrombolysis or PTCA is more 
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predictable and is under the clinician's control. Furthermore spontaneous reperfusion may 
occur in some patients before any hospital intervention due to dislodgment of the thrombus 
or relieved coronary spasm (Christian et al., 1998). In this respect, the newly described 
phenomenon of ischemic postconditioning, in which the application of intermittent 
episodes of myocardial ischemia and reperfusion at the start of reperfusion period following 
a period of lethal ischemia confer a cardioprotective effect similar to ischemic 
preconditioning (Zhao et al., 2003), provides one such intervention. Reintroduction of 
mechanical ischemia at the time of reperfusion following a period of lethal ischemia may 
lead to potential complications, therefore, the concept of "pharmacological 
postconditioning", where pharmacological agents that mimic the effect of ischemic 
postconditioning is more clinically applicable. 
 
Abundant research have shown that caspase mediated cell death (apoptosis) contributes 
significantly to cell death during ischemia reperfusion injury (Gottlieb et al., 1994, Saraste 
et al., 1997, Zhao et al., 2000) as has been discussed in chapter 1. Synthetic caspase 
inhibitors showed promising cardioprotective results. Broad spectrum caspase inhibitor 
(ZVAD) reduced infarction size and apoptotic cellular death when administered either 
during ischemia (Haung et al., 2000, Okamura et al., 2000, Holly et al., 1999) or shortly 
before starting reperfusion (Haung et al., 2000, Mocanu et al., 2000, McCully et al., 2004). 
However, specific caspase inhibitors showed contravesial results. Kovacs et al (2001) 
found that specific caspase 3 and 9 inhibitors failed to reduce infarction size or apoptotic 
cellular death after ischemia reperfusion injury when administed for only 10 minutes after 
starting reperfusion using langendorff working model. Okamura et al (2000) found that 
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administration of caspase-1 and caspase-3 inhibitors 5 minutes before ischemia resulted in 
significant reduction in apoptotic cell death, but they failed to show any significant change 
in infarct size using in vivo model. In contrast Mocanu et al (2000) found a significant 
reduction in infarct size after using caspase 8, 9 and 3 inhibitors, which were added at the 
time of reperfusion throughout using langendorff model. This discrepancy in results could 
be attributed to differences in timing of administration of the caspase inhibitors and models 
used.  
 
Caspase inhibitors post reperfusion therapeutic window is not yet known. Previous 
literature showed controversial results, as Armstrong et al (2001) presented an abstract at 
the American Heart Association showing that caspase inhibitors (unspecified, still under 
investigation) significantly reduced infarct size even when administered one hour after the 
heart attack using in vivo  rat model. However Li et al (2001) using isolated adult rabbit 
cardiomyocytes showed that caspase inhibitors (unspecified, labeled with numbers) were 
partially protective if added 15 min after reperfusion and the cardioprotective effect was 
completely lost with a delay of 30 or 60 minutes. This discrepancy could be attributed to 
the different inhibitors used (both used unknown inhibitors identified by numbers) and 
different models used. Therefore further research is needed to identify the effect of delayed 
administration of caspase inhibitors before applying them in the clinical field. 
 
Therefore, the aim of this study is to determine whether broad spectrum caspase inhibitor 
(ZVAD) or specific caspase-3 inhibitor (DEVD) administered at different time points 
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during reperfusion (at start of reperfusion, 15 min, 30 min and 60 min after starting 
reperfusion) protect the rat myocardium from ischemia reperfusion injury using langendorff 
heart reperfusion model and isolated adult rat ventricular myocytes model.  
 
The hypothesis of this study is that broad spectrum caspase inhibitor (ZVAD) or specific 
caspase inhibitor (DEVD) are cardioprotective at different time points during reperfusion 




4.2.1 Langendorff heart reperfusion model (chapter 3 methods, section 3.4) 
 
Isolated rat hearts were subjected to 20 min stabilisation, and then underwent 35 min 
regional ischemia followed by 120 min reperfusion using Langendorff perfusion system. 
Caspase inhibitors (Broad spectrum caspase inhibitor,ZVAD, 0.1 µM and Specific caspase-
3 inhibitor, DEVD, 0.07 µM) were added at different time points during reperfusion (at 
start of reperfusion. 15 min, 30 min and 60 min after starting reperfusion). At the end of the 
experimental protocol, infarction size to risk area ratio (I/R %) determined using TTC 
staining. The haemodynamic parameters assessed were Left Ventricular Developed 
Pressure (LVDP, mmHg), Heart Rate (HR, beats per minute) and Coronary flow (CF, 
ml/min). These parameters were monitored throughout the experiment to monitor the hearts 
stability. 
4.2.3 Analysis of isolated adult rat ventricular myocytes using flow cytometry (chapter 
3 methods, section 3.6) 
 
Isolated adult rat ventricular myocytes underwent 6 hours of hypoxia followed by 18 hours 
of reoxygenation. Caspase inhibitors (ZVAD, DEVD) were added at different time points 
during reoxygenation, at the start of reoxygenation, 15 min, 30 min and 60 min after 
starting reoxygenation following 6 hours of hypoxia. At the end of the experimental 
protocol, apoptotsis, necrosis, viability and intracellular caspase-3 activity were measured 




4.3.1 Myocardial infarct size to risk area ratio (I/R %). 
4.3.1.1 The effect of the broad spectrum caspase inhibitor (ZVAD; 0.1µM) on I/R % 
when added at different time points during reperfusion. 
 
Previous research has shown that broad spectrum caspase inhibiton during either ischemia 
period or start of reperfusion period protects the myocardium from ischemia reperfusion 
injury. In the present study, we aimed at assessing whether delayed administration of the 
broad spectrum caspase inhibitor (ZVAD, 0.1 µM) at different time points during 
reperfusion period is still cardioprotective. Isolated perfused rat hearts underwent 35 
minutes of ischemia followed by 120 minutes of reperfusion where ZVAD was 
administered at the start of reperfusion, 15 minutes, 30 minutes and 60 minutes after 
starting reperfusion throughout the reperfusion period. Infarct size is represented as the 
percentage of tetrazolium negative tissue in the ischemic risk zone. Results showed that 
ZVAD added at the start reperfusion significantly reduce I/R % by 37% when compared to 
control hearts (17.3 ± 2.0% vs 54.2 ± 6.6% control, Tukey’s post-hoc test p<0.001) Figure 
4.1. This significant cardioprotection was also observed when ZVAD was added at 15 min 
after starting reperfusion, I/R% was significantly reduced by 24% when compared to 
control hearts (30.5± 3.4% vs 54.2 ± 6.6 % control, p<0.01) Figure 4.1. Adding ZVAD 30 
min and 60 min after starting reperfusion was still cardioprotective, I/R% significantly 
reduced by 23% when compared to control hearts (31.6 ± 4.0%, 31.5± 6.6 % respectively 
vs 54.2 ± 6.6 % control, Tukey’s post-hoc test p<0.01) Figure 4.1. Statistical analysis also 
showed that, there was no significant difference between the different treatment groups 
when compared to each other (Tukey’s post-hoc test p>0.05) Figure 4.1. This implies that 
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adding ZVAD at the start of reperfusion is equally cardioprotective as if added one hour 



























Figure 4.1: Infarct size to Risk ratio (%) in control and broad spectrum caspase 
inhibitor (ZVAD, 0.1µM) treated hearts. Isolated perfused rat hearts where subjected 
to 35 minutes of ischemia and 120 minutes of reperfusion where the ZVAD was 
administered at different time points during reperfusion. *P<0.01 vs. Control, Tukey’s 
post-hoc test. Results are shown as Mean + SEM, n=5 
 
4.3.1.2 The effect of the specific caspase-3 inhibitor (DEVD, 0.07µM) on I/R % when 
added at different time points during reperfusion. 
 
Previous literature also showed promising cardioprotective results after using specific 
caspase inhibiton. In this study we aimed at assessing whether delayed administration of 
specific caspase-3 inhibitor (DEVD, 0.07 µM) is still cardioprotective. Isolated perfused rat 
hearts underwent 35 minutes of ischemia followed by 120 minutes of reperfusion where 
DEVD was administered at the start of reperfusion, 15 minutes, 30 minutes and 60 minutes 
after starting reperfusion throughout the reperfusion period. The percentage of tetrazolium-






control ischemic group was used as ZVAD studies. The I/R% was significantly reduced by 
40% in hearts treated with DEVD added at the start of reperfusion when compared to 
control hearts (14.4 ± 3.9 % vs 54.2 ± 6.6 % control; Tukey’s post-hoc test p<0.001) Figure 
4.2. Significant cardioprotection compared with control hearts was also found when DEVD 
was added at 15 min, 30 min and 60 min after starting reperfusion (15.7 ± 3.6%, 18.5 ± 3.7 
and 26.5 ± 5.1 % respectively vs 54.2 ± 6.6 % control; Tukey’s post-hoc test p< 0.01) 
Figure 4.2. There was no significant difference in I/R% when treatment groups were 
compared to each other (Tukey’s post-hoc test p>0.05) Figure 4.2. The cardioprotection 
offered by broad spectrum caspase inhibitor (ZVAD) was not significantly different from 
the cardioprotection conferred by the specific caspase-3 inhibitor (DEVD) at all time points 



























Figure 4.2: Infarct size to Risk ratio (%) in control and specific caspase-3 inhibitor 
(DEVD, 0.07µM) treated hearts. Isolated perfused rat hearts were subjected to 35 
minutes of ischemia and 120 minutes of reperfusion. The DEVD-CMK (0.07µM) was 
administered at different time points during reperfusion. *P<0.01 vs. Control, 
Tukey’s post hoc test. Results are shown as Mean + SEM, n=5 
* 
* * * 
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4.3.2 Haemodynamic parameters 
4.3.2.1 Left ventricular developed pressure (LVDP) 
 
LVDP was measured using inflated latex ballon inserted into the left ventricle and 
connected to a pressure transducer. LVDP was measured evry 5 minute throught the 
stabilisation, ischemia and reperfusion period. Results are expressed as % mean 
stabilisation LVDP and two- way ANOVA statistical analysis was used to assess for any 
significant difference between the experimental groups. % mean stabilization LVDP 
showed same general response outline in all the experimental groups. It dropped upon 
starting ischemia and showed significant decrease at the end of ischemia period when 
compared to stabilisation period. Upon starting reperfusion % mean stabilization LVDP 
increased, however it wasn’t statistically significant when compared to end of ischemia 
period. Then it showed gradual drop tendency throughout reperfusion period. There was no 
significant difference in % mean stabilization LVDP between broad spectrum caspase 
inhibitor (ZVAD, 0.1 µM) treated groups when compared to control ischemia reperfusion 
group (ANOVA P>0.05) Figure 4.3. In specific caspase-3 inhibitor (DEVD, 0.07µM) 
treated experimental groups, there was no significant difference when compared to control 



























Control ZVAD@Rep ZVAD@15 min Rep ZVAD@30 min Rep ZVAD@60 min Rep
 
Figure 4.3: % mean stabilisation LVDP in control and broad spectrum caspase 
inhibitor (ZVAD, 0.1µM) treated hearts. Isolated perfused rat hearts subjected to 35 
minutes of ischemia and 120 minutes of reperfusion where ZVAD was administered at 
different time points during reperfusion. Results are shown as mean percentages of 


























Control DEVD@Rep DEVD@15 min Rep DEVD@30 min Rep DEVD@60 min Rep
 
Figure 4.4: % mean stabilisation LVDP in control and the specific caspase-3 inhibitor 
(DEVD, 0.07µM) treated hearts. Isolated perfused rat hearts subjected to 35 minutes 
of ischemia and 120 minutes of reperfusion where DEVD was administered at 
different time points during reperfusion. Results are shown as mean percentages of 







4.3.2.2 Heart rate (HR) 
 
HR was measured also through the inflated latex ballon inserted into the left ventricle and 
connected to a pressure transducer. HR showed a smaller response to ischemia and 
reperfusion when compared to LVDP and CF. It showed a stable response throught the 
experimental period. Results are expressed as % mean stabilisation HR. There was no 
significant differences in % mean stabilization HR between the different ZVAD treated 
experimental groups when compared to ischemia control group (ANOVA p>0.05) Figure 
4.5. DEVD treated groups showed no significant difference when compared to control 






















Control ZVAD@Rep ZVAD@15 min Rep ZVAD@30 min Rep ZVAD@60 min Rep
 
Figure 4.5: % mean stabilisation HR in control and broad spectrum caspase inhibitor 
(ZVAD, 0.1 µM) treated hearts. Isolated perfused rat hearts subjected to 35 minutes 
of ischemia and 120 minutes of reperfusion where ZVAD was administered at 
different time points during reperfusion. Results are shown as mean percentages of 


























Control DEVD@Rep DEVD@15 min Rep DEVD@30 min Rep DEVD@60 min Rep
 
Figure 4.6: % mean stabilisation HR in control and the specific caspase-3 inhibitor 
(DEVD, 0.07µM) treated hearts. Isolated perfused rat hearts subjected to 35 minutes 
of ischemia and 120 minutes of reperfusion where the DEVD was administered at 
different time points during reperfusion. Results are shown as mean percentages of 
the stabilisation period + SEM, n=5. 
4.3.2.3 Coronary flow (CF) 
 
CF was stable during the stabilisation period and then decreased immediately during 
ischemia and it is a good indicator of ischemia. Upon starting reperfusion CF increased for 
the first 15 minutes, which thereafter showed a tendency to gradually decrease during the 
reperfusion period. This general response was observed in all the experimental groups. 
There were no significant differences in CF between the different experimental groups 
treated with ZVAD (0.1µM) or DEVD (0.07 µM) when compared to control (ANOVA 




























Control ZVAD@Rep ZVAD@15 min Rep ZVAD@30 min Rep ZVAD@60 min Rep
 
Figure 4.7: % mean stabilisation CF in control and broad spectrum caspase inhibitor 
(ZVAD, 0.1 µM) treated hearts. Isolated perfused rat hearts subjected to 35 minutes 
of ischemia and 120 minutes of reperfusion where the ZVAD was administered at 
different time points during reperfusion. Results are shown as mean percentages of 

























Control DEVD@Rep DEVD@15 min Rep DEVD@30 min Rep DEVD@60 in Rep  
Figure 4.8: % mean stabilisation CF in control and the specific caspase-3 inhibitor 
(Ac-DEVD, 0.07µM) treated hearts. Isolated perfused rat hearts subjected to 35 
minutes of ischemia and 120 minutes of reperfusion where the DEVD was 
administered at different time points during reperfusion. Results are shown as mean 







4.3.3 Analysis of isolated adult rat ventricular myocytes using flow cytometry. 
4.3.3.1 The effect of Hypoxia and Reoxygenation injury on viable, necrotic and 
apoptotic myocyte populations 
 
Exposure of isolated adult rat ventricular myocytes to 6 hours of hypoxia followed by 18 
hours of reoxygenation resulted in a significant reduction of cellular viabilty by 50% when 
compared to control normoxia cells, which had not been exposed to hypoxic conditions 
(18.2 ± 5.1 % vs 68.0 ± 2.9 % Normoxia, Tukey’s post-hoc test p<0.001, Figure 4.8). 
Correspondingly there was a significant increase in necrotic cell death in the control group 
exposed to hypoxia and reoxygenation conditions when compared to the control normoxia 
cells (33.5 ± 2.2 % vs 18.2 ± 2.0 % Normoxia, Tukey’s post-hoc test p<0.01, Figure 4.8). 
Hypoxia/Reoxygenation injury significantly increased the apoptotic cell population when 
compared to control normoxia cells not exposed to hypoxia and reoxygenation (48.2 ± 3.8 
% vs 13.8 ± 3.0 % Normoxia, Tukey’s post-hoc test p<0.001, Figure 4.8). The contribution 
of apoptosis to cellular death during hypoxia/reoxygenation injury was significantly more 
than necrosis by a factor of 15% (48.2 ± 3.8 % apoptosis vs 33.5 ± 2.2 necrosis, Tukey’s 
























Figure 4.8: The effect of 6 hours hypoxia and 18 hours reoxygenation on adult rat 
ventricular myocyte viability, necrosis and apoptosis analysed by flow cytometry. * p 
< 0.05 vs. Normoxia, $ p<0.05 vs. apoptosis in Hypox/Reox group, Tukey’s post-hoc 
test. Results are shown as means +SEM, n=5. 
4.3.3.2 Preliminary results to decide the appropriate cardioprotective dose of the 
broad spectrum caspase inhibitor (ZVAD) and the specific caspase-3 inhibitor 
(DEVD) using adult rat ventricular myocyte model of hypoxia and reoxygenation 
 
Preliminary studies using caspase inhibitors at low doses similar to langendorff model 
(ZVAD, 0.1 µM and DEVD, 0.07 µM) added at the start of reoxygenation showed no 
significant increase in cellular viability or significant decrease in necrosis and apoptosis 
cellular death when compared to control cells exposed to hypoxia and reoxygenation 
conditions (p>0.05, Figure 4.9, Figure 4.10). In previous studies investigating the 
cardioprotective effects of ZVAD and DEVD, high dose of 25 µM (Gottlieb et al., 1996, 
Kang et al., 2000, Hai et al., 2001) for both caspase inhibitors has been used. At this high 
dose, a significant increase in cellular viability was observed with both caspase inhibitors, 
similar to control normoxia group values. There was also a significant decrease in apoptotic 







(p< 0.05, Figure 4.9, Figure 4.10). Therefore 25µM dose of both ZVAD and DEVD was 



























Figure 4.9: Assessment of cellular viability, necrosis and apoptosis in isolated adult rat 
cardiomyocytes subjected to 6 hours hypoxia and 18 hours of reoxygenation. The 
broad spectrum caspase inhibitor (ZVAD) was added at the onset of reoxygenation. 
Two doses of ZVAD were used (0.1µM, 25µM). Results are shown as mean + SEM 
and are expressed as a percentage of the total cells counted.* p<0.05 vs. Normoxia 
viable cells, $ p<0.05 vs Normoxia necrosis, £ p< 0.05 vs. Normoxia apoptosis, ** p< 
0.05 vs. Hypox/Reox viable cells, $$ p< 0.05 Hypox/Reox necrosis, ££ p< 0.05 vs. 































Viable Necrosis Apoptosis  
Figure 4.10: Assessment of cellular viability, necrosis and apoptosis in isolated adult 
rat cardiomyocytes subjected to 6 hours hypoxia and 18 hours of reoxygenation. The 
specific caspase-3 inhibitor (DEVD) was added at the onset of reoxygenation. Two 
doses of DEVD were used (0.07 µM, 25 µM). Results are shown as mean + SEM and 
are expressed as a percentage of the total cells counted.* p<0.05 vs. Normoxia viable 
cells, $ p<0.05 vs Normoxia necrosis, £ p< 0.05 vs. Normoxia apoptosis, ** p< 0.05 vs. 
Hypox/Reox viable cells, $$ p< 0.05 vs. Hypox/Reox necrosis, ££ p< 0.05 vs. 
Hypox/Reox apoptosis, n=4. 
4.3.3.3 The effect of the broad spectrum caspase inhibitor (ZVAD, 25µM) on myocyte 
viability when added at different time points during reoxygenation 
 
Same control Hypox.Reox group was used in all ARVMs studies. Adding ZVAD (25 µM) 
at the start of reoxygenation resulted in a significant increase in cellular viability almost to 
the same degree as normoxia control myocytes (73.9 ± 6.2 vs 68.0 ± 2.9 Normoxia, 
Tukey’s post-hoc test p<0.05 Figure 4.11. Delayed administration of ZVAD (25 µM) 15 
min, 30 min and 60 min after starting reoxygenation also resulted in significant increases in 
myocytes viability compared to Hypoxia/Reoxygentaion control myocytes (42.1 ± 6.5, 47.0 












p<0.05) Figure 4.11. The cytoprotective effect of ZVAD was significantly greater when 
added at the start of reoxgenation than other delayed time points(15 min, 30 min and 60 
min after starting reoxgenation) when compared to hypoxia/reoxygenation control 































Figure 4.11: Assessment of myocytes viability in isolated adult rat cardiomyocytes 
subjected to 6 hours hypoxia and 18 hours of reoxygenation. The broad spectrum 
caspase inhibitor (ZVAD, 25µM) was added at different time points during 
reoxygenation. Results are shown as mean + SEM and are expressed as a percentage 
of the total cells counted.* p<0.05 vs. Normoxia, $ p<0.05 vs Hypox/Reox, £ p< 0.05 vs. 
ZVAD at Reox, n=5. 
4.3.3.4 The effect of the broad spectrum caspase inhibitor (ZVAD, 25µM) on apoptotic 
myocyte death when added at different time points during reperfusion 
 
ZVAD-fmk (25 µM) administered immediately at the start of reoxygenation and 15 min, 30 
min and 60 minutes after starting reoxygenation resulted in a significant decrease in % 
apoptotic myocytes when compared to hypoxia/reoxygenation control myocytes (16.1 ± 3.0 
%, 26.8 ± 1.7 %, 28.5 ± 1.9 %, 21.5 ± 2.3 % respectively vs 48.2 ± 3.8 % Hypox/Reox, 











anti-apoptotic effect at different time points of administration (Tukey’s post-hoc test 



































Figure 4.12: Assessment of myocytes apoptosis in isolated adult rat cardiomyocytes 
subjected to 6 hours hypoxia and 18 hours of reoxygenation. The broad spectrum 
caspase inhibitor (ZVAD, 25µM) was added at different time points during 
reoxygenation. Results are shown as mean + SEM and are expressed as a percentage 
of the total cells counted.* p<0.05 vs. Normoxia, $ p<0.05 vs Hypox/Reox, n=5. 
4.3.3.5 The effect of the broad spectrum caspase inhibitor (ZVAD, 25µM) on necrotic 
myocyte death when added at different time points during reoxygenation 
 
Adding ZVAD (25µM) at the start of reoxygenation period reduced the necrotic cell death 
significantly when compared to hypoxia/reoxygenation control myocytes (10.0 ± 3.4 vs 
33.5 ± 2.2 %, Tukey’s post-hoc test p<0.001) Figure 4.13. Delayed administration of 
ZVAD at 15 min, 30 min and 60 min after starting reoxygenation had no significant effect 
on necrotic cell death when compared to hypoxia/reoxygenation myocytes (31.0 ± 4.5, 24.4 
± 3.3, 23.5 ± 2.1 respectively vs 34.69± 2.27 % Hypox/Reox, Tukey’s post-hoc test p>0.05) 
Figure 4.13. 
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Figure 4.13: Assessment of myocyte necrosis in isolated adult rat cardiomyocytes 
subjected to 6 hours hypoxia and 18 hours of reoxygenation. The broad spectrum 
caspase inhibitor (ZVAD, 25µM) was added at different time points during 
reoxygenation. Results are shown as mean + SEM and are expressed as a percentage 
of the total cells counted.* p<0.05 vs. Normoxia, $ p<0.05 vs Hypox/Reox. £ p<0.05 vs. 
ZVAD at Reox, n=5. 
4.3.3.6 The effect of the broad spectrum caspase inhibitor (ZVAD, 25µM) on 
intracellular Caspase-3 activity level when added at different time points during 
reperfusion 
 
Caspase-3 is a pivotal effector caspase and an essential protease of the apoptotic machinery. 
Caspase-3 activity was measured using intracellular staining methods and analysed using 
flow cytometry. Isolated myocytes underwent 6 hours of hypoxia in 5% CO2 0% O2 
followed by 18 hours of reoxygenation. ZVAD (25µM) was administered at the start of 
reoxygenation, 15 minutes, 30 minutes and 60 minutes after starting reoxygenation 
throughout. 6 hours hypoxia followed by 18 hours reoxygenation resulted in a significant 
increase in intracellular caspase-3 activity when compared to the control normoxia cells 







significantly decreased caspase-3 activity when administered at all time points during 
reoxygenation (ZVAD at Reox 141.92 ± 26.63, ZVAD at 15 min Reox 123.84 ± 13.73%, 
ZVAD at 30 min Reox 138.50 ± 29.58 %, ZVAD at 60 min Reox 155.13 ± 21.35, vs 








































Figure 4.14. Caspase 3 activity in isolated adult rat cardiac myocytes subjected to 6 
hours of hypoxia followed by 18 hours of reoxygenation. The broad spectrum caspase 
inhibitor (ZVAD, 25 µM) was administered at different time points during 
reoxygenation. *p<0.05 vs. Normoxia, $ p<0.05 vs. Hyp/Reox. Results are shown as 
means +SEM, n=6. 
4.3.3.7 The effect of the specific caspase-3 inhibitor (DEVD, 25µM) on myocytes 
viability when added at different time points during reperfusion 
 
DEVD (25µM) restored viable cells back to normoxia control values when added at the 
start of reoxygenation, 15 minutes, 30 minutes and 60 minutes after starting reoxygenation. 
This cytoprotection was significantly different to the hypoxia/reoxygention control 







DEVD at 30 min Reox, 53.4 ± 3.8 DEVD at 60 min Reox vs 18.2 ± 2.6 % Hypox/Reox, 



































Figure 4.15: Assessment of cellular viability in isolated adult rat cardiomyocytes 
subjected to 6 hours hypoxia and 18 hours of reoxygenation. The specific caspase-3 
inhibitor (DEVD, 25µM) was added at different time points during reoxygenation. 
Results are shown as mean + SEM and are expressed as a percentage of the total cells 
counted.* p<0.05 vs. Normoxia, $ p<0.05 vs Hypox/Reox, n=5. 
4.3.3.8 The effect of the specific caspase-3 inhibitor (DEVD, 25µM) on apoptotic 
myocyte death when added at different time points during reoxygenation 
 
DEVD (25µM) significantly reduced the apoptotic cell population to almost the normoxia 
control cells level when administered at the start of reoxygenation, 15 minutes, 30 minutes 
and 60 minutes after starting reoxygenation (22.4 ± 4.6 % DEVD at Reox, 18.9 ± 5.2 % 
DEVD at 15 min Reox, 28.8 ± 5.5 % DEVD at 30 min Reox, 23.3 ± 4.5 % DEVD at 60 








































Figure 4.16: Assessment of cellular apoptosis in isolated adult rat cardiomyocytes 
subjected to 6 hours hypoxia and 18 hours of reoxygenation. The specific caspase-3 
inhibitor (DEVD, 25µM) was added at different time points during reoxygenation. 
Results are shown as mean + SEM and are expressed as a percentage of the total cells 
counted.* p<0.05 vs. Normoxia, $ p<0.05 vs Hypox/Reox, n=5. 
4.3.3.9 The effect of the specific caspase-3 inhibitor (DEVD, 25µM) on necrotic 
myocytes death when added at different time points during reperfusion 
 
Adding DEVD (25µM) at the start of reoxygenation period significantly reduced the % 
necrotic cells when compared to the Hypox/Reox control myocytes (16.0 ± 5.2 vs 33.5 ± 
2.2 %, Tukey’s post-hoc test P< 0.05) Figure 4.17. There was no significant effect of 
delayed administration of DEVD at 15, 30 or 60 minute after starting reoxgenation on % 
necrotic myocytes when compared to the Hypox/Reox control myocytes (34.3 ± 4.5%, 28.4 
± 6.5%, 22.3 ± 3.8 % respectively vs 33.5 ± 2.2 % Hypox/Reox, Tukey’s post-hoc test p> 









































Figure 4.17: Assessment of cellular necrosis in isolated adult rat cardiomyocytes 
subjected to 6 hours hypoxia and 18 hours of reoxygenation. The specific caspase-3 
inhibitor (DEVD, 25µM) was added at different time points during reoxygenation. 
Results are shown as mean + SEM and are expressed as a percentage of the total cells 
counted.* p<0.05 vs. Normoxia, $ p<0.05 vs. Hypox/Reox, n=5. 
4.3.3.10 The effect of the specific caspase-3 inhibitor (DEVD, 25µM) on intracellular 
Caspase-3 activity level when added at different time points during reperfusion 
 
Hypoxia/Reoxygenation injury resulted in a significant increase in caspase-3 activity when 
compared to the control normoxia cells (375.47 ± 90.88 % vs 100 %, Tukey’s post-hoc test 
p<0.001) Figure 4.18. DEVD (25µM) significantly decreased caspase-3 activity when 
administered at the start of reoxygenation, 15 minutes, 30 minutes and 60 minutes after 
starting reoxygenation (DEVD at Reox 127.52 ± 21.19, DVD at 15 min Reox 145.18 ± 
54.38 %, DEVD at 30 min Reox 136.03 ± 22.86 %, DEVD at 60 min Reox 155.20 ± 33.37 
















































Figure 4.18: Caspase 3 activity in isolated adult rat cardiac myocytes subjected to 6 
hours of hypoxia followed by 18 hours of reoxygenation. The specific caspase 3 
inhibitor (DEVD, 25 µM) was administered at different time points during 
reoxygenation. *p<0.05 vs. Normoxia. $ p<0.05 vs. Hyp/Reox. Results are shown as 
means +SEM, n=6. 
4.3.3.11 Results summary 
In summary both the broad spectrum caspase inhibitor (ZVAD) and the specific caspase 3 
inhibitor (DEVD) resulted in significant cardioprotection by siginicant reduction in 
infarction size within the risk area, significant reduction in apoptotic and necrotic cellular 
death and siginificant reduction in intracellular caspase 3 acitivity. This cardioprotection 
was observed at all times of administration as shown n table 4.1. Same control ischemic 
group was used for all langendorff experiments and same control hypox/reox group was 











Normoxia  68.0± 2.9 13.8± 3.0 18.2 ±2.0 100% 
Control 
Ischemia/Rep 
54.2±6.6 18.2±5.1 48.2± .8 33.5± 2.2 375.5±90.88 
ZVAD@Rep 17.3±2.0* 73.9±6.2* 6.1±3.0* 10.0±3.4* 141.9±26.6* 
ZVAD@15min 
Rep 
30.5±3.4* 42.1± 6.5* 26.8±1.7* 31.0±4.5 123.8±13.7* 
ZVAD@30min 
Rep 
31.6±4.0* 47.0±3.6* 28.5±1.9* 24.4±3.3 38.5±29.6* 
ZVAD@60min 
Rep 
31.5±6.6* 55.0±4.3* 21.5±2.3* 23.5±2.1 155.1± 1.4* 
DEVD@Rep 14.4±3.9* 61.5±8.6* 22.4±4.6* 16.0±5.2* 127.5±21.2* 
DEVD@15min 
Rep 
15.7±3.6* 46.8±3.3* 18.9±5.2* 34.3±4.5 145.2±54.4* 
DEVD@30min 
Rep 
18.5±3.7* 42.8±6.5* 28.8±5.5* 28.4±6.5 136.0±22.9* 
DEVD@60min 
Rep 
26.5± 5.1* 53.4 ±3.8* 23.3± 4.5* 22.3 ±3.8 155.2±33.4* 
 
Table 4.1 Summary table showing the effect of the broad spectrum caspase inhibitor 
(ZVAD) and the specific caspase 3 inhibitor (DEVD) on I/R%, cellular viability, 
apoptosis, necrosis and intracellular caspase 3 activity. Results are shown as mean ± 
SEM * p<0.05 vs. control ischemia reperfusion. 
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4.4 Discussion  
4.4.1 Cardioprotective effect of caspase inhibitors when administered at different time 
points during reperfusion 
 
This study demonstrated that, the broad spectrum caspase inhibitor (ZVAD) and the 
specific caspase-3 inhibitor (DEVD) were cardioprotective when introduced immediately at 
the start of reperfusion by reducing infarct size through an anti-apoptotic and anti-necrotic 
effect. Delayed administration of aforementioned caspase inhibitors at 15 min, 30 min and 
60 min after starting reperfusion were still cardioprotective by reducing infarct size through 
an anti-apoptotic effect.  
 
This cardioprotective effect of the aforementioned caspase inhibitors when introduced 
immediately after starting reperfusion were in agreement with previous studies (Mocanu et 
al., 2000, McCully et al., 2004), where they showed cardioprotective effect of caspase 
inhibitors when introduced immediately after starting reperfusion. Studies investigating the 
effect of introducing caspase inhibitors after starting reperfusion are limited in number and 
their results are contradictory. Armstrong et al., (2001) presented an abstract at the 
American Heart Association showing that unidentified caspase inhibitor (IDN6734) 
reduced infarct size up to 50% when added at the start of reperfusion and only by 27% 
when administered one hour after the heart attack using rat in vivo model. However Li et 
al., (2001) using isolated adult rabbit cardiomyocytes showed that caspase inhibitors 
(unidentified) were partially protective if added 15 min after reperfusion but that effect was 
completely lost with a delay of 30 or 60 minutes after the start of reperfusion. In our study 
we showed that both broad spectrum and specific caspase-3 inhibitors were 
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cardioprotective even when administered one hour after reperfusion. Furthermore, this 
study compared the effect of these caspase inhibitors at different time points during 
reperfusion, to show that caspase inhibitors introduced one hour after reperfusion are 
almost as cardioprotective as if they were introduced at the time reperfusion started.  
 
We observed a dose dependent effect of ZVAD and DEVD on its ability to increase cellular 
viability and decrease cellular necrosis and apoptosis using adult rat ventricular myocytes 
model (ARVMs) when compared to their cardioprotective effect using langendorff model. 
A high dose of 25µM was required to show significant cardioprotection using ARVMs 
model which is the lowest effective dose found by a previous study using similar model 
(Kang et al., 2000). The effective inhibitory concentration of caspase inhibitors is variable 
among different studies, cytoprotective effect was showed at a doses ranging from 10µM -
100µM using the ARVMs model of hypoxia/Reoxygenation (Gottlieb et al., 1996, Kang et 
al., 2000, Hai et al., 2001), on the other hand infarction size was significantly reduced at 
lower doses of the caspase inhibitors as 0.07µM and 0.1µM (Mocanu et al., 2000). This 
variability could be attributed to the different models used and to the prolonged reperfusion 
period in ARVMs model when compared to langendorff model. Isolated hearts perfused 
using Langendorff model is viewed as an invaluable and first choice in vitro model in the 
development and assessment of anti-ischemic protective interventions (Hearse & 
Suttherland, 2000), however the maintainance of cellular homeostasis is limted and porn to 
deterioration over short time (Ytrhus, 2000). ARVMs model allows studying ischemia 
reperfusion injury over extended time course when we compare it to langendorff model 
(Ytrhus, 2000). Furthermore it allows measurment of differential cellular death types. 
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Therefore using these two models in our study is essential to expand our knowledge about 
the role of caspase inhibitors in myocardial ischemia reperfusion injury befor applying 
them in clinical field. 
4.4.2 Differential contribution of apoptosis and necrosis to ischemia reperfusion 
injury and the effect of caspase inhibitors when administered at different time points 
during reoxygenation 
 
The results of this study showed that ischemia reperfusion of the cardiomyocytes resulted 
in a significant increase in apoptosis, necrosis and caspase-3 activity level. The individual 
contribution of apoptosis and necrosis to cell death during myocardial ischemia reperfusion 
injury and at what point they contribute to myocyte death is still controversial (Gottlib & 
Engler, 1999). In our model of hypoxia/reoxygenation using adult rat ventricular myocytes, 
results showed a significant increase in both apoptotic and necrotic myocyte death with 
hypoxia/reoxygenation injury when compared to myocytes under normal conditions. This 
implies that both types of myocyte death are involved in ischemia reperfusion injury, these 
results were in agreement with previous studies (Buja & Entman, 1998, Yoaita et al., 1998, 
Fliss et al., 1996). Interestingly, this study showed that apoptosis contribution to myocytes 
death during hypoxia reoxygenation injury is significantly greater than necrotic myocyte 
death. However McCully et al., (2004) showed that contribution of necrosis to infarct size 
is greater than apoptosis using rabbit isolated hearts. They might be underestimated 
apoptosis in their 3 hours reperfusion model compared to 18 hours of oxygenation in our 
model, as previous studies have shown that apoptosis increased progressively with time 
after starting reperfusion and peaked out within several hours after myocardial ischemia 
(Anversa et al., 1998, Buja & Entman 1998). 
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Both Caspase inhibitors when administered at the start of reperfusion in this study resulted 
in a significant reduction of infarct size which could be attributed to a significant increase 
in cell viability, significant decrease in apoptosis and significant decrease in necrosis. 
However infarction reducing effect of delayed administration of caspase inhibitors 15 min, 
30 min and 60 min after starting reperfusion was mainly through anti-apoptotic effect 
without any significant change in necrosis. The anti-apoptotic and anti-necrotic effect of 
caspase inhibitors in this study was in agreement with previous studies, where it has been 
suggested that caspase inhibitors might have both anti apoptotic and anti-necrotic effect; 
furthermore it was revealed that caspase inhibitors retarded necrotic cell death as well as 
apoptotic cell death in an in vitro system of chemical hypoxia (Shimizu et al., 1996 a, 
Shimizu et al., 996b, Shimizu et al., 1996c). This significant cardioprotection by caspase 
inhibitors through anti-apoptotic effect without any anti-necrotic effect when administered 
at delayed time points during reperfusion highlighted the significant role played by 
apoptosis in exacerbation and extension of ischemia reperfusion injury. This also indicates 
that apoptosis contribution to cellular death during ischemia reperfusion injury is 
significantly more at later time points after starting reperfusion. In addition this provides 
evidence that caspase activation, which might be initiated during ischemia, but their 
irreversible cellular injury, does not occur until later time during reperfusion. This is 
supported by a study by Vanden Hoek et al., (2003), where they reported that at least 2 
hours of reperfusion was required to detect a significant level of caspase-3 activity required 




The similar significant cardioprotection through anti-apoptotic effect offered by the broad 
spectrum and selective caspase inhibitors in this study raises the possibility that these 
compounds might have non-specific actions. Berger et al., (2006) tested different selective 
caspase inhibitors and the results showed that none of the compounds are highly selective 
and all exhibit broad inhibition and cross reactivity. In addition even though both caspase 
inhibitors in our study resulted in a significant decrease in caspase-3 activity (downstream 
effector caspase), they might have an inhibitory effect on other proteases implicated in 
myocardial ischemia reperfusion injury such as calpains (Yoshida et al., 1995, 1999, 
Iwamoto et al., 1999, Khalil et al., 2005). Calpains, which are also cysteine proteases and 
share many common substrates with caspase 3 (Wang, 2000), are involved in both necrotic 
and apoptotic cell death as shown by McGinnis et al., (1999). Calpain inhibitors have also 
been shown to reduce ischemia reperfusion injury (Perrin et al., 2003, Khalil et al., 2005). 
Therefore the inhibitory effect of caspase inhibitors on Calpains can not be ruled out in this 
study. In addition caspase inhibitors have also been found to efficiently inhibit cathepsin B 
activity in vitro and in tissue culture cells (Schotte et al., 1998, Gray et al., 2001), which is 
another cystein protease enzyme that has already been, implicated in some apoptotic 
models (Guicciardi et al., 2000, Stoka et al., 2001). Therefore non-caspase related 






4.4.3 The effect of caspase inhibitors on heart haemodynamics when added at 
different time points during reperfusion 
 
An analysis of hemodynamic parameters were taken in the isolated perfused rat heart 
langendorff studies in order to determine if there were any functional changes occurring 
with caspase inhibitors treatment. In this study we found that both broad spectrum caspase 
inhibitor (ZVAD) and specific caspase-3 inhibitor (DEVD) had no significant effect on 
systemic hemodynamic, LVDP and HR or on coronary flow compared to control 
ischemia/reperfusion hearts. Insignificant effect of caspase inhibitors on functional 
recovery has been shown by different studies using langendorf model (Mocanu et al., 2000, 
McCully et al., 2004). Using langendorff perfusion model; functional parameters declined 
steadily during the experimental time course even without any ischemic intervention 
(Mocanu et al., 2000), therefore it is not a truly reliable model to assess functional recovery 
of the hearts post treatment. 
4.4.4 Clinical implications of the study 
 
Clinically, patients rarely present to hospital before the onset of ischemia (heart attack), 
however they usually seek medical attention after the onset of ischemia and reperfusion. 
Therefore, the implementation of cardioprotective therapy at the time of reperfusion is 
clinically feasible because the onset of reperfusion is more predictable and is under the 
clinician's control. In comparison to well established and gold standard ischemic 
preconditioning which protects myocardial tissue through adaptive mechanisms exerted 
primarily during ischemia (Murray et al., 1986), postconditioning applied at the onset of 
reperfusion, exerts protection during very early reperfusion (Zhao et al., 2003). Ischemic 
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postconditioning is a new evolving and promising area in clinical medicine, introducing 
drugs after starting reperfusion as indicated in our study can be considered as a form of 
pharmacological postconditioning which is more clinically feasible for patients. The results 
of our study, suggest that delayed administration of caspase inhibitors after reperfusion (as 
in the clinical setting of heart attack), may still salvage myocardium. In addition, the results 
of our study provide evidence that the therapeutic window of myocardial infarction 
treatment can be prolonged for at least an hour after starting reperfusion using caspase 
inhibitors, which is again more clinically applicable. This implies that the therapeutic 
window for caspase inhibition in myocardial ischemia reperfusion treatment is longer than 
for most cardioprotective drugs tested. Hussain (2006) showed that administration of A3 
agonist CL-IB-MECA 15 min and 30 min after starting reperfusion is still cardioprotective, 
howeverer cardioprotection was lost with delayed administration of 60 min after starting 
reperfusion. Boucher et al., (2004) reported that delaying administration of A2a agonist 5 
minutes after reperfusion abolishes its protective effect seen when administered at the start 
of reperfusion. Jonassen et al., 2000 showed that administration of hormone insulin 15 
minutes after the onset of reperfusion resulted in a loss of the protection seen when 
administered at reperfusion.  
 
The effective inhibitory dose of caspase inhibitors varied betweeen models used as we 
mentioned above. Using high dose of caspase inhibitors might have unwanted side effects 
when applied in clinical field. As apotosis and caspase activation occurred in pathological 
as well as physiological conditions, therefore applying caspase inhibitors in high doses 
might affect more essential physiological process leading to more unwanted side effect. 
 
 119 
Therefore further studies needed to evaluate the effective inhibitory dose to be used in 
ischemic heart disease treatment with inimal unwanted side effect.  
4.4.5 Conclusion 
 
In conclusion, this study showed that caspase inhibitors significantly reduced myocardial 
infarction size and increased cellular viability through an anti-apoptotic effect via inhibition 
of downstream effector caspase-3, when administered at different time points during 
reperfusion. This implies that the therapeutic window of caspase inhibitors could be 
prolonged for at least one hour after starting reperfusion, which is more clinically 
applicable time frame in treating patients with myocardial infarction. Furthermore, this 
study adds to current literature further evidencing about the significant role played by 






Myocardial Protection during Early Reperfusion by Administration of 
Caspase Inhihibitors is mediated via PI3-Akt Survival Pathway 
 
5.1 Introduction and objectives 
 
The caspase are group of cysteine proteases, which represent the executionary machine of 
apoptosis (Cryns & Yaun, 1998). Caspase, can be activated by two main pathways, the first 
is mediated by cell surface death receptors, leading to autoactivation of caspase-8, which in 
turn activates downstream effector caspase such as caspase-3, 6 and 7 (Budihardjo et al., 
1999). The second pathway is mediated by mitochondria, which release cytochrome c, 
which can associate with Apaf-1 (apoptosis protease activating factor) and pro-caspase-9, 
triggering the activation of caspase-3 and apoptosis (Kromer et al., 1997). Synthetic 
caspase inhibitors have been shown to be cardioprotective in our previous study (chapter 4) 
and in other studies (Haung et al., 2000, Mocanu et al., 2000); however the precise 
mechanism behind their cardioprotection is not yet clear. The caspase inhibitor (ZVAD) 
also failed to inhibit cytochrome c release from mitochondria using primary neonatal rat 
cardiomyocytes culture model, which suggests that cytochrome c release is upstream and 
independent of caspase activation (Bialik et al., 1999). Therefore, research indicates that 
caspase inhibitors mediated cardioprotection is not dependent on mitochondrial cytochrome 
c pathway. An alternative mechanism operating at the level of cytosolic caspase activation 
can be suggested. The fact that both the broad and the specific caspase inhibitors were 
effective to approximately the same degree, in spite of the fact that the inhibitors were 
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reported to exert specific and selective anti-caspase effects, raise a question about the 
specificity of these drugs and the mechanism behind their cardioprotection. This again 
raised the possibility that they might share the simillar pathways. 
 
There is abundant evidence in the literature suggesting that activation of PI3-Akt signalling 
pathway is a powerful survival signaling pathway leading to anti-apoptosis and anti-
necrosis and cell survival (Wu et al., 2000, Yin et al., 2004, Hausenloy et al., 2006). 
Cardioprotection conferred by postconditioing and preconditioning has been found to be 
mediated through activation of PI3-Akt survival signaling pathway (Hausenloy et al., 
2006). Furthermore, cadioprotection by pharmacological agents that mimic preconditioning 
effect such as bradykinin (Baxter & Ebrahim 2002), AMP579 (Strickler et al., 1996) and 
drugs applied during the early phase of reperfusion such as Insulin (Jonassen et al., 2001), 
Urocortin (Brar et al., 2000, Schulman et al., 2002), Bradykinin (Li & Sato 2001) and 
adenosine agonists (Schulte & Fredholm 2000), were also mediated through activation of 
PI3-Akt cell signalling pathway. Therefore, it appeared that activation of PI3-Akt survival 
kinase pathway may constitute a common survival pathway sufficient to induce a cardio-
protective response during early reperfusion phase (Hausenloy & Yellon, 2004). Caspase 
inhibitors showed a promising cardioprotection when applied during early phase of 
reperfusion, which could also be mediated by activation of PI3-Akt pathway. 
 
The aim of this study was to investigate whether cardioprotection by administration of the 
broad spectrum caspase inhibitor (ZVAD, 0.1µM and 25µM) or specific caspase-3 inhibitor 
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(DEVD, .07µM and 25µM) at different time points during reperfusion (at start of 
reperfusion, 15 min and 30 minutes after starting reperfusion) is mediated via PI3-Akt cell 





5.2.1 Langendorff heart reperfusion model (chapter 3 methods, section 3.4) 
 
Isolated rat hearts were subjected to 20 min stabilisation, and then underwent 35 min 
regional ischemia followed by 120 min reperfusion using Langendorff perfusion system. 
Caspase inhibitors (Broad spectrum caspase inhibitor, ZVAD, 0.1 µM and Specific 
caspase-3 inhibitor, DEVD, 0.07 µM) were added at the start of reperfusion, 15 minutes 
and 30 minutes after starting reperfusion in the presence and absence of PI3-Akt specific 
inhibitor Wortmannin (WORT, 100nM). At the end of the experimental protocol, infarction 
size to risk area ratio (I/R %) determined using TTC staining.  
5.2.3 Analysis of isolated adult rat ventricular myocytes using flow cytometry (chapter 
3 methods, section 3.6) 
 
Isolated adult rat ventricular myocytes underwent 6 hours of hypoxia followed by 18 hours 
of reoxygenation. Caspase inhibitors (ZVAD 25µM, DEVD 25µM) were added at the start 
of reoxygenation, 15 minutes and 30 minutes after starting reoxygenation in the presence 
and absence of PI3-Akt specific inhibitor Wortmannin (WORT, 100nM). At the end of the 
experimental protocol, apoptotsis, necrosis, viability and intracellular caspase-3 activity 
were measured using flow cytometry analysis. 
5.2.3 Western blot analysis (chapter 3 methods, section 3.5) 
 
Western blot analysis was used to determine the protein expression level of cytosolic 
cytochrome c in hearts treated with ZVAD (0.1µM) and DEVD (0.07µM) administerd at 
start of reperfusion, 15 minutes, 30 minutes and 60 minutes after starting reperfusion. 
Western blot analysis was also used to determine the protein expression level of phospho-
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Akt in hearts treated with ZVAD (0.1µM) and DEVD (0.07µM) in the presence and 
absence of PI3-Akt specific inhibitor Wortmannin (WORT, 100nM). A time course of 
administration with ZVAD and DEVD (5, 10, 20 and 120 minutes reperfusion) and 
analagous control ischemic-reperfused hearts was performed. Hearts treated with WORT 
were administered for only 10 minutes of reperfusion. Densitometry was measured using 
Quantity-One software.The mean density of control ischemic/reperfused hearts were 




5.3.1 Caspase inhibitors cardioprotection during early reperfusion phase is mediated 
via PI3-Akt kinase pathway. 
5.3.1.1 Myocardial infarct size to risk area ratio (I/R %) 
5.3.1.1.1 The cardioprotective effect of the broad spectrum caspase inhibitor (ZVAD, 
0.1µM) when added at the start of reperfusion is blocked by PI3-Akt inhibitor, 
Wortmannin (WORT, 100nM) 
 
In the present study, we aimed at assessing whether administration of PI3-Akt specific 
inhibitor Wortmannin (WORT, 100nM) would abolish the protection offered by the broad 
spectrum caspase inhibitor (ZVAD, 0.1µM) thus suggesting that the cardioprotective 
effects of ZVAD was via PI3-Akt pathway. There was a significant reduction in 
infarction/risk ratio (I/R %) with ZVAD treatment at the start of reperfusion throughout 
when compared to ischemic controls (ZVAD at reperfusion 17.3± 2, vs Control 54.3± 6.6, 
Tukey’s post-hoc test p<0.01) Figure 5.1. To test whether ZVAD mediated 
cardioprotection was via PI3-Akt kinase pathway, PI3-Akt inhibitor (WORT), was added at 
the onset of reperfusion simultaneously with ZVAD. WORT blocked ZVAD 
cardioprotection, showing a significant increase in I/R% compared to ZVAD treated group 
(WORT+ZVAD 50.8± 6.2 vs ZVAD at reperfusion 17.3± 2 Tukey’s post-hoc test p<0.01) 
Figure 5.1. Adding WORT alone at the start of reperfusion had no significant effect on 
I/R% compared to control (WORT 50 ± 4.4% vs Control 54.3 ± 6.6, Tukey’s post-hoc test 
p>0.05) Figure 5.1. Overall, there was a significant reduction in I/R% with ZVAD 
reperfused hearts in comparison to ischemic/reperfusion control hearts which was blocked 

























Figure 5.1: Infarct size to Risk ratio (%) in control and broad spectrum caspase 
inhibitor (ZVAD, 0.1µM) treated hearts. Isolated perfused rat hearts subjected to 35 
minutes of ischemia and 120 minutes of reperfusion where the ZVAD was 
administered at the start of reperfusion period throughout in the presence and 
absence of the of PI3-Akt inhibitor; Wortmannin (WORT, 100n M). *P<0.01 vs. 
Control $P<0.01 vs ZVAD. Results are shown as mean + SEM, n=5. 
5.3.1.1.2 The cardioprotective effect of the specific caspase-3 inhibitor (DEVD, 
0.07µM) when added at the start of reperfusion is blocked by PI3-Akt inhibitor, 
Wortmannin (WORT, 100nM) 
 
Treatment with specific caspase-3 inhibitor (DEVD, 0.07µM) immediately after starting 
reperfusion throughout resulted in significant cardioprotection when compared to ischemic 
control group (14.38 ± 3.87 % vs 54.25 ± 6.60 % control, Tukey’s post-hoc test p<0.01) 
Figure 5.2. This cardioprotection was significantly reduced by PI3-Akt inhibitor; 
Wortmannin (WORT, 100nM) when co-administered with DEVD at the start of reperfusion 
throughout, showing a significant increase in I/R% compared to DEVD treated group 
(DEVD+WORT 41.0 ± 5.5 % vs 14.38 ± 3.87 % EDVD at reperfusion, Tukey’s post-hoc 






reperfused hearts in comparison to ischemic/reperfusion control hearts which was blocked 























Figure 5.2: Infarct size to Risk ratio (%) in control and specific caspase-3 inhibitor 
(DEVD) treated hearts. Isolated perfused rat hearts subjected to 35 minutes of 
ischemia and 120 minutes of reperfusion. The DEVD (0.07µM) was administered at 
the start of reperfusion period throughout in the presence and absence of the PI3-Akt 
inhibitor; Wortmannin (WORT, 100nM). *P<0.01 vs. Control $P<0.01 vs DEVD. 
Results are shown as mean + SEM, n=5. 
5.3.1.2 Analysis of isolated adult rat ventricular myocytes using flow cytometry. 
5.3.1.2.1 The anti-apoptotic effect of the broad spectrum caspase inhibitor (ZVAD, 
25µM) when added at the start of reoxygenation is blocked by PI3-Akt inhibitor, 
Wortmannin (WORT, nM) 
 
Isolated cardiomyocytes underwent 6 hours of hypoxia in 5% CO2 0% O2 followed by 18 
hours of reoxygenation. Broad spectrum caspase inhibitor (ZVAD, 25µM) was 
administered throughout reoxygenation in the presence and absence of PI3-Akt inhibitor, 
Wortmannin (WORT, 100nM). Mean % apoptotic myocytel populations was significantly 
decreased with ZVAD treatment administered at the start of reoxygenation throughout in 






vs Hypox/Reox 48.25 ± 3.70 %, Tukey’s post-hoc test P<0.01) Figure 5.3. Treatment with 
PI3-Akt inhibitor (WORT) simultaneously with ZVAD abolished the anti-apoptotic 
cardioprotection afforded by ZVAD, showing a significant increase in % apoptotic 
myocytes compared to ZVAD treated myocytes (WORT+ZVAD at Reox 40.02 ± 6.2 % vs 
ZVAD at Reox 22.90 ± 4.77, Tukey’s post-hoc test p<0.05) Figure 5.3. % Apoptotic 
myocytes populations in treatment with WORT alone were comparable to control treated 
myocytes (Hypox/Reox 48.25 ± 3.70 vs WORT: 40.79 ± 5.136, Tukey’s post-hoc test p> 
0.05) Figure 5.3. Overall, there was a significant reduction in % apoptotic myocytes 
populations with ZVAD treated myocytes in comparison to control hypoxia/reoxygenation 

























Figure 5.3: Assessment of apoptosis in isolated adult rat cardiomyocytes subjected to 6 
hours hypoxia and 18 hours of reoxygenation. The broad spectrum caspase inhibitor 
(ZVAD, 25µM) was added at the onset of reoxygenation throughout in the presence 
and absence of the of PI3-Akt inhibitor; Wortmannin (WORT, 100nM). Results are 
shown as mean + SEM and are expressed as a percentage of the total cells counted.* 










5.3.1.2.2 The cytoprotective effect of the broad spectrum caspase inhibitor (ZVAD, 
25µM) when added at the start of reoxygenation is blocked by PI3-Akt inhibitor, 
Wortmannin (WORT, 100nM) 
 
Mean % viable myocytes populations was significantly increased with broad spectrum 
caspase inhibitor (ZVAD, 25µM) treatment administered at the start of reoxygenation 
throughout in comparison to control hypoxic / reoxgenenated myocytes (ZVAD at Reox 
63.62 ± 7.68 % vs Hypox/Reox 18.25 ± 3.89 %, P<0.01) Figure 5.4. Co-administration of 
PI3-Akt inibitor (WORT, 100nM) with ZVAD at the start of reoxygenation throughout 
significantly abrogated the protection afforded by ZVAD (ZVAD+WORT 35.58 ± 10.22 % 




























Figure 5.4: Assessment of cell viability in isolated adult rat cardiomyocytes subjected 
to 6 hours hypoxia and 18 hours of reoxygenation. The broad spectrum caspase 
inhibitor (ZVAD, 25µM) was added at the onset of reoxygenation in the presence and 
absence of the of PI3-Akt inhibitor; Wortmannin (WORT, 100n M).  Results are 
shown as mean + SEM and are expressed as a percentage of the total cells counted.* 











5.3.1.2.3 The anti-necrotic effect of the broad spectrum caspase inhibitor (ZVAD, 
25µM) when added at the start of reoxygenation is blocked by PI3-Akt inhibitor, 
Wortmannin (WORT, 100nM) 
 
Treatment with PI3-Akt inhibitor (WORT, 100 n M) and ZVAD (25µM) at the start of 
reoxygenation abolished the anti-necrotic effect afforded by ZVAD alone, showing a 
significant increase in % necrotic cells compared to ZVAD treated myocytes (ZVAD 10.0 
± 3.4 vs. WORT + ZVAD 24.4 ± 4.4, Tukey’s post-hoc test p<0.05) Figure 5.5. Treatment 
with WORT alone was comparable to hypoxia/reoxygenation control treated myocytes 
























Figure 5.5: Assessment of necrosis in isolated adult rat cardiomyocytes subjected to 6 
hours hypoxia and 18 hours of reoxygenation. The broad spectrum caspase inhibitor 
(ZVAD, 25µM) was added at the onset of reoxygenation throughout in the presence 
and absence of the of PI3-Akt inhibitor; Wortmannin (WORT, 100nM). Results are 
shown as mean + SEM and are expressed as a percentage of the total cells counted.* 








5.3.1.2.4 The inhibitory effect of the broad spectrum caspase inhibitor (ZVAD, 25µM) 
when added at the start of reoxygenation on caspase-3 activity level is blocked by PI3-
Akt inhibitor, Wortmannin (WORT, 100nM) 
 
To determine the role of the PI3K-Akt cell survival pathway on Caspase 3 activity level in 
broad spectrum caspase inhibitor (ZVAD, 25µM) mediated cardioprotection, isolated adult 
rat cardiac myocytes underwent 6 hours of hypoxia and 18 hours of reoxygenation where 
the ZVAD was administered in the presence and absence PI3-Akt inhibitor Wortmannin 
(100nM) throughout reoxygenation. Administration of ZVAD at reoxygenation 
significantly reduced caspase 3 activity compared to control non treated isolated adult rat 
cardiomyocytes subjected to 6 hours of hypoxia and 18 hours of reoxygenation (ZVAD at 
Reox 141.92 ± 26.63 % vs Hypo/Reox 375.47 ± 90.88%, Tukey’s post-hoc test p<0.05) 
Figure 5.6. Administration of the PI3-Akt inhibitor (WORT, 100nM) with the ZVAD at 
reoxygenation blocked the decrease in caspase 3 activity afforded by ZVAD when 
administered alone at reoxygenation (ZVAD+WORT at Reox 248.89 ± 37.85 % vs ZVAD 
at Reox 141.92 ± 26.63 %, Tukey’s post-hoc test P<0.05) Figure 5.6. WORT when 
administered alone had no significant effect on caspase 3 activity level compared to the 
control hypoxia/eoxygenation myocytes (WORT 308.0 ± 37.85 % vs Hypo/Reox 375.5 ± 



































Figure 5.6: Caspase 3 activity in isolated adult rat cardiac myocytes subjected to 6 
hours of hypoxia followed by 18 hours of reoxygenation. The broad spectrum caspase 
inhibitor (ZVAD, 25µM) was administered at the onset of reoxygenation in the 
presence and absence of the of PI3-Akt inhibitor; Wortmannin (WORT, 100nM). 
Results are shown as mean + SEM and are expressed as a percentage of the normoxia 
control values. * p<0.05 vs. Normoxia & p<0.05 vs. Hypox/Reox Control $ p<0.05 vs. 
ZVAD at Reox, n=5. 
5.3.1.2.5 The anti-apoptotic effect of the specific caspase-3 inhibitor (DEVD, 25µM) 
when added at the start of reoxygenation is blocked by PI3-Akt inhibitor, 
Wortmannin (WORT, 100nM) 
 
Treatment with specific caspase-3 inhibitor (DEVD, 25µM) at the start of reoxygenation 
throughout resulted in a significant decrease in % apoptotic myocyte population when 
compared to hypoxia/reoxygenation control myocytes (DEVD at Reox 22.39 ± 5.94%. vs 
Hypo/Reox 48.24 ± 3.70 %, Tukey’s post-hoc test p<0.05) Figure 5.7. Results showed that 
PI3-Akt inhibitor; wortmannin (WORT, 100nM) abolished anti-apoptotic effect afforded by 
DEVD when added simultaneously at the start of the reoxygenation throughout 
(DEVD+WORT at Reox 40.79 ± 5.13 vs DEVD at Reox 22.39 ± 5.94%, Tukey’s post-hoc 

































Figure 5.7: Assessment of apoptosis in isolated adult rat cardiomyocytes subjected to 6 
hours hypoxia and 18 hours of reoxygenation. The specific caspase-3 inhibitor 
(DEVD, 25µM) was added at the onset of reoxygenation in the presence and absence 
of the of PI3-Akt inhibitor; Wortmannin (WORT, 100nM). Results are shown as 
mean + SEM and are expressed as a percentage of the total cells counted.* p<0.05 vs. 
Normoxia & p<0.05 vs. Hypox/Reox Control $ p<0.05 vs. DEVD at Reox, n=5. 
5.3.1.2.6 The cytoprotective effect of the specific caspase-3 inhibitor (DEVD, 25µM) 
when added at the start of reoxygenation is blocked by PI3-Akt inhibitor, 
Wortmannin (WORT, 100nM) 
 
Mean % viable cell populations were significantly increased with DEVD treatment in 
comparison to control hypoxic/reoxgenenated myocytes (Hypox/Reox 18.25 ± 3.89 % vs. 
DEVD at Reox 61.54 ± 3.89 %, Tukey’s post-hoc test p<0.05) Figure 5.8. Treatment with 
PI3-Akt inhibitor (WORT, 100nM) abolished the protection afforded by DEVD showing a 
significant decrease in % viable cells compared to DEVD treated myocytes (DEVD at Reox 
































Figure 5.8: Assessment of cells viability in isolated adult rat cardiomyocytes subjected 
to 6 hours hypoxia and 18 hours of reoxygenation. The specific caspase-3 inhibitor 
(DEVD, 25µM) was added at the onset of reoxygenation in the presence and absence 
of the of PI3-Akt inhibitor; Wortmannin (WORT, 100nM). Results are shown as 
mean + SEM and are expressed as a percentage of the total cells counted.* p<0.05 vs. 
Normoxia & p<0.05 vs. Hypox/Reox Control $ p<0.05 vs. DEVD at Reox, n=5. 
5.3.1.2.7 The anti-necrotic effect of the specific caspase-3 inhibitor (DEVD, 25µM) 
when added at the start of reoxygenation is blocked by PI3-Akt inhibitor, 
Wortmannin (WORT, 100nM) 
 
Administration of the specific-caspase-3 inhibitor (DEVD, 25µM) at the start of 
reoxygenation throughout significantly decreased the necrotic cell population when 
compared to control Hypoxia/reoxygenated myocytes (16.0 ± 5.2 % vs. 33.5 ± 2.1 % 
Hyp/Reox, Tukey’s post-hoc test p<0.05) Figure 5.9. This anti-necrotic effect of DEVD 
was abolished in the presence of the PI3-Akt inhibitor (WORT, 100nM) (25.2 ± 2.0 % vs 
16.0 ± 2.1 DEVD at Reox, Tukey’s post-hoc test p<0.05) Figure 5.9. The PI3-Akt inhibitor 
alone had no significant effect on necrotic cell populaton when compared to control 
hypoxia/reoxenated myocytes (24.5 ± 4.2 vs 33.5 ± 2.1 Hypox/Reox, Tukey’s post-hoc test 
































Figure 5.9: Assessment of necrosis in isolated adult rat cardiomyocytes subjected to 6 
hours hypoxia and 18 hours of reoxygenation. The specific caspase-3 inhibitor 
(DEVD, 25µM) was added at the onset of reoxygenation in the presence and absence 
of the of PI3-Akt inhibitor; Wortmannin (WORT, 100nM). Results are shown as 
mean + SEM and are expressed as a percentage of the total cells counted.* p<0.05 vs. 
Normoxia & p<0.05 vs. Hypox/Reox Control $ p<0.05 vs. DEVD at Reox. n=5 
5.3.1.2.8 The inhibitory effect of the specific caspase3 inhibitor (DEVD, 25µM) when 
added at the start of reoxygenation on caspase-3 activity is blocked by PI3-Akt 
inhibitor, Wortmannin (WORT, 100nM) 
 
Administration of the specific caspase-3 inhibitor (DEVD, 25µM) at reoxygenation 
throughout significantly reduced caspase 3 activity compared to non treated isolated adult 
rat cardiomyocytes subjected to 6 hours of hypoxia and 18 hours of reoxygenation (127.5 ± 
21.2 % vs Hypo/Reox 375.5 ± 91.0%, Tukey’s post-hoc test p<0.05) Figure 5.10. 
Administration of the PI3-Akt inhibitor (WORT, 100nM) with the DEVD at reoxygenation 
blocked the decrease in caspase 3 activity afforded by DEVD when administered at 
reoxygenation (242.4 ± 19.7 % vs DEVD at Reox 127.5 ± 21.2 %, Tukey’s post-hoc test 





3 activity level compared to the hypoxia/reoxygenated control myocytes (WORT 308.1 ± 

































Figure 5.10: Caspase 3 activity in isolated adult rat cardiac myocytes subjected to 6 
hours of hypoxia followed by 18 hours of reoxygenation. The specific caspase-3 
inhibitor (DEVD, 25µM) was administered at the onset of reoxygenation in the 
presence and absence of the of PI3-Akt inhibitor; Wortmannin (WORT, 100nM). 
Results are shown as mean + SEM and are expressed as a percentage of the normoxia 
control values. * p<0.05 vs. Normoxia & p<0.05 vs. Hypox/Reox Control $ p<0.05 vs. 
DEVD at Reox, n=5. 
 
5.3.1.2.9 Results summary 
In summary both the broad spectrum caspase inhibitor (ZVAD) and the specific caspase 3 
inhibitor (DEVD) resulted in significant cardioprotection by siginicant reduction in 
infarction size within the risk area, significant reduction in apoptotic and necrotic cellular 
death and siginificant reduction in intracellular caspase 3 acitivity when administered 
immediately after starting reperfusion. This cardioprotection was blocked by co 










Group I/R % Viability Apoptosis Necrosis Caspase 3 
activity (%of 
Normoxia) 
Normoxia  68.0± 2.9 13.8± 3.0 18.2 ±2.0 100% 
Control Ischemia/Rep 54.2±6.6 18.2±5.1 48.2± .8 33.5± 2.2 375.5±90.8 
ZVAD@Rep 17.3±2.0* 73.9±6.2* 16.1±3.0* 10.0±3.4* 141.9±26.6* 
DEVD@Rep 14.4±3.9* 61.5±8.6* 22.4±4.6* 16.0±5.2* 127.5±21.2* 
WORT 50.0±4.4 34.6±5.8 41.0±5.1 24.5 ±1.9 308.0 ±37.8 
ZVAD+WORT@Rep 50.8±6.2 35.6±10.2 40.0±6.2 24.4±4.4 249.0± 37.8 
DEVD+WORT@Rep 41.0±5.5 34.7±8.5 41.0±5.1 25.2±2.0 242.4±19.7 
 
Table 5.1 Summary table showing the effect of the broad spectrum caspase inhibitor 
(ZVAD) and the specific caspase 3 inhibitor (DEVD) on I/R%, cellular viability, 
apoptosis, necrosis and intracellular caspase 3 activity when admisitered at the start 
of reperfusion in the presence and absence of the of PI3-Akt inhibitor; Wortmannin 





5.3.2 Caspase inhibitors cardioprotection during late phase of reperfusion is not 
mediated via PI3-Akt kinase pathway. 
5.3.2.1 Myocardial infarct size to risk area ratio (I/R %) 
5.3.2.1.1 The cardioprotective effect of the broad spectrum caspase inhibitor (ZVAD, 
0.1µM) when added at 15 minutes and 30 minutes after starting reperfusion is not 
blocked by PI3-Akt inhibitor, Wortmannin (WORT, 100nM) 
 
As we demonstrated in chapter 4, delayed administraton of the broad spectrum caspase 
inhibitor (ZVAD, 0.1µM) 15 minutes and 30 minutes after starting reperfusion was still 
cardioprotective. In this study, we aimed at assessing whether administration of PI3-Akt 
specific inhibitor Wortmannin (WORT, 100nM) would abolish the protection offered by 
ZVAD thus suggesting that the cardioprotective effects of ZVAD at 15 minutes and 30 
minutes after starting reperfusion was via PI3-Akt pathway. There was significant reduction 
in infarction/risk ratio (I/R %) with ZVAD administered at 15 minutes and 30 minutes after 
starting reperfusion when compared to ischemic controls hearts (ZVAD at 15 minutes 
30.48 ± 3.41%, ZVAD at 30 minutes 31.60 ± 3.99% vs Control 54.3± 6.6, p<0.01) Figure 
5.11. However, adding PI3-Akt inhibitor; Wortmannin (WORT) simultaneously with 
ZVAD at 15 minutes and 30 minutes after starting reperfusion did not block ZVAD 
mediated cardioprotection (WORT+ZVAD at 15 minutes 29.6± 4.7, WORT+ZVAD at 30 














































Figure 5.11: Infarct size to Risk ratio (I/R %) in control and broad spectrum caspase 
inhibitor (ZVAD, 25µM) treated hearts. Isolated perfused rat hearts  subjected to 35 
minutes of ischemia and 120 minutes of reperfusion where the ZVAD was 
administered at 15 and 30 minutes after starting reperfusion period in the presence 
and absence of the of PI3-Akt inhibitor; Wortmannin (WORT, 100nM). *P<0.01 vs. 
Control. Results are shown as mean + SEM, n=5. 
 
5.3.2.1.2 The cardioprotective effect of the specific caspase-3 inhibitor (DEVD, 
0.07µM) when added at 15 minutes and 30 minutes after starting reperfusion is not 
blocked by PI3-Akt inhibitor, Wortmannin (WORT, 100nM) 
 
Treatment with specific caspase-3 inhibitor (DEVD, 0.07 µM) at 15 minutes and 30 
minutes after starting reperfusion resulted in a significant decrease in I/R % (DEVD at 15 
minutes 15.71 ± 3.59 %. DEVD at 30 minutes 18.51 ± 3.69 % vs Control 54.25 ± 6.60 % 
p<0.01) Figure 5.12. Results showed that PI3-Akt inhibitor; wortmannin (WORT, 100nM) 
did not block DEVD mediated cardioprotection when added simultaneously at 15 minutes 
and 30 minutes after starting reperfusion (DEVD+WORT at 15 minutes reperfusion 17.96 
* * * * 
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± 4.3 %, DEVD+WORT at 30 minutes reperfusion 18.9 ± 3.6 % vs Control 54.25 ± 6.60 % 
































Figure 5.12: Infarct size to Risk ratio (I/R %) in control and specific caspase-3 
inhibitor (DEVD, 0.07µM) treated hearts. Isolated perfused rat hearts subjected to 35 
minutes of ischemia and 120 minutes of reperfusion.The DEVD was administered at 
15 and 30 minutes after starting reperfusion period in the presence and absence of the 
of PI3-Akt inhibitor; Wortmannin (WORT, 100nM). *P<0.01 vs. Control Results are 
shown as mean + SEM, n=5. 
5.3.2.2 Analysis of isolated adult rat ventricular myocytes using flow cytometry. 
5.3.2.2.1 The anti-apoptotic effect of the broad spectrum caspase inhibitor (ZVAD, 
25µM) when added at 15 minutes and 30 minutes after starting reoxygenation is not 
blocked by PI3-Akt inhibitor, Wortmannin (WORT; 100nM) 
 
Delayed administration of the broad spectrum caspase inhibitor (ZVAD, 25µM) 15 minutes 
and 30 minutes post reoxygenation significantly decreased the % apoptotic myocytes when 
compared to contol Hypox/Reox myocytes (26.8 ± 1.7 %, 28.5 ± 5.1 % respectively vs. 
48.2 ± 3.8 % Hyp/Reox, Tukey’s post-hoc test, p<0.01) Figure 5.13. This anti-apoptotic 
effect by ZVAD at 15 minutes and 30 minutes was not affected by the PI3-Akt specific 
* * * * 
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inhibitor Wortmannin (WORT, 100nM) (23.7 ± 4.6 %, 20.3 ± 4.2 % respectively vs. 48.2 ± 







































Figure 5.13: Assessment of apoptosis in isolated adult rat cardiomyocytes subjected to 
6 hours hypoxia and 18 hours of reoxygenation. The broad spectrum caspase inhibitor 
(ZVAD, 25µM) was added at 15 minutes and 30 minutes after starting reoxygenation 
in the presence and absence of the of PI3-Akt inhibitor; Wortmannin (WORT, 
100nM). Results are shown as mean + SEM and are expressed as a percentage of the 
total cells counted.* p<0.05 vs. Normoxia & p<0.05 vs. Hypox/Reox Control, n=5. 
5.3.2.2.2 The cytoprotective effect of the broad spectrum caspase inhibitor (ZVAD, 
25µM) when added at 15 minutes and 30 minutes after starting repxygenation is not 
blocked by PI3-Akt inhibitor, Wortmannin (WORT/100nM) 
 
Delayed administration of (ZVAD, 25µM) 15 minutes and 30 minutes post reoxygenation 
significantly increased myocytes viabilty when compared to contol Hypox/Reox myocyte 
(42.1 ± 5.1 %, 47.0 ± 3.6 % respectively vs. 18.2 ± 5.1 % Hyp/Reox, Tukey’s post-hoc test, 
p<0.01) Figure 5.14. This cytoprotective effect by ZVAD at 15 minutes and 30 minutes 
was not abolished by the PI3-Akt specific inhibitor Wortmannin (WORT, 100nM) (47.0 ± 





4.3 %, 48.0 ± 2.2 % respectively vs. 18.2 ± 5.1 % Hyp/Reox, Tukey’s post-hoc test, 


































Figure 5.14: Assessment of myocytes viabilty in isolated adult rat cardiomyocytes 
subjected to 6 hours hypoxia and 18 hours of reoxygenation. The broad spectrum 
caspase inhibitor (ZVAD, 25µM) was added at 15 minutes and 30 minutes after 
starting reoxygenation in the presence and absence of the of PI3-Akt inhibitor; 
Wortmannin (WORT, 100nM). Results are shown as mean + SEM and are expressed 
as a percentage of the total cells counted.* p<0.05 vs. Normoxia, & p<0.05 vs. 
Hypox/Reox Control, n=5. 
5.3.2.2.3 The inhibitory effect of the broad spectrum caspase inhibitor (ZVAD, 25µM) 
when added at 15 minutes and 30 minutes after starting reoxygenation on caspase-3 
level is not blocked by PI3-Akt inhibitor, Wortmannin (WORT, 100nM) 
 
Results showed that there is a significant reduction in caspase-3 activity level after 
treatment with the broad spectrum caspase inhibitor (ZVAD, 25µM) administered at 15 
minutes and 30 minutes after starting reperfusion when compared to control myocytes 
exposed to hypoxia and reoxgenation conditions (ZVAD at 15 minutes 123.84 ± 13.70 %, 
ZVAD at 30 minutes 138.5 ± 29.58 % vs Hypox/Reox 375.5 ± 90.88 %, p<0.05) Figure 
5.15. However, adding PI3-Akt inhibitor; Wortmannin (WORT, 100nM) simultaneously 
* 
& & & & 
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with ZVAD at 15 minutes and 30 minutes after starting reoxygenation did not block ZVAD 
mediated reduction in caspase 3 activity (WORT+ZVAD at 15 minutes Reox 185.2 ± 26.8 
%, WORT+ZVAD at 30 minutes Reox 146.5 ± 35.26 % vs Hypox/Reox 375.5 ± 90.88 %, 






































Figure 5.15: Caspase 3 activity in isolated adult rat cardiac myocytes subjected to 6 
hours of hypoxia followed by 18 hours of reoxygenation. The broad spectrum caspase 
inhibitor (ZVAD, 25µM) was administered at 15 minutes and 30 minutes after 
starting reoxygenation in the presence and absence of the of PI3-Akt inhibitor; 
Wortmannin (WORT, 100nM). Results are shown as mean + SEM and are expressed 
as a percentage of the normoxia control values. * p<0.05 vs. Normoxia, & p<0.05 vs. 
Hypox/Reox Control, n=5. 
5.3.2.2.4 The anti-apoptotic effect of the specific caspase-3 inhibitor (DEVD, 25µM) 
when added at 15 minutes and 30 minutes after starting repxygenation is not blocked 
by PI3-Akt inhibitor, Wortmannin (WORT, 100nM) 
 
Treatment with PI3-Akt inhibitor (WORT, 100nM) and DEVD (25µM) simultaneously at 
15 minutes and 30 minutes after starting reoxygenation did not affect the anti-apoptotic 
effect afforded by DEVD alone, showing a significant decrease in % apoptotic 







7.4 %, 26.5 ± 5.0 % respectively vs. 19.0 ± 5.2 % DEVD at 30 min Reox and DEVD at 30 
minutes Reox 28.8 ± 5.5 %, Tukey’s post-hoc test p>0.05) Figure 5.16. Treatment with 
WORT alone was comparable to Hypox/Reox control treated cells (Hypox/Reox 33.5 ± 2.2 


































Figure 5.16: Assessment of myocyte apoptosis in isolated adult rat cardiomyocytes 
subjected to 6 hours hypoxia and 18 hours of reoxygenation. The specific caspase-3 
inhibitor (DEVD, 25µM) was added at 15 minutes and 30 minutes after starting 
reoxygenation in the presence and absence of the of PI3-Akt inhibitor; Wortmannin 
(WORT, 100nM). Results are shown as mean + SEM and are expressed as a 
percentage of the total cells counted.* p<0.05 vs. Normoxia, & p<0.05 vs. Hypox/Reox 
Control, n=5. 
5.3.2.2.5 The cytoprotective effect of the specific caspase-3 inhibitor (DEVD, 25µM) 
when added at 15 minutes and 30 minutes after starting repxygenation is not blocked 
by PI3-Akt inhibitor, Wortmannin (WORT, 100nM) 
 
Mean % viable myyocte populations were significantly increased with DEVD (25 µM) 
treatment at 15 minutes and 30 minutes after starting reoxygenation in comparison to 
control Hypox / Reox myocytes (46.8 ± 3.3 %, 42.8 ± 6.5 % respectively vs. 18.2 ± 3.9 % 
Hypox/Reox control, Tukey’s post-hoc test p<0.05) Figure 5.17. Treatment with PI3-Akt 
* 
& 




inhibitor (WORT,100nM) simultaneously with DEVD at 15 minutes and 30 minutes after 
reoxygenation did not affect the protection afforded by DEVD, showing a significant 
increase in % viable myocytes compared to Hypox/Reox control myocytes (54.3 ± 9.7 %, 



































Figure 5.17: Assessment of myoctes viability in isolated adult rat cardiomyocytes 
subjected to 6 hours hypoxia and 18 hours of reoxygenation. The specific caspase-3 
inhibitor (DEVD, 25µM) was added at 15 minutes and 30 minutes after starting 
reoxygenation in the presence and absence of the of PI3-Akt inhibitor; Wortmannin 
(WORT, 100nM). Results are shown as mean + SEM and are expressed as a 
percentage of the total cells counted.* p<0.05 vs. Normoxia, $ p<0.05 vs. Hypox/Reox 
Control, n=5. 
5.3.2.2.6 The inhibitory effect of the specific caspase-3 inhibitor (DEVD, 25µM) when 
added at 15 minutes and 30 minutes after starting reoxygenation on caspase-3 activity 
level is not blocked by PI3-Akt inhibitor, Wortmannin (WORT, 100nM) 
 
Results showed that there is a significant reduction in caspase-3 activity level after 
treatment with the specific caspase-3 inhibitor (DEVD, 25 µM) administered at 15 minutes 







hypoxia and reoxgenation conditions (145.2 ± 54.4 %, 136.8 ± 22.8 % respectively vs 375.5 
± 90.9 % Hypox/Reox, Tukey’s post-hoc test p<0.05) Figure 5.18. However, adding PI3-
Akt specific inhibitor; Wortmannin (WORT, 100nM) simultaneously with DEVD at 15 
minutes and 30 minutes after starting reoxygenation did not block DEVD mediated 
inhibitory effect on caspase-3 activity (190.7 ± 31.9 %, 131.3 ±  22.0 % rspectively vs 











































Figure 5.18: Caspase 3 activity in isolated adult rat cardiac myocytes subjected to 6 
hours of hypoxia followed by 18 hours of reoxygenation. The specific caspase-3 
inhibitor (DEVD, 25µM) was administered at 15 minutes and 30 minutes after 
starting reoxygenation in the presence and absence of the of PI3-Akt inhibitor; 
Wortmannin (WORT, 100nM). Results are shown as mean + SEM and are expressed 
as a percentage of the normoxia control values. * p<0.05 vs. Normoxia, & p<0.05 vs. 












5.3.2.2.7 Results summary 
In summary both the broad spectrum caspase inhibitor (ZVAD) and the specific caspase 3 
inhibitor (DEVD) resulted in significant cardioprotection when administered at 15 min and 
30 min after starting reperfusion by siginicant reduction in infarction size within the risk 
area, significant reduction in apoptotic and siginificant reduction in intracellular caspase 3 
acitivity. This cardioprotection was not mediated via PI3-Akt kinase pathway as co 
administration of PI3-Akt inhibitor (WORT, 100nM) did not block their cardioprotection at 
15 min and 30 min as shown in table 5.2. The same control ischemia reperfusion group was 
















Group I/R % Viability Apoptosis Caspase 3 
activity (%of 
Normoxia) 
Normoxia  68.0± 2.9 13.8± 3.0 100% 
Control Ischemia/Rep 54.2±6.6 18.2±5.1 48.2± .8 375.5±90.8 
ZVAD@15min Rep 30.5±3.4 42.1± 6.5 26.8±1.7 123.8±13.7 
ZVAD@30min Rep 31.6±4.0 47.0±3.6 28.5±1.9 138.5±29.6 
DEVD@15min Rep 15.7±3.6 46.8±3.3 18.9±5.2 145.2±54.4 
DEVD@30min Rep 18.5±3.7 42.8±6.5 28.8±5.5 136.0±22.9 
WORT 50.0±4.4 34.6±5.8 41.0±5.1 308.0 ±37.8 
ZVAD+WORT 
@15min Rep 
29.6±4.7* 47.0 4.3* 23.7±4.6* 123.8±13.7* 
ZVAD+WORT 
@30min Rep 
26.2±6.6* 48.0±2.2* 20.3±4.2* 138.5±29.6* 
DEVD+WORT 
@15min Rep 
18.0±4.3* 54.3±9.7* 22.8±7.4* 190.7±31.9* 
DEVD+WORT 
@30min Rep 
18.9±3.6* 49.8±6.2* 26.5±5.1* 131.3±22.0* 
 
Table 5.2 Summary table showing the effect of the broad spectrum caspase inhibitor 
(ZVAD) and the specific caspase 3 inhibitor (DEVD) on I/R%, cellular viability, 
apoptosis and intracellular caspase 3 activity when admisitered at 15 min and 30 min 
after starting reperfusion in the presence and absence of the of PI3-Akt inhibitor; 









5.3.2 Western blot analysis 
5.3.2.1 Mitochondrial Markers  
 
Cytochrome c is localized to the mitochondrial intermembrane space. It is released from the 
mitochondrial intermembrane space into the cytosole after induction of apoptosis. In this 
study cytosolic samples were isolated from mitochondrial samples and then were tested for 
mitochondrial markers to evaluate for any mitochondrial damage. Citrate synthase is a 
mitochondrial matrix enzyme, which can be considered as a mitochondrial marker. Citrate 
synthase enzyme did not differ between experimental groups (p>0.05), thus indicating that 
release of mitochondrial matrix proteins into the cytosolic fraction was similar for all 















































Figure 5:19 Assessment of citrate synthase activity level in isolated hearts subjected to 
35 min ischemia followed by 120 minutes of reperfusion in control and either the 
broad spectrum caspase inhibitor (ZVAD, 0.1µM) or specific caspase-3 inhibitor 
(DEVD, 0.07µM) treated hearts at different time points during reperfusion 




The voltage-dependent anion channel (VDAC) is an integral membrane protein present in 
the mitochondrial outer membrane, which is another mitochondrial marker. In this study we 
tested for VDAC using western blot analysis to assess any mitochondrial contamination of 
cytosolic samples. The VDAC was undetectable in all cytosolic samples when compared to 
mitochondrial samples (Figure 5.20). 
Figure5.20: Representative western blots for Voltage dependent anion channel 
(VDAC) in all cytosolic fractions of all experimental groups compared to 
mitochondrial fractions. Protein loaded was 30 µg per lane. C denotes cytosolic 




















5.3.2.2 Role of caspase inhibitors (ZVAD, 0.1µM or DEVD, 0.07µM) on cytochrome c 
release 
 
In this study we are investigated wether caspase inhibitors mediated cardioprotection is 
dependent on mitochondrial cytochrome c pathway. Isolated rat hearts were exposed to 35 
minutes ischemia followed by 120 minutes reperfusion, where caspase inhibitors (ZVAD, 
0.1µM or DEVD, 0.07µM) added at different time points during reperfusion throughout. 
Tissue for western blot analysis for cytosolic cytochrome c collected at the end of 120 
minutes reperfusion period. Cytosolic cytochrome c showed a significant increase in 
ischemic control hearts compared to basal non ischemic control hearts, which confirmed 
that cytochrome c is released from mitochondria to cytosole during ischemia reperfusion 
injury (75.0 ± 5.0 vs 38.0 ± 3.0 basal controls, LSD post hoc test p<0.05) Figure 5.21. 
However, neither caspase inhibitors significantly reduced cytochrome c release when added 


























































































Figure 5.21: Assessment of cytosolic cytochrome c in isolated hearts subjected to 35 
min ischemia followed by 120 minutes of reperfusion in control and either the broad 
spectrum caspase inhibitor (ZVAD, 0.1µM) or specific caspase-3 inhibitor (DEVD, 
0.07µM) treated hearts. Results are shown as mean + SEM of fife individual 
experiments. *P<0.05 vs. basal non-ischemic control. 
5.3.2.3 Phospho-Akt is upregulated with broad spectrum caspase inhibitor (ZVAD, 
0.1µM) during early reperfusion. 
 
In this study we aimed to invstigated wether caspase inhibitors mediated cardioprotection is 






after onset of reperfusion where the broad spectrum caspase inhibitor (ZVAD, 0.1µM) was 
administered at the onset of reperfusion in the presence and absence of PI3-Akt specific 
inhibitor (WORT, 100 nM). Western blot analysis was used to determine the protein 
expression levels of Phospho-Akt. 
 
Hearts treated with ZVAD at reperfusion for 5 and 10 minutes demonstrated a significant 
increase in phosphorylated Akt in comparison to control ischemia reperfusion hearts at 
analogous time points (47.2 ±20.4, 64.3 ± 7.4 vs. 6.1 ± 3.9, 20.2 ± 1.9 ischemic controls at 
5 and 10 minutes reperfusion, LSD post-hoc test p<0.05) Figure 5.22. However there was 
no significant difference in phospho-Akt expression level at 20 and 120 minutes in ZVAD 
treated hearts when compared to control ischemia reperfusion hearts at analogous time 
points (55.7 ± 12.0, 33.9 ± 16.4 vs 32.7 ± 28.7, 27.7 ± 14.5 ischemic controls at 20 and 120 
minutes reperfusion, LSD post-hoc test p>0.05) Figure 5.22. Treatment with PI3-Akt 
specific inhibitor (WORT, 100nM) and ZVAD for 10 minutes of reperfusion showed a 
significant decrease in expression levels of phospho-Akt compared to ZVAD alone treated 
hearts at the same time point (4.5 ± 25.4 vs. 64.3 ± 7.4 ZVAD at 10 min reperfusion, LSD 
post-hoc test p<0.05) Figure 5.22. Treatment with WORT alone was comparable to same 
time Control hearts group (20.1 ± 6.0 vs. 20.2 ± 1.9 ischemic control at 10 min reperfusion, 
LSD post-hoc test p>0.05) Figure 5.22. The presence of additional non specific band in the 
western blot below the phosphor-Akt band shown in figure 5.22 was observed when home 
made gel used. Overall, a significant increase in phosphorylated Akt protein expression was 
observed in ZVAD treated hearts at 5 and 10 minutes time points compared to analogous 








































































Figure 5.22: Assessment of phospho-Akt phosphorylation in isolated hearts subjected 
to 35 min ischemia followed by 5, 10, 20 or 120 minutes of reperfusion in control and 
the broad spectrum caspase inhibitor (ZVAD, 0.1µM) treated hearts. The ZVAD was 
administered at reperfusion in presence and absence of the PI3K inhibitor 
Wortmannin (WORT, 100nM). Results are shown as mean + SEM of three individual 
experiments. *P<0.05 vs. Control 5 min Reperfusion. & P<0.05 vs. Control 10 min 
Reperfusion. $ P<0.05 vs. ZVAD 10 min Reperfusion. 
5.3.2.4 Phospho-Akt is upregulated with specific caspase-3 inhibitor (DEVD, 0.07µM) 
during early reperfusion 
 
Administration of the specific caspase-3 inhibitor (DEVD, 0.07µM) at reperfusion 







6.2 ischemic control, LSD post-hoc test p<0.05, Figure 5.23) and 10 min (50.1 ± 11.7 vs 
36.1 ± 15.4 ischemic control, LSD post-hoc test p<0.05, Figure 5.23) of reperfusion 
compared to non treated time matched ischemic controls. This up regulation of phospho-
Akt by DEVD after 10 minutes of reperfusion was abrogated by the co-administration of 
the specific Akt inhibitor (WORT, 100nM) (50.1 ± 11.7 vs 19.7 ± 4.2, LSD post hoc test 
p<0.01, Figure 5.23). However, there was no significant difference in phospho-Akt 
expression level at 20 minutes reperfusion with DEVD when compared to control ischemia 
reperfusion hearts at analogous time point (35.4 ± 20.8 vs 64.4 ± 34.9 ischemic control at 
20 minutes, LSD post-hoc test p>0.05, Figure 5.23). At 120 minutes reperfusion with 
DEVD, the expression level of phospho-Akt was significantly decreased when compared to 
ischemic control at matched time point (20.4 ± 5.3 vs 46.8 ± 8.2, LSD post-hoc test p<0.05, 
Figure 5.23). In this western blot the non specific band was not seen because this gel was 
purchased from Bio-Rad (Hemel Hempstead, UK) which could be attributed to more 







































































Figure 5.23: Assessment of phospho-Akt phosphorylation in isolated hearts subjected 
to 35 min ischemia followed by 5, 10, 20 or 120 minutes of reperfusion in control or 
the specific caspase-3 inhibitor (DEVD, 0.07µM) treated hearts. The DEVD was 
administered at reperfusion in presence and absence of the PI3K inhibitor 
Wortmannin (WORT, 100nM). Results are shown as mean + SEM of three individual 
experiments. *P<0.05 vs. Control 5 min Reperfusion. &P<0.05 vs. Control 10 min 










In this study we demonstrated that the broad spectrum caspase inhibitor (ZVAD) and the 
specific caspase-3 inhibitor (DEVD) were cardioprotective when administered immediately 
after starting reperfusion. Coadministration of wortmannin, inhibitor of PI3-Akt survival 
pathway abolished the cardioprotective effect of aforementioned caspase inhibitors by 
significant increase in infarction size, apoptosis, necrosis and caspase-3 activity level. 
These results can suggest that caspase inhibitors mediated cardioprotection could be 
hypothesized to be mediated via PI3-Akt survival pathway. However, cardioprotection 
offered by delayed administration of aforementioned caspase inhibitors, 15 minutes and 30 
minutes after starting reperfusion was shown to be independent of PI3-Akt survival 
pathway.  
5.4.1 Role of mitochondrial pathway on caspase inhibitors mediated cardioprotection 
 
The mechanism by which apoptosis is induced by ischemia and/or reperfusion is still 
unclear. Caspase, which are considered as a key biochemical hallmark of apoptosis, can be 
activated by two main pathways (Budihardjo et al., 1999). One is mediated by cell surface 
death receptors, leading to autoactivation of caspase -8, which in turn activates downstream 
caspase such as caspase-3, 6 and 7 (Budihardjo et al., 1999). The second pathway is 
mediated by mitochondria, which release cytochrome c, which can associate with Apaf-1 
(apoptosis protease activating factor) and pro-caspase-9, triggering the activation of 
downstream caspase-3 and apoptosis (Kromer et al., 1997). At present it is not clear which 
pathway is involved in initiation of apoptosis in myocardial ischemia/reperfusion injury. 
Several studies have implicated mitochondrial pathway in the cell injury in models of 
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myocardial infarction and cardimyocyte death (Vanden Hoek et al., 2003, Takamichi et al., 
2004). In addition Date et al., (2003) showed that cardiomyocytes apoptosis predominantly 
proceeds via the mitochondrial pathway. 
 
The results of our study confirmed the role of cytochrome c in ischemia reperfusion injury, 
as results showed significant increase of cytosolic cytochrome c in all groups exposed to 
ischemia and reperfusion compared to basal non-ischemic group. This suggests that 
mitochondrial pathway is involved in mediating apoptosis during myocardial ischemia 
reperfusion injury through cytochrome c release which is in agreement with previous 
literature. It is possible that this cytochrome c loss from mitochondrial matrix to cytosolic 
fraction could be an artifact due to mitochondrial damage during isolation procedure. 
However, this is unlikely as we found no significant change in citrate synthase activity (a 
mitochondrial matrix enzyme) between different experimental groups. Furthermore, VDAC 
(mitochondrial inner membrane protein) was undetectable in all cytosolic samples. In 
addition, inclusion of cyclosporine in the isolation buffer reduced the possibility of opening 
of mitochondrial transition pre and during the isolation procedure. 
 
Previous studies showed that ischemia/reperfusion of the heart induces both caspase 
activation and cytochrome c release (Bialik et al 1999, De Moissac et al 2000, Borutaite et 
al 2001), however it is unclear whether cytochrome c release causes caspase activation or 
caspase activation causes cytochrome c release. Our study results showed that caspase 
inhibitors failed to inhibit cytochrome c release from mitochondria, which suggests that 
cytochrome c release from mitochondria is caspase independent. These results are in 
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agreement with previous studies that concluded that cytochrome c release is upstream of 
caspase activation (Bialik et al., 1999, de Moissac at al., 1999, Suzuki et al., 2001). Qin et 
al (2004) showed that caspase 8, 9 and 3 inhibitors failed to block cytochrome c release 
which is in agreement with the present study results. However they showed that caspase 2 
inhibitor significantly blocked cytochrome c in chick cardiomyocytes exposed to simulated 
ischemia and reperfusion conditions and suggested a critical role of caspase 2 in initiating 
apoptosis in their model. In our present study we included a broad spectrum caspase 
inhibitor ZVAD, which is expected to have inhibitory effect on caspase 2 also; however we 
showed no significant effect on cytochrome c release. This discrepancy could be attributed 
to differences in cell type used as we used whole heart prepeartion compared to cheick 
cardiomyocytes grown in culture media used by Qin group. Also this discrepancy could be 
attributed to different synthetic caspase inhibitors used which vary in their specificity 
between manufactures, therefore we used two types of caspase inhibitors a broad spectrum 
one and more specific down stream caspase 3 inhibitos to compare their effect..  
 
The possibility that cytochrome c release occurred during ischemic period should be 
considered. Therefore caspase inhibitors in our study model introduced at the onset of 
reperfusion period couldn’t affect cytosolic cytochrome c level which has already being 
released during ischemic period. However this possibility could be ruled out as different 
studies reported that cytochrome c released only during reperfusion period using isolated 




Lundberg & Szweda (2004) showed that a significant increase in cytosolic cytochrome c 
started at 30 minutes after starting reperfusion with greater overall increase between 30 and 
60 minutes reperfusion with no further increase evident with extended reperfusion (120 
minutes). Thus, the results of their experiments demonstrated a time-dependent increase of 
cytosolic cytochrome c with reperfusion. As we introduced caspase inhibitors at different 
time points (15 minutes, 30 minutes and 60 minutes) during reperfusion and found that 
there was no significant effect on cytochrome c release, we can rule out the effect of time 
distribution of cytochrome c release from mitochondria during reperfusion which again 
support that cytochrome c release from mitochondria is caspase independent. Therefore, the 
mechanism of caspase inhibitors cardioprotection might involve different route other than 
cytochrome c release from mitochondria.  
5.4.2 Role of PI3-Akt cell survival pathway on caspase inhibitor mediated 
cardioprotecton during early phase of reperfusion 
 
PI3-Akt and Erk1/2 cell survival pathways have been shown to be activated during 
ischemia reperfusion injury (Wu et al., 2000) and are considered as exciting innate cellular 
anti-apoptotic pathways of survival during myocardial ischemia reperfusion injury 
(Hausenloy & Yellon, 2004). Therefore, activation of these survival pathways may afford 
an opportunity for protecting the heart against ischemia reperfusion injury. A number of 
growth factors and pharmacological agents, together with ischemic postconditioing 
introduced immediately after starting reperfusion have been shown to induce 
cardioprotection via PI3-Akt and Erk1/2 survival pathway. These findings led Hausenloy & 
Yellon (2004) to postulate that these pathways might constitute a common pathway for 
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cardioprotection and termed them as reperfusion injury salvage kinase (RISK) pathway. 
Therefore caspase inhibitor mediated cardioprotection when administered during early 
reperfusion phase could also be via the RISK pathway. The results of the present study 
showed that there was an increase in phosph-Akt during the first 5 and 10 minutes of 
reperfusion with caspase inhibitors which further supports Hausenloy & Yellon theory. 
Using wortmannin, a potent irreversible inhibitor of PI3-Akt (Powise et al., 1994), further 
supports our results. Co-administration of wortmannin with both caspase inhibitors 
(ZVAD+DEVD) significantly abolished caspase inhibitors mediated cardioprotection via 
significant decrease in phosphorylation of Akt. 
 
The present study showed that blocking Akt with wortmannin resulted in a significant 
increase in caspase 3 activity level in the caspase inhibitors treated groups, which suggest 
that Akt has an inhibitory effect on caspase-3 activity. This inhibitory effect could be 
through direct effect on caspase 3 at the cytosolic level or through Akt established effect on 
mitochondrial pathway. The effect of Akt on mitochondrial pathway of caspase activation 
is well estabilished through phosphorylation of Bad and Bax (pro-apoptotic proteins) and 
mitochondrial permeability transition pore (Hausenloy & Yellon, 2004). However, in this 
study, the Akt role in caspase inhibitors mediated cardioprotection is not through 
mitochondrial pathway as we mentioned earlier as there was no significant effect on 
mitochondrial cytochrome c release, therefore it is most likely via direct effect at the 
cytosolic level. These findings are in agreement with Wu et al (2000) as they showed that 
activation of PI3-Akt pathway led to suppression of caspase 3 activity independent of Bad 
phosphorylation. Uchiyama et al (2004) showed that Akt overexpression resulted in 
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inhibition of hypoxia reperfusion induced caspase 3 and 9 activation. Furthermore, PI3-Akt 
pathway has been found to inhibit caspase mediated apoptosis through direct 
phosphorylation of caspase 9 (Cardone et al., 1998).  
 
Widmann et al (1998) demonstrated that caspase turn off survival signals in addition to 
activating death signals. They found for the first time that Akt and other signalling proteins 
were degraded during apoptosis by active caspase and that Akt degradation was inhibited 
by a caspase inhibitor using Jurkat and U937 cell model. Loss of these signalling proteins 
contributes significantly to caspase-mediated apoptosis. This study finding supports our 
study results, as we found that caspase inhibitors significantly increased the expression of 
Akt, which could be via elimination of the degradation effect of active caspase on Akt. 
 
Wortmannin used in high dose of 100nM found to have inhibitory effect on other MAPKs 
signaling pathways (Davies et al., 2000). Therfore involvement of other signaling pathways 
in caspase inhibitors mediated cardipprotection could not be ruled out. Using lower doses 
of wortmanning like 5nM partilly blocked Akt activity (Khan et al., 2006) , that’s why we 
decided to use 100nM in our studies baring in mind that it might have inhibitory effect on 
other pathways. 
5.4.3 Cardioprotection by delayed administration of caspase inhibitors 15 minutes and 
30 minutes after starting reperfusion is independent on PI3-Akt survival pathway 
 
Cardioprotection by delayed administration of caspase inhibitors (ZVAD and DEVD) at 15 
minutes and 30 minutes after starting reperfusion was not abolished by co-administration of 
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PI3-Akt specific inhibitor; Wortmannin. This suggests that the caspase inhibitors mediated 
cardioprotection during late phase of reperfusion is independent of PI3-Akt cell survival 
pathway. These findings are again consistent with the observation of Hausenloy & Yellon 
(2004) that PI3-Akt pathway played an important and critical role in cardioprotection 
during only the first minutes of reperfusion. However, Solenkova et al (2006) found that 
activation of PI3-Akt pathway is needed for the first 60 minutes of reperfusion for ischemic 
preconditioning (IPC) cardioprotective effect to take place, however, after 6o minutes 
reperfusion blocking the PI3-Akt pathway did not abolish the cardioprotecive effect of IPC 
using isolated rabbit heart model. They suggested that the hearts after 60 minutes don’t 
need the support of PI3-Akt survival pathway. In our model of this study, we found that 
blocking the PI3-Akt survival pathway as early as 15 minutes did not abolish the caspase 
inhibitor cardioprotection. This discrepancy in the time window could be attributed to 
different cardioprotective strategies used. Precondiotioning cardioprotective strategy might 
have different mediators, growth factors and other signaling pathways affecting Akt 
activation compared to caspase inhibitors. 
 
The involvement of another survival pathway, at delayed phase of reperfusion could be 
suggested. The Erk1/2 pathway is the other member in the RISK survival pathways. Erk1/2 
activation has been demonstrated in the setting of ischemia reperfusion injury and can 
mediate cellular protection (Shimizu et al., 1998, Yue et al., 2000). Erhardt et al., (1999) 
showed that the B-Raf/MEK/Erk pathway interferes with apoptosis at the level of cytosolic 
caspase activation, downstream of the release of cytochrome c from mitochondria. Such 
postmitochondrial effect of Erk pathway at the level of caspase activation is consistent with 
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our study results, as we showed that caspase inhibitor cardiopotection is downstream of 
mitochondrial level. These findings raise the possibility that Erk signalling may play a 
significant role in mediating caspase inhibitors cardioprotection. Recently Hausenloy et al 
(2004) demonstrated that PI3-Akt and Erk1/2 pathways appear to interact in such a way 
that inhibiting one kinase cascade upregulates the activity of the other pathway, thereby 
acting as a compensatory safeguard, ensuring the signal for cellular protection is executed. 
Therefore the possibility of involvement of Erk1/2 pathway in mediating caspase inhibitors 
cardioprotection after inhibiting PI3-Akt pathway can not be excluded and needs further 
study. 
5.4.4 Clinical implications and conclusion 
 
It is important to establish the underlying mechanism of action of any drug and considered 
important in clinical field. This enables clinicians to decide about drug interaction and 
allows them to differentiate between drugs with synergistic or contradictory action. The 
recruitment of the PI3-Akt pathway at the time of reperfusion exerts powerful protection 
against ischemic–reperfusion injury, through various cellular protective mechanisms, 
including the inhibition of caspase, known executioners of apoptosis. Therefore, in a 
clinical setting, administrating Caspase inhibitors during early reperfusion provides a novel 
target for protecting the heart against lethal reperfusion injury through activation of PI3-Akt 





CHAPTER 6  
 
Broad spectrum caspase inhibitor improves post ischemic contractile 
function of isolated rat heart papillary muscle when administered during 
reperfusion and analysed using work loop technique 
 
6.1 Introduction and objectives 
 
One of the primary determinants of mortality following myocardial infarction is the extent 
of residual contractile function (Pasternak et al., 1988). Cellular death through apoptosis 
during ischemia reperfusion injury is thought to play an important role in the deterioration 
of myocardial contractile function, ventricular remodelling and heart failure after a 
myocardial ischemia reperfusion injury (Beltrami et al., 1994, Narula et al., 1996). Caspase 
play a crucial role in myocardial apoptosis (Bialik et al., 1997). Furthermore, caspase can 
also influence the contractile machinery of myocytes through cleavage of troponin and α-
actinin, both are myofibrillar proteins (Haider et al., 1999, Communal et al., 2002), which 
can result in contractile dysfunction. We and several previous studies have found that broad 
spectrum and specific caspase inhibitor are cardioprotective in terms of reducing infarction/ 
risk ratio and apoptotic myocyte death when administered at the start of reperfusion 
(Mocanu et al., 2000). The effect of caspase inhibitors on functional recovery of the 
myocardium post ischemia is still under investigation and showed controversial results. 
Ysrbrough et al., (2003) showed promising results using broad spectrum caspase inhibitor. 
They showed that caspase inhibitors administerd at the start of reperfusion reduced post 
myocardial infarction left ventricular remodelling using in vivo pig model. Kovacs et al., 
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(2001) again showed that broad spectrum caspase inhibition administered at onset of 
reperfusion for just 10 minutes, imporoved significantly the recovery of post ischemic 
cardiac function (coronary flow, aortic flow and left ventricular developed pressure). 
However they also reported that the hearts infused with specific caspase inhibitors (caspase 
3 and caspase 9) showed no significant improvement in post ischemic cardiac function 
using isolated rat langendorff working model. On the other hand Rutten et al., (2001) using 
the same model, showed that caspase 3 inhibition significantly improved myocardial 
functional recovery post ischemia. Again Balsam et al., (2005) using in vivo mouse model, 
showed that caspase 3 inhibiton administerd at the onset of ischemia prevented ventricular 
diltation and dysfunction significantly. These controversial results could be attributed to the 
end target measured to assess ventricular function and the time of caspase inhibitors 
administration. Therefore, in this present study, we will investigate the effect of both broad 
spectrum (ZVAD) and specific caspase 3 (DEVD) inhibitors when administered at the 
onset of reperfusion period throughout on the power out put of the rat ventricular papillary 
muscle. 
 
Contractile function assessment is strongly dependent on the index used (Chiu et al., 1989). 
Maximum power output has been proposed by Ford (1991) to be the more reliable index to 
assess the effects of inotropic interventions. He proposed three advantages of this index: 1) 
it is determined by interpolation rather than by extrapolation, therefore it is subjected to less 
error than extrapolated values like Vmax. 2) it is sensitive to changes in both the force 
generating ability and the shortening capability of the muscle, in other words it measures 
the ability of the muscle to do work, which is the muscle’s principal function and 3) it can 
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be normalized to muscle mass, which allows reliable comparison with results of other 
experiments results that are also normalized to muscle mass. 
 
Working cardiac muscles undergo cyclical length changes, in which force development and 
shortening occur simultaneously and resultant work is produced (Semafuko & Bowie, 
1975). Using the work loop technique allows in vitro measurement of maximum power 
output during cyclical length changes which simulates physiological contractions, making it 
a more reliable measure of in vitro performance than isometric or force-velocity studies 
(Josephson, 1985, James et al., 1996). Layland et al., (1997) demonstrated that the power 
and work-frequency relationships derived using work loop techniques are sensitive to 
changes in force, velocity, activation and relaxation rates. Therefore, they proposed that the 
work loop technique may represent a useful and sensitive approach for assessing the effects 
of pharmacological interventions on cardiac contractility.  
 
Therefore, the aim of this experiment is to investigate the effect of the broad spectrum 
(ZVAD) and specific caspase-3 inhibitor (DEVD) administered at the start of reperfusion 
on post ischemic recovery of contractile function using an isolated rat ventricular papillary 
muscle model. Contractile function was measured using the work loop technique to give a 






Work loop technique was used to measure the power output of isolated rat ventricular 




6.3.1 Isometric studies 
 
Mean isometric stress was not significantly different between experimental groups (One 
way ANOVA, p>0.05, table 1). These stress results were similar to those previously found 
for rat papillary muscle (Layland et al., 1994, 1995). The mean power output in the first 20 
minutes stabilization period was not significantly different between experimental groups 
(One way ANOVA, p>0.05, table 1), which are within the same range of results found by 
Layland et al., (1994,1995). 
 
Group Isometric stress  
(kN m-2) 
Mean power output 




48.4 ± 18.3 14.8 ± 3.3 
Ischemic control group  
(n=6) 
78.8 ± 28.5 23.4 ± 10.4 
ZVAD (0.1 µM) 
 (n=6) 
49.0 ± 8.9 16.3 ± 2.4 
ZVAD (2.5µM) 
 (n=6) 
49.2 ± 23.0 14.0 ± 2.8 
DEVD (2.5 µM) 
(n=6) 
48.9 ± 4.9 18.3 ± 1.6 
 
Table 6.1: Baseline values (mean ± SEM) of isometric stress and mean power output 




6.3.2 Baseline non-ischemic contractile function of papillary muscle 
 
The power output was stable for 150 minutes, signifying non deterioration in the papillary 




























Figure 6.1: Power output of the rat heart papillary muscle exposed to normal 
oxygenated KHB for 150 minutes. Values are presented as mean percentages of the 
first 20 minutes stabilization period ± SEM. n=6 
 
6.3.3 Effect of ischemia and reoxygenation on contractile function of papillary muscles 
(Ischemic control group) 
 
Ischemia caused a significant rapid reduction in power output, reaching an 80% reduction 
within 15 minutes (Figure 2). Power output then gradually reduced to 9% of control 
stabilization power output (One-way ANOVA, Tukey’s post hoc test p<0.05, Figure 2). 
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The power output recovered gradually during reoxygenation period to a maximum of 43% 
of control stabilization power output, which is significantly different to end ischemic values 
(One-way ANOVA, Turkey’s post hoc test, p<0.05, Figure 6.2). However it didn’t reach 
100% recovery, this confirms the permanent damage caused by ischemia to the muscle, 



























Figure 6.2: Changes in power output of the rat heart papillary muscle exposed to 35 
minutes ischemia and 100 minutes reoxygenation. Values are presented as mean 
percentages of the stabilization period ± SEM. * p<0.05 vs. 20 min stabilization $ 
p<0.05 vs. 25 and 30 min ischemia, n=6. 
6.3.4 The effect of the broad spectrum caspase inhibitor (ZVAD) on papillary muscle 
contractile function 
 
The effect of the caspase inhibitor ZVAD was dose dependent in its ability to improve the 
contractile recovery post ischemia (Figure 6.3). The post ischemia contractile recovery of 
muscles treated with 0.10µM ZVAD was not significantly different when compared to 
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however when the dose increased to 2.5µM, the contractile recovery post ischemia 
significantly improved (Two-way ANOVA, Tukey’s post-hoc test p<0.05, Figure 6.3). The 
significant improvement started 20 minutes after starting reperfusion throughout 
reperfusion period when compared to matched ischemic control time points (One way 






























Control ZVAD 0.1 ZVAD 2.5
 
Figure 6.3: Changes in power output of the heart papillary muscles exposed to 35 
minutes ischemia and 2 hours reoxygenation in the presence of different 
concentrations of broad spectrum caspase inhibitor; ZVAD (0.1µM, 2.5µM). Values 
are presented as mean percentages of the stabilization period ± SEM. * p<0.05 vs. 
ischemic control at matched time points, n=6. 
µM µM 
Ischemia Reoxygenation 




6.3.5 The effect of the specific caspase-3 inhibitor (DEVD) on papillary muscle 
contractile function 
 
The post ischemia contractile recovery of muscles treated with 2.5µM DEVD was not 
significantly different when compared to ischemic control muscles (Two-way ANOVA, 
































Figure 6.4: Changes in power output of the heart papillary muscles exposed to 35 
minutes ischemia and 2 hours reoxygenation in the presence of specific caspase-3 
inhibitor; DEVD (2.5µM). Values are presented as mean percentages of the 







Cardiac contractile function is considered an important determinant of mortality following 
acute myocardial ischemia (Pasternak et al., 1988). Numerous studies have shown that 
apoptosis is a significant contributor to myocyte death during ischemia/reperfusion injury 
and have also highlighted the essential role of caspase as an executioner of apoptosis 
(Gottlieb et al., 1994, Saraste et al., 1997, Haung et al., 2000, Mocanu et al., 2000 and 
Zhao et al., 2000). In addition; these studies have also demonstrated that synthetic caspase 
inhibitors, both specific and broad spectrum, play a cardioprotective role by reducing 
infarction size and apoptotic myocyte death.  
 
The main finding of the present study is that the broad spectrum caspase inhibitor (ZVAD) 
when administered at the start of reperfusion also plays another cardoprotective role by 
significantly improving the contractile recovery post ischemia in a dose dependent manner. 
However, the specific caspase-3 inhibitor (DEVD) at increased dose of 2.5µM failed to 
improve the contractile recovery post ischemia when administered at the start of 
reperfusion. These findings are in agreement with Kovacs et al., (2001) who showed that 
the non-specific caspase inhibition improved post-ischemic recovery, while selective 
caspase inhibition failed to improve post-ischemic cardiac function using langendorff 
working heart model and drugs administered at the start of reperfusion for just 10 minutes. 
However Rutten et al., (2001) showed that administration of caspase-3 inhibitor for 15 min 
during ischemia and 5 minute before starting reperfusionn improved contractile recovery 
using the same langendorff working heart model. This discrepancy in results could be 
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attributed to the different time of caspase inhibitor administration, local versus global 
ischemia and Rutten et al (2001) also used only 30 minutes reperfusion. However, our 
study is the first study to examine the direct effect of caspase inhibitors on cardiac muscle 
contractility using work loop technique (rather than using langendorff working heart 
model) and caspase inhibitors were added from the start of reperfusion, throughout 
reperfusion, which is clinically more feasible. In addition, our study model was the first to 
use the heart papillary muscle model. Definitive analysis of ventricular function requires 
more thorough understanding of the activation and contraction of each of its muscular 
elements like papillary muscles. Onset of contraction of the papillary muscles, as well as 
the epicardial muscle segments play more than a passive role in determining pressure 
development, valve action and flow patterns within the ventricle (Semafuko & Bowie, 
1975).The ventricular papillary muscles contraction is generally assumed to be important 
for closure of atrioventricular valves. The isolated papillary muscle preparation has proven 
to be a useful tool for studying myocardial interaction and contraction (Wiegner et al., 
1978, Shimizu et al., 1996d). 
 
Apoptosis contributes significantly to cell death following myocardial ischemia reperfusion 
injury (Zhao et al., 2000, Gottlieb et al., 1994, Saraste et al., 1997), however the 
relationship between apoptosis, where caspase activation is the hallmark, and the 
deterioration of functional contractility of the heart following myocardial 
ischemia/reperfusion injury is not clear and has not been investigated thoroughly. 
Following myocardial infarction in humans, apoptosis has been found in the core of 
ischemic zone, border zone of the infarction and also in the viable myocardium away from 
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ischemic area (Saraste et al., 1997, Olivetti et al., 1996). Therefore, due to this wide spread 
of apoptosis, determining its exact contribution to functional deterioration post infarction is 
considered an important question to be answered. This could be answered indirectly by 
evaluating the effect of apoptosis inhibition on recovery of the functional parameters. We 
have previously (chapter 4) demonstrated increased rate of apoptosis with 
ischemia/reperfusion injury, which was significantly reduced by caspase inhibitors. 
Therefore, the effect of caspase inhibitor on contractile recovery can be attributed to their 
inhibitory effect on apoptosis. The broad spectrum caspase inhibitor at high dose of 2.5 µM 
afforded a significant improvement in the recovery of contractile function in reoxygenated 
rat ventricular papillary muscles. This improvement may have been due to reduction in the 
apoptotic myocytes as ZVAD has consistently been shown to significantly reduce apoptotic 
myocyte death following ischemia/reperfusion injury in different models (Yaoita et al., 
1998, Holly et al., 1999, Mocanu et al., 2000). Therefore, the results of the present study 
indirectly confirm that apoptosis plays an essential role in the decline of functional 
contractility following myocardial ischemia and reoxyenation injury. However specific-
caspase-3 inhibitor failed to show any significant improvement in post ischemic contractile 
function, despite its anti-apoptotic activity as shown in our previous work (chapter 4) and 
other studies (Okamura et al., 2000, Perrin et al., 2003). This may be due to the broad 
spectrum caspase inhibitor affected more caspase that might more specifically affect 
contractile machinery of the papillary muscle than did caspase-3 inhibitor in our study 
model. This is in agreement with Perrin et al., (2003) as they showed that specific caspase-
3 inhibitor significantly inhibit apoptosis without any significant improvement in 
contractile function using langendorff perfusion model. However, Ruetten et al., (2001) 
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found that caspase 3 inhibition resulted in a functional contractile recovery independent of 
its apoptosis-inhibitory effects. This discrepancy between studies could be attributed to 
different factors including the functional model used, ischemic injury applied and time of 
drug administration. In addition, the caspase inhibitors dose was also different, as Ruetten 
et al., (2001) used a low dose range of 0.1µM-1µM; this dose may be insufficient to reduce 
apoptosis to a statistically significant value as we and other studies shown previously (Gai 
et al., 2002).  
 
In addition the possibility of inhibiting other proteases by broad spectrum caspase inhibitor 
such as calpain can not be ruled out. Different studies have shown calpain activation during 
ischemia-reperfusion injury (Yoshida et al., 1995a, Yoshida et al., 1995b), and its cleavage 
of the thin-filament regulatory protein troponin I with this being suggested as one of the 
mechanisms of myocardial stunning after ischemia reperfusion injury (Bolli et al., 1997). 
 
The significant recovery of contractile function during treatment with the broad spectrum 
caspase inhibitor could be attributed, as mentioned above, to its ability to reduce the 
fraction of myocytes injured during hypoxia/reoxygenation injury as it has consistently 
been shown to significantly reduce apoptotic cell death following ischemia/reperfusion 
injury in different models (Yaoita et al., 1998, Holly et al., 1999), in addition it also 
reduces infarction size (Mocanu et al., 2000) which collectively may enhance contractile 
recovery. However, it could also be attributed to recovery of stunning effect post ischemia. 
Stunning defined as post-ischemic myocardial dysfunction that is fully reversible over time 
providing perfusion is not hindered (Bolli, 1990). In addition Bolli (1990) stated that in in-
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vito experimental settings, the diagnosis of myocardial stunning should not be made unless 
reasonable assurance can be provided that the tissue in question is still entirely viable and 
that flow is normal or near-normal. Accordingly, our isolated muscle preparation is usually 
associated with significant cell death (TTC staining of papillary muscles showed significant 
infarction, data not shown), therefore stunning effect is unlikely. Furthermore, recovery in 
the present study was not complete and it reached a maximum of 59%, therefore, we can 
say that the recovery seen with broad spectrum caspase inhibitor is mainly due to cellular 
recovery rather than a transient stunning effect.  
 
We observed a dose dependent effect of broad spectrum caspase inhibitor (ZVAD) on its 
ability to improve contractile recovery of papillary muscles post ischemia. ZVAD at 0.1µM 
concentration, has no significant recovery effect, however, with a relatively high dose of 
2.5µM, significant improvement of contractile recovery was observed. The effective 
inhibitory concentration of ZVAD is variable among different studies. Cytoprotective effect 
was shown at a dose range from 10µM -100µM using isolated cardiomyocytes model 
(Gottlieb et al., 1996, Kang et al., 2000, Hai et al., 2001), on the other hand infarction size 
was significantly reduced at a dose as low as 0.1µM (Mocanu et al., 2000). This variability 
could be attributed to the different models used and the end factor used to assess the effect 
of ZVAD. Specific caspase 3 inhibitor (DEVD) showed no significant effect at high dose of 
2.5µM as compared to ZVAD. DEVD showed significant myocyte protection at a higher 
dose of 25µM as we demonstrated in chapter 4. Therefore, the possibility that DEVD can 





In conclusion, developing pharmacological therapies administered adjunctively to standard 
reperfusion interventions to limit the severe consequences of ischemia reperfusion injury is 
still considered as a challenge. Our and previous results demonstrated that caspase 
inhibitors are cardioprotective by reducing myocyte death and also by improving post 
ischemic contractile recovery when administered at the start of reperfusion. This provides a 
promising route by which it is clinically feasible to treat patients presented with acute 






7.1 General Discussion 
Limiting the impact of ischemic heart disease is of vital importance given the astronomical 
figures of ischemic heart related mortality and morbidity in the world. Early and complete 
reperfusion of the ischemic myocardium is essential for reduction of infarct size and 
preservation of cardiac function. This is currently achieved by thrombolysis, percutaneous 
transluminal coronary angioplasty (PTCA) and coronary artery bypass graft (CABG) 
surgery. The benefits of early reperfusion are well established but associated reperfusion 
injury is increasingly recognised to account for a proportion of the patient morbidity and 
mortality seen after reperfusion treatment. This reperfusion-induced injury can take the 
form of myocardial stunning, reperfusion arrhythmias, microvascular injury or lethal 
reperfusion injury. Lethal reperfusion injury is defined as “the death of myocytes, alive at 
the time of reperfusion, as a direct result of some aspect of reperfusion” (Hearse & Bolli 
1992, Yellon & Baxter 2000). Therefore there is an imperative need for the development of 
pharmacological agents that can be used as adjunct therapies to limit ischemia reperfusion 
injury to be administered in a clinical setting. 
 
Significant advances have been made in the past decade in understanding the underlying 
mechanisms of reperfusion injury and recognizing the distinct intracellular pathways 
involved in the mechanisms that influence cell death during reperfusion injury. Apoptotic 
cellular death found to contribute significantly to cell death during ischemia/reperfusion 
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injury. Our study results together with previous studies showed that apoptosis contribute 
significantly to myocytes death during ischemia reperfusion. Furthermore, our results 
showed that the contribution of apoptosis to myocytes death is significantly greater than 
necrotic myocyte death, which might suggest that apoptosis is the predominant mode of cell 
death during reperfusion injury. Therefore developing anti apoptotic therapies provides a 
novel target for protecting the heart against lethal reperfusion injury. Caspase represent the 
executionary machine of apoptosis (Cryns & Yaun, 1998) and responsible for the cleavage 
of the key cellular proteins that lead to the typical morphological changes observed in cells 
undergoing apoptosis, culminating in cellular death (Enari et al., 1996). Therefore caspase 
inhibitors could provide a promising therapeutic strategy to limit reperfusion injury.  
 
Caspase inhibitors showed promising cardioprotective results in previous studies, however, 
their therapeutic window and whether their delayed administration after starting reperfusion 
will be cardioprotective, is still controversial. Our study results showed that broad and 
specific inhibition of caspase significantly attenuated myocardial infarction development in 
the risk zone, when administered immediately at the start of reperfusion, 15 min, 30 min 
and 60 min after starting reperfusion. These results were in agreement with Armstrong et al 
(2001) study results where they showed that caspase inhibitors (unspecified, still under 
investigation) significantly reduced infarct size even when administered one hour after the 
heart attack using in vivo  rat model. Furthermore, our study results showed that caspase 
inhibitors introduced one hour after reperfusion are almost as cardioprotective as if they 
were introduced at the time reperfusion started. However, Li et al (2001) using isolated 
adult rabbit cardiomyocytes showed that caspase inhibitors (unspecified, labeled with 
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numbers) were partially protective if added 15 min after reperfusion and the 
cardioprotective effect was completely lost with a delay of 30 or 60 minutes. This 
discrepancy could be attributed to different types of inhibitors used and different models. In 
our study we tried to clarify this discrepancy by using both specific down stream caspase 3 
inhibitor and a broad spectrum caspase inhibitor and also using different models, isolated 
heart langendorff model and isolated adult rat ventricular myocytes model. 
 
Our study results demonstrated that the therapeutic window of myocardial infarction 
treatment with caspase inhibitors can be prolonged for at least one hour after starting 
reperfusion. This prolonged therapeutic window is clinically more feasible as patients are 
usually presented to hospital after the onset of ischemic attack and only at the start of 
reperfusion which is under clinician’s control. Furthermore spontaneous reperfusion may 
occur in some patients before any hospital intervention due to dislodgment of the thrombus 
or relieved coronary spasm (Christian et al., 1998) and therefore they presented to hospital 
at delayed time after starting spontaneous reperfusion. This therapeutic window is longer 
than for most cardioprotective drugs tested previously. A3 agonist CL-IB-MECA lost its 
cardioprotective effect if administered 60 min after reperfusion (Hussain 2006) and A2a 
agonist lost its cardioprotective effect when delayed 5 minutes only after starting 
reperfusions (Boucher et al., 2004). Administration of the insulin hormone 15 minutes after 
the onset of reperfusion resulted in a loss of the protection seen when administered at 




Cardioprotection by delayed administration of caspase inhibitors mainly achieved through 
anti-apoptotic mechanism. These findings suggest that apoptosis contribution to cellular 
death during ischemia reperfusion injury is a continuous process and don’t stop by starting 
reperfusion alone; however it might indicate that caspase activation could be initiated 
during ischemia but their irreversible cellular injury does not occur until later times. These 
suggestions can be supported by Vanden Hoek et al., (2003) results, where they reported 
that at least 2 hours of reperfusion was required to detect a significant level of caspase-3 
activity required for fodrin cleavage to be detected. Furthermore human studies support our 
conclusion as they documented the occurrence of apoptosis in human heart specimens 
obtained from patients who died following myocardial infarction and they showed that 
apoptotic cells were significantly more numerous in the border zone of the infarcted tissue 
(Olivetti et al., 1996, Saraste et al., 1997) which suggests that apoptosis may be in part 
responsible for extending infarction over time after the onset of reperfusion (Olivetti et al., 
1996). Using animal model Zhao et al., (2001) found that myocardial apoptosis in the peri-
necrotic myocardium progressively developed during the reperfusion period and was 
consistent with extension of infarction size and attenuation of contractile function and 
inhibition of apoptosis during reperfusion was associated with a reduction in infarction size 
and improvement in contractile function (Zhao et al., 2003). Therefore apoptosis can be 
considered as an important factor in exacerbation and extension of reperfusion injury and 
using caspase inhibitors could provide a potential therapeutic target. 
 
Together with the significant reduction in infarction size and apoptotic cellular death, broad 
inhibition of caspase significantly improved the post ischemic contractile recovery of the 
 
 184 
isolated adult rat papillary muscle when using the work-loop technique to measure the 
power output. These results were in agreement with previous studies were they showed that 
non-specific caspase inhibition improved left ventricular function and remodeling using in 
vivo rat and pig models (Yarbrough et al., 2003, Chandrashekhar et al., 2004). Even though 
haemodynamic parameters measured using langendorff model did not show any significant 
changes after caspase inhibitors administration. Using langendorff perfusion model to 
measure functional parameters is not truly reliable as usually they declined steadily during 
the experimental time course even without any ischemic intervention (Mocanu et al., 2000). 
However the working langendorff model allows measurement of cardiac output with 
different filling pressures and afterloads which provides more sensitive parameters of 
contractile function of the whole heart (Ytreuhs, 2000). In our laboratory experimental 
settings, it was difficult to use the working heart model due to lack of equipments and the 
expertise, therefore we decided to use the work loop technique to provide a more reliable 
assessment of caspase inhibitors effect on functional recovery using isolated ventricular 
papillary muscles. Using the work loop technique allows in vitro measurement of 
maximum power output during cyclical length changes of the muscle which simulates 
physiological contractions as working cardiac muscles undergo cyclical length changes, in 
which force development and shortening occur simultaneously and resultant work is 
produced, making it a more reliable measure of in vitro performance (Josephson, 1985, 
James et al., 1996). In addition, our study model was the first to use the heart papillary 
muscle model. The ventricular papillary muscles contraction is generally assumed to be 
important for closure of atrio ventricular valves and the isolated papillary muscle 
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preparation has proven to be a useful tool for studying myocardial interaction and 
contraction (Wiegner et al., 1978, Shimizu et al., 1996d). 
 
However specific inhibition of caspase 3 failed to improve the functional recovery of the 
isolated papillary muscle post ischemia. At present there is a little which could explain the 
discrepancies in the effect of the broad caspase inhibitor and the specific caspase inhibitor 
in their functional recovery effects. One explanation could be that the broad spectrum 
caspase inhibitor may have additional chemical characteristics which the specific caspase 3 
inhibitor does not have. Broad caspase inhibitor could have inhibitory effect on caspase that 
might more specifically affect contractile machinery of the papillary muscle than did the 
specific one in our study model. In addition the possibility of inhibiting other proteases by 
the broad caspase inhibitor such as calpain can not be ruled out, as calpain has been shown 
to cleave the thin-filament regulatory protein troponin I, which has been suggested as one 
of the mechanisms of myocardial stunning after ischemia reperfusion injury (Bolli et al., 
1997). 
 
Despite the knowledge that caspase inhibitors can reduce injury in response to myocardial 
ischemia/reperfusion, very little is known about the intracellular signaling pathways that 
may be involved in mediating this protection. Caspases, can be activated by two main 
pathways, the extrinsic death receptor pathway and the intrinsic mitochondrial cytochrome 
c pathway. The role of the death receptor pathway in cardiac myocyte apoptosis is less well 
understood. Although Fas signalling has been implicated in cardiac hypertrophy (Badorff et 
al., 2002), heart failure (Levine et al., 1990) and calcium signaling (Felzen et al., 1998), its 
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role in cardiac myocyte apoptosis during ischemia reperfusion injury has been 
controversial. Some studies have demonstrated data suggesting that the CD95/Fas is 
directly involved in cell death after myocardial ischemia using isolated rat heart model and 
primary adult rat cardiomyocytes culture model (Jeremias et al., 2000) and in vivo model 
(Lee et al., 2003). However, Comiz et al., (2005) reported that mitochondrial permeability 
transition rather than activation of Fas plays a pivotal role in cardiomyocyte death after a 
prolonged ischemia-reperfusion insult in mice model. Moreover, mice treated systemically 
with an activating Fas antibody die from massive hepatocyte apoptosis but exhibit no 
cardiac pathology (Ogasawara et al., 1993). Scarabelli et al., (2004) (cited in Comiz et al., 
2005) also demonstrated, by using the isolated rat heart model, that even after inhibition of 
caspase 8, release of cytochrome c and downstream activation of caspase 9 are seen during 
reperfusion, suggesting that mitochondrial damage and cardiomyocyte death is triggered 
independently of Fas activation. This suggests that cardiomyocytes apoptosis 
predominantly proceeds via the mitochondrial cytochrome c pathway (Date et al., 2003). 
The results of our study confirmed the role of mitochondrial cytochrome c pathway in 
ischemia reperfusion injury, as results showed significant increase of cytosolic cytochrome 
c in all groups exposed to ischemia and reperfusion compared to basal non-ischemic group 
which is in agreement with previous literature.  
 
Broad and specific caspase inhibitors failed to inhibit cytochrome c release from 
mitochondria following ischemia reperfusion which is in agreement with previous studies 
(Bialik, 1999, de Moissac at al., 1999, Suzuki et al., 2001). This suggests that cytochrome c 
release from mitochondria is caspase independent and upstream of caspase activation step. 
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Therefore, caspase inhibitors mediated cardioprotection is not dependent on mitochondrial 
cytochrome c pathway and an alternative mechanism operating at the level of cytosolic 
caspase activation downstream of mitochondria can possibly be suggested.  
 
Our study results showed that both broad and specific caspase inhibitors dependent 
cardioprotection during early phase of reperfusion is abrogated by the presence of the PI3-
Akt inhibitor Wortmannin, implying PI3-Akt is required for caspase inhibitors dependent 
protection. Western blot studies also showed a significant increase in phoshorylation of 
PI3-Akt pathway during the first 5 and 10 minutes of reperfusion with both caspase 
inhibitors and using wortmannin significantly reduced PI3-Akt phosphorylation. Previous 
studies showed that activation of PI3-Akt survival kinase pathway constitutes a common 
survival pathway sufficient to induce a cardio-protective response during early reperfusion 
phase (Hausenloy & Yellon, 2004) and it seems from our results that caspase inhibitors 
shared the same cardioprotective signaling pathway. This conclusion could be supported by 
Wu et al., (2000) who showed a novel link between PI3-kinase pathway and suppression of 
caspase 3 activation independent of Bad phosphorylation using cardiac muscle cells. In 
addition Akt pathway also has been found to inhibit caspase mediated apoptosis through 
direct phosphorylation of caspase 9 (Cardone et al., 1998). Furthermore Widmann et al 
(1998) demonstrated that active caspase turn off survival signals by degradation of Akt and 
other signaling proteins using Jurkat and U937 cell model. Therefore caspase inhibitors 
cardioprotection during reperfusion could be suggested to be mediated through PI3-Akt 
pathway via elimination of the degradation effect of active caspase on Akt. (Figure 7.1). 
Utilization of wortmannin to dissect out the role of PI3-Akt poses limitations. Experimental 
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evidence showed that wortmannin inhibits PI 3-kinase at a concentration of 100nM, 
however wortmannin also inhibits other members of the MAPKs pathway at this 
concentration (Davies et al., 2000). Therfore the possibility of involvement of other cell 
signaling pathways could not be ruled out in our experimental study. On the other hand 
using wortmannin at lower doses partially blocked Akt (Khan et al., 2006), making it 
unfeasible to judge their effect. Therefore the kinetics of activation of Akt and the effective 
dose of wortmannin to attain significant Akt activation in the myocardium after ischemia 
reperfusion need to be addressed thoroughly and results should be taken with caution. 
 
The cardioprotection by delayed administration of caspase inhibitors during reperfusion 
was not abolished by co-administration of PI3-Akt specific inhibitor; Wortmannin. This 
suggests that the caspase inhibitors mediated cardioprotection during late phase of 
reperfusion is independent of PI3-Akt cell survival pathway. The possibility that 
wortmannnin would have been degraded at later times of reperfusion because of its short 
half life of 10 minutes should be considered. However with our experimental setting of 
non-circulating continous infusion of the wortmainnin using langendorff perfusion system 
could rule out this possibility.The involvement of another survival pathway, at delayed 
phase of reperfusion could be suggested. Erk1/2 pathway was found to interfere with 
apoptosis at the level of cytosolic caspase activation, downstream of the release of 
cytochrome c from mitochondria (Erhardt et al., 1999). Furthermore Hausenloy et al (2004) 
demonstrated that PI3-Akt and Erk1/2 pathways appear to interact in such a way that 
inhibiting one kinase cascade upregulates the activity of the other pathway, thereby acting 




Our study results and previous studies put caspase inhibitors in the front line of clinical 
research because of their promising cardioprotective results and prolonged therapeutic 
window, however several issues need to be clarified before applying them in clinical field. 
The long term effect of caspase inhibitors still not known, whether myocytes rescued by 
caspase inhibition continue to survive or may undergo early death because of injury already 
sustained. As we showed in our study and previous studies that caspase inhibitors failed to 
inhibit mitochondrial dysfunction and cytochrome c release which implies that the 
mitochondrial dysfunction occurred earlier than caspase activation. Furthermore some 
studies showed an increase in cellular necrosis associated with caspase inhibitors use 
(Suzuki et al., 2000). This might suggest that cellular fate is dependent on the extent of 
mitochondrial dysfunction more than extent of caspase activation. This area needs more 
investigation whether therapeutic strategies will be more effective if applied before or at the 
mitochondrial dysfunction stage or after caspase activation stage and whether combined 
interventions are more effective is also still not known and needs further study.In addition, 
Vercammen et al., (1998) showed evidence with noncardiac cell lines that caspase 
inhibitors accelerates endogenous generation of reactive oxygen species leading to 
cytotoxic action in association with caspase inhibition. All these studies highlighted an 
important issue regarding the long term effect of caspase inhibitors and their future use of 
caspase inhibitors in clinical field. 
 
Capsaes activation and resultant apoptosis occurred in physiological process as well as 
pathological process, so, caspase inhibitors could potentially not only induce death in 
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unwanted pathological cells, but also might prevent cells damaged by lack of oxygen or 
other degenerative disease from killing themselves. Therefore using caspase inhibitors 
might result in unwanted side effects in clinical life. Better understanding of the entire 
caspase cascade that leads to apoptosis, along with the selection of specific targets and 
more selective inhibitors might improve the future clinical use of caspase inhibitors. Up-to-
date there is no clinical studies used caspase inhibitors in ischemic heart disease treatment, 
however a phase I clinical trial of the pan-caspase inhibitor, IDN-6556 administered to 
patients with hepatic impairment showed the drug to be well tolerated and significantly 
reduced liver enzymes. Thus, the pan-caspase inhibitor, IDN-6556 is a potential agent for 
the treatment of human liver injury characterized by excessive apoptosis (Valentino et al., 
2003). This study was based on animal studies that found that administration of IDN-6556 
resulted in portal drug concentrations 3-fold higher than systemic concentrations, indicating 
a significant first-pass effect (Hoglen et al., 2004). Therefore before applying caspase 
inhibitors in treating ischemic heart disease further studies needed about the 
pharmacokinetics and pharmacodynamics and the doses required to get the significant drug 
level to affect the heart with minimum side effect. 
 
Our study results can be considered important as one of the pre-clinical studies that tried to 
clarify the cardioprotective effect of caspase inhibitors and their mechanism of action 
before applying them in clinical studies for treatment of ischemic heart diseases. In short 
term basis caspase inhibitors proved to be cardioprotective by reducing infarct size, 
reducing apoptotic cellular death and improve post ischemic contrctile funtion. Our results 
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sugges that this cardioprotection is mediated through recruitment of the innate cell survival 































Figure 7.1: Proposed schematic pathway of caspase inhibitors mediated 
cardioprotection during ischemia reperfusion injury. 
 




























8.1 Suggested examples of further investigations 
 
 Caspase inhibitors showed cardioprotective results using different animal models; 
however their effect on human tissue/cells still limited and needs further 
investigation.This can be done using isolated human atrial trabecula preparation or 
human atrial muscle slices in tissue culture. The end points that can be measured are 
contractile function (force of contraction as a percentage of the baseline) in the 
isolated trabecula as an indirect measure of myocardial function. Assessment of cell 
death (by assay of creatine kinase release) and apoptosis (by annexin V labelling 
indicating an early event in apoptosis and using the modified TUNEL method with 
propidium iodide counterstaining indicating a later event in apoptosis). Different 
administration timing could be evaluted to evaluate caspase inhibitors theraputic 
window. 
 
 Akt cell survival pathway has been shown to be involved in caspase inhibitors 
cardioprotection during early reperfusion, however its down stream mediators are 
not known yet and needs further investigation. Further studies needed to determine 
the role of P70S6K, BAD, NOS and mPTP. This can be done using specific 
inhibitors of these mediators in the presence and absence of caspase inhibitors. 
Western blot studies can be used to determine the protein expression level and 




 Erk pathway is considered to be one of the cell survival signalling pathways. 
Different studies have shown that it is activated during ischemia reperfusion injury 
and involved in cardioprotection mediated by different cardioprotective strategies. 
However whether it could mediate caspase inhibitors cardioprotection still needs 
further investigation. This can be done by studying the effect of caspase inhibitors 
in the presence and absence of UO126 an Erk inhibitor. Western blot studies can be 
used to evalute phosphorylated Erk protein level. 
 
 The long term effect of caspase inhibitors needs to be investigated before applying 
caspase inhibitors in the clinical field. Developing a reliable model to study the 
effect of caspase inhibitors over prolonged period of reperfusion considered 
important. In vivo model could provide a reliable model where caspase inhibitors 
effect can be studies over weeks and apoptosis assessment can be done using 
TUNEL technique. 
 
 To verify whether therapeutic interventions applied at pre-mitochondrial and 
mitochondrial stage (befor caspase activation) is more effective than interventions 
applied at post mitochondrial stage (after caspase activation) needs further 
evaluation. Whether combined interventions are more effective is also still not 
known and needs further study. This can be done by studying the effect of caspase 
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Langendorff Perfusion Studies 
 
Krebs-Henseleit bicarbonate buffer (in mM):  
NaCl - 118.5,  
NaHCO3 - 25.0 
KCl - 4.8 
MgSO4 - 1.2 
KH2PO4 - 1.2 
Glucose - 12 
CaCl2 - 1.7 
Prepared freshly each day prior to each experiment, dissolved and gassed with 95% O2 / 5% 
CO2, at a pH of 7.4-7.5 at 37 °C. 
 
Evans blue (Sigma):  
0.25 % w/v Evans blue in 100ml 10% saline solution 
 
TTC preparation:  
2 mL 0.1M NaH2PO4  
8 mL 0.1M Na2HPO4  
1g Triphenyl Tetrazolium Chloride (Sigma) 
 
Western Blotting reagents 
Sample Buffer 
Tris-HCl 250 mM, pH6.8 
Glycerol 10% 
Bromophenol Blue 0.006% 
SDS 4% 
ß-mercaptoethanol 2%, pH 6.8 
 
Protein Lysis Buffer for Akt analysis 
NaCl-0.1M 
Tris base-10 mM 







Protease cocktail tablet-1/1.5 tablets  
 
Protein lysis buffer for cytochrome c analysis 
Mannitol 210 mM 
Sucrose 70 mM 
EDTA 1mM 
PMSF 0.5 mM 
Protease inhibitor cocktail 1.5tablet 
Cyclosporine 0.1 µM 
 pH 7.4 
 
Running gel base (100ml) 
1.5 M Tris base - 18.16 g 
0.4% SDS – 0.4g 
DH2O – 60 ml 
Correct to pH 8.8 with hydrochloric acid 
make up to100ml with DH2O 
 
Stacking gel base (100ml) 
0.5M Tris base – 6.05 g 
0.4% SDS – 0.4 g 
DH2O – 60 ml 
make up to 100ml with DH2O 
 
Running gel (12.5%)  
Distilled water – 12 ml 
Running gel base – 9 ml 
30% acrylamide – 15 ml 
TEMED – 40 µl 
10% Amonnium persulfate –200 µl  
 
Stacking gel (5%)  
Distilled water – 7 ml 
Stacking gel base – 3 ml 
30% acrylamide – 2 ml 
TEMED – 24 µl 
10% APS – 120 µl 
 
10% Ammonium Persulfate (APS) 





10% Sodium Dodecyl Sulfate (SDS) 




10X Running buffer 
Glycine – 144.2 g 
SDS – 10 g 
TRIS base – 30.3 g 
Distilled water -1 litre 
For 1X running buffer diluted 1:10 in ddH20 
 
10X Transfer buffer  
Glycine – 144.2 g 
Tris base – 30.3 g 
Distilled water – 1 litre 
 
1X Transfer buffer 
x10 transfer buffer – 100 ml 
20% MeOH – 200 ml 
Distilled water – 700 ml 
 
10X TBS/T (Tris Buffered Saline + Tween) 
Tris Base – 24.2 g 
NACL – 80 g 
Correct to pH 7.6 with hydrochloric acid 
make up to 1L with DH2O 
Add 1mL Tween (final 0.1%) 
 
Blocking buffer  
(5% Milk in TBS/T) 
Dehydrated Milk - 1.25 g 
TBS/T – 25 ml  
 
Antibody Dilution Buffer 
(5% BSA in  TBS/T) 
Bovine Serum Albumin – 2.5g 
TBS/T – 50ml 
 
Isolated Myocyte Studies 
 
Kreb’s Henseleit Buffer (in mM): 
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Na2HPO4.12H20 - 0.9  
Pyruvate - 5  
Taurine - 20  
Glucose - 10  
MgSO4.7.H20 - 0.4 
KCl - 5.4 
NaCl - 116 
 
Kreb’s Henseleit Buffer with CaCl2: 
200mL Krebs (above)  




0.15g Collagenase (Worthington Biochemicals) 
200mL Krebs Buffer 2 
8.8ul of 1M CaCl2 Stock 






100ul 100mM CaCl2 
2mL Pen-Strep 
200mL Krebs Buffer 2 
 
Hypoxic Buffer 
                                                            Grams/Liter 
12mM KCl 0.89 
0.49mM MgCl2 0.09 
0.9mM CaCl2 0.13 
4mM HEPES 0.953 
10mM Deoxyglucose  1.64 
20mM Lactate 1.7 
 
Caspase-3 Assay Reagents 
 
6% Formaldehyde 
6ml 10% formaldehyde 
4ml Phosphate Buffered Saline (PBS) 
 
90% Methanol 
45ml 100% HPLC grade MeOH 
 
 235 
5ml ddH20 
 
Incubation Buffer 
0.5g BSA 
100mL PBS 
 
